Prevalence of pheripheral neuropathy and effects of physiotherapeutic exercises on peripheral neuropathy in people living with Hiv on antiretroviral therapy in Rwanda. by Tumusiime, David Kabagema
 PREVALENCE OF PERIPHERAL NEUROPATHY AND EFFECTS 
OF PHYSIOTHERAPEUTIC EXERCISES ON PERIPHERAL 
NEUROPATHY IN PEOPLE LIVING WITH HIV ON 
ANTIRETROVIRAL THERAPY IN RWANDA 
 
 
 
 
 
 
David Kabagema Tumusiime 
 
 
 
 
 
 
A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, in fulfillment of the requirements for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
Johannesburg, 2014 
ii 
 
DECLARATION 
 
I, David K. Tumusiime, declare that this thesis is my own work. It is being submitted 
for the degree of Doctor of Philosophy in the University of the Witwatersrand, 
Johannesburg. It has not been submitted before for any degree or examination at this 
or any other University. 
 
 
 
 
 
 
 
 
 
 
 
 
29th day of August, 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
DEDICATION 
 
 
To my beloved wife; Florence, for the love and kindness, encouragement and 
“standing in my feet” whenever I was away, 
 
To my children; Solomon and Shiloh; “you missed me at the time of most need”, 
 
To my mother; Edinance; and father; late Kabagema “the foundation you laid makes 
me what I am today”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
PUBLICATIONS AND PRESENTATIONS IN SUPPORT OF 
THIS THESIS 
 
 
DK Tumusiime  
 
 
 
PUBLICATIONS 
 
 
Tumusiime DK, Stewart A, Venter F & Musenge E, 2014. Prevalence of Peripheral 
Neuropathy and associated demographic and health status characteristics, among 
People living with HIV on Antiretroviral Therapy in Rwanda: BMC, public health, under 
review 
 
Tumusiime DK, Stewart A, Venter F & Musenge E, 2014. The validity and reliability of 
modified lower extremity functional scale among adult people living with HIV on 
Antiretroviral Therapy, in an African environment: SAHARA Journal, under review. 
 
 
Tumusiime DK, Musabeyezu E, Mutimura E, Hoover DR, Shi Q, Rudakemwa E, 
Ndacyayisenga E, Dusingize JC, Sinayobye JD, Stewart A, Venter WDF & Anastos K, 
2014. Over-reported peripheral neuropathy symptoms in a cohort of HIV infected and 
uninfected Rwandan women: the need for validated locally appropriate questionnaires: 
African Health Science, 14(2): 460 – 467.  
 
 
 
 
 
 
 
v 
 
CONGRESS AND CONFERENCE PRESENTATIONS 
 
 
Tumusiime DK, Stewart A, Venter F, 2010, Reliability of Lower Extremity Functional 
Scale (LEFS) among African adult individuals living with HIV and on Antiretroviral 
Therapy (ART), Platform presentation, World Confederation of Physiotherapy Congress 
– Africa region; Accra Ghana 21st - 23rd July 2010 
 
Tumusiime DK, Stewart A, Venter F, 2010, Prevalence of neuropathic pain and 
associated quality of life, among people living with HIV on Antiretroviral Therapy in Kigali 
Rwanda, Platform presentation, Eastern African Physiotherapy Scientific Conference; 
Kigali Rwanda 19th   October,  2010. 
 
Tumusiime DK, Stewart A, Venter F, 2011, Prevalence of Peripheral Neuropathy and 
associated functional limitations of lower extremity, among people living with HIV on 
Antiretroviral Therapy, Platform presentation, World Confederation of Physiotherapy 
Congress Amsterdam Netherlands 21st  -  23rd  June  2011 
 
Tumusiime DK, Stewart A, Venter F, 2012, The effect of physiotherapeutic exercises 
on peripheral neuropathy, related lower extremity functional limitations and quality of 
life, among People living with HIV on Antiretroviral Therapy, Platform presentation, HIV 
and rehabilitation Symposium; School of Therapeutic Sciences, University of the 
Witwatersrand   6th  - 7th  August,  2012. 
 
 
vi 
 
ABSTRACT  
Background 
HIV-associated peripheral neuropathy (PN), and related functional limitations that affect 
the quality of life (QoL), may now be one of the most formidable challenges in the health 
care of people living with HIV (PLHIV). The most common PN is distal sensory 
polyneuropathy (DSP). It is likely that there is a high prevalence of PN among PLHIV in 
Rwanda. The available data on the prevalence of PN are poor and there are none on 
how PN is associated with functional abilities and the QoL of PLHIV, which can guide 
management. In addition, current management of PN is mostly related to symptomatic 
management and is mainly pharmacological which may not rehabilitate the 
neuromuscular function that has been affected by PN. This thesis planned to re-validate 
and adapt the lower extremity functional scale (LEFS) and the brief peripheral 
neuropathy screen (BPNS), establish the prevalence of PN, and determine the effects 
of physiotherapeutic exercises on PN,  lower extremity functional limitations and QoL, 
among Rwandan PLHIV receiving antiretroviral therapy (ART).  
Methods  
Study 1 translated LEFS from English to Kinyarwanda, modified it accordingly, and 
tested its reliability among 50 adult PLHIV on ART. The study also piloted and adapted 
the BPNS.  
Study 2 conducted cross sectional PN assessments among 507 PLHIV aged between 
18 and 60 years, on ART, randomly selected from eight Rwandan clinics.  
Study 3 tested the effects of physiotherapeutic exercises (PTExs) on PN, lower 
extremity functional limitation and QoL, in a 12 weeks randomised controlled trial (RCT). 
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One hundred and twenty PLHIV with PN on ART were randomised equally to PTExs or 
no intervention.  
Results  
Study 1: The LEFS reliability with rho ≥ 0.7 for most of the lower extremity functional 
activities was obtained.  
Study 2: The overall prevalence of PN was high at 59% [95% Cl (54%, 63%)], with 78% 
among urban and 40% in rural participants. Participants with PN had lower mean 
functional ability scores than those without PN (p<0.001). PLHIV with PN had QoL 
domain scores significantly lower than those without PN, (p<0.001); for physical, 
psychological and social relationships, (p<0.05); for environmental and general QoL 
and health satisfaction.  
Study 3: Improvements in PN symptoms (neuropathic pain [p< 0.001], PN symptom 
severity [p<0.001], and location of PNS [p<0.001]), were observed at 12 weeks in the 
intervention group compared to the control. Non-significant differences were noted 
between the intervention and control groups for PN signs; sense of vibration [p=0.26], 
and ankle tendon reflex [p=0.73]), after the 12 weeks period. All the lower extremity 
functional activities assessed were improved in the intervention group compared to the 
control group (p<0.001). Almost all facets of QoL domains improved in the intervention 
group, compared to the control group (p<0.01), with the exception of non-significant 
differences in the facet of “having enough money to meet your needs” (p=0.23).  
Conclusions 
LEFS, originally validated in the USA, was re-validated in Rwanda. This is the first 
validation of the LEFS in PLHIV on ART, from English into Kinyarwanda and the 
appropriate adaptation to a specific cultural context. It demonstrates the importance of 
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validating tools derived from developed world contexts to an African environmental 
setting. The prevalence of PN among PLHIV on ART in Rwanda is high and was higher 
in urban than in rural areas. Peripheral neuropathy was significantly associated with low 
performance of functional activities of the lower extremities, and thus resulted in poorer 
QoL. Physiotherapeutic exercises improved PN symptoms, lower extremity functional 
abilities, and almost all QoL domains. Physiotherapeutic exercises should be integrated 
into the routine management of PN and may serve as a prioritised approach in HIV and 
rehabilitation. 
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CHAPTER 1 
1.0 INTRODUCTION 
 
This chapter highlights the background of the study, problem statement, research 
questions, aim and specific objectives, the justification/significance and lastly the 
summary and outline of the thesis. 
 
1.1 Background  
Although the rate of new human immunodeficiency virus (HIV) infection declined by 
33% between 2001 and 2012, the infection is still a burden and a concern for global 
health, development and economies (Joint United Nations Programme on HIV and 
AIDS [UNAIDS], 2013). The global prevalence of people living with HIV (PLHIV) was 
estimated to be 35.3 million in 2012. The prevalence has increased as the number of 
PLHIV on antiretroviral therapy (ART) increased by 1.6 million in 2012 over 2011, in low 
and middle income countries (UNAIDS, 2013). ART has prevented PLHIV from getting 
the acquired immunodeficiency syndrome (AIDS) and saved an estimated 6.6 million 
people from AIDS-related deaths globally, between 1995 and 2012. Out of the 6.6 
million, 5.5 million people are from low and middle income countries (UNAIDS, 2013).  
 
Sub Saharan Africa is the most affected region with 23.5 million PLHIV, equivalent to 
69% of the global HIV prevalence at the end of 2011 (UNAIDS, 2012). Thus, the 
problem of HIV and AIDS is still a threatening pandemic in sub Saharan Africa. It caused 
70% of the mortality and morbidity in the region in 2011 (UNAIDS, 2012).  
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HIV and AIDS has affected the economic development and growth of various nations 
around the globe (Ogbuji and Oke, 2010; Imam et al., 2011). Data from more than 15 
sub Saharan African countries indicate that regions with a high prevalence of HIV, 
declined in educational attainment (Fortson, 2010), have effects of mortality and 
infertility, that impact on their economies (Kalemli-ozcan, 2005).  
 
Rwandan national estimates are that adult HIV and AIDS prevalence is at 3% in the 
general population (Rwanda Demographic Health Survey, [RDHS], (2010). The country 
has one of the highest national ART coverage levels in sub Saharan Africa, reaching 
an estimated 90% and above of those eligible, in December 2010 (UNAIDS, 2012). 
 
HIV and AIDS causes various health problems including neurological ones, which are 
the first manifestations of symptomatic HIV infection in approximately 20-40% of 
persons (Miura and Kishida, 2013). The neurological abnormalities is evident in about 
60% of people with progressed HIV disease, during the period of their illness (McArthur 
et al., 2005). Literature shows that peripheral neuropathy (PN) is the most frequent 
neurological complication in PLHIV (Wulff et al., 2000; Verma, 2001; Sacktor, 2002; 
Simpson et al., 2002; Luciano et al., 2003; McGurie, 2003; McArthur et al., 2005; 
Conradie et al., 2014). Furthermore, with the introduction of ART, there is a dramatically 
reduced mortality rate of PLHIV in the countries where these treatments are available 
(Iwuji et al., 2011). But because of the likely increased life expectancy and the long-
term use of ART, some chronic complications which include ART-associated PN have 
become a challenge (Morgello et al., 2004; Ferrari et al., 2006; Arendt and Nolting, 
2012).  
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Peripheral neuropathy is defined as a damage to the peripheral nerves (Torpy et al., 
2010). There are various types of HIV-associated PN which include; the “inflammatory 
demyelinating polyneuropathy, progressive polyradiculopathy, mononeuropathy 
multiplex, autonomic neuropathy, distal sensory polyneuropathy (DSP) and diffuse 
infiltrative lymphocytosis syndrome” (Wulff et al., 2000; Ferrari et al., 2006; Hahn et al., 
2010), and the most common type is DSP (Simpson et al., 2006; Ellis et al., 2010; 
Robert  et al., 2012).  
 
The prevalence of PN in PLHIV was documented to be about 30 – 67% of PLHIV with 
advanced HIV disease (Simpson et al., 2006; Ellis et al., 2010). In pre-ART patients, 
the first manifestations of symptomatic DSP is about 55% and 53% in post ART patients 
(Sarah and Nath, 2012).  
 
Distal sensory polyneuropathy therefore is said to occur in PLHIV due to two main 
causes; as a complication from HIV infection (HIV-DSP) or ART-associated toxic 
neuropathy (ATN) (Gonzalez-Duarte et al., 2008). Overall, both HIV and ART-
associated PN commonly manifest as DSP (Morgello et al., 2004; Kim et al., 2007; 
Nicholas et al., 2007; Gonzalez-Duarte et al., 2008), and because of that reason, 
“peripheral neuropathy” and “PN” is used to mean DSP for both HIV and ART-
associated PN, in this thesis except otherwise indicated.  
 
However, there are still debates on the aetiology of PN and it is said to be unclear, but 
the “neurotoxic effects of cytokines, toxicity of HIV proteins, and mitochondrial damage” 
are mentioned associated, as reported by Gonzalez-Duarte et al. (2008). Many risk 
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factors are reported to be associated with PN; such as old age, progressed HIV disease, 
and use of ART or other neurotoxic medications (Simpson et al., 2006). Antiretroviral 
drugs, namely; the nucleoside reverse transcriptase inhibitor (NRTI) drugs mainly 
stavudine (d4T); didanosine (ddI), and zalcitabine (ddC) were known causes of PN as 
one of common adverse effects (Morgello et al., 2004; Kim et al., 2007; Nicholas et al., 
2007; Gonzalez-Duarte et al., 2008). Thus, all of those drugs have been reduced or 
replaced with other alternatives from the ART regimens. Nevertheless, it is not yet clear 
whether the prevalence of PN reduced with the elimination or reduction of those ART 
drugs commonly used to cause the neuropathy. In addition, PN may occur because of 
overlapping toxicity of various drug combinations, including medication used to treat 
HIV-related complications. Symptoms of ART-PN may start immediately after beginning 
on one of the PN-causing drugs, but generally the PN occurs after taking the drug for a 
long time, for instance after months or years (Skopelitis et al., 2006).   
 
The first appearances of PN are reported as “slowly progressive numbness and 
paraesthesia, with burning sensations in the feet usually in a symmetrical pattern” 
(Nicholas et al., 2007; Gonzalez-Duarte et al., 2008). The signs of PN include reduced 
or no ankle jerks, reduced sense of vibration in the feet, reduced sense of pain and 
temperature in a “stocking” distribution, and sometimes intrinsic foot muscle weakness 
(Schifitto et al., 2002).  
 
The PN symptoms and signs, are reported as the most common causes of morbidity 
among PLHIV (McArthur et al., 2005; Dubey et al., 2013). Peripheral neuropathy affects 
functional ability and hence results in considerably compromised QoL of PLHIV (Smyth 
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et al., 2007; Ellis et al., 2010; Robinson-Papp et al., 2010; Dubey et al., 2013). With PN 
negatively impacting on the QoL of PLHIV, it may compromise their adherence to ART 
(Gonzalez-Duarte et al., 2008).  
 
According to Gonzalez-Duarte et al. (2008), the present management for PN is 
symptomatic, particularly in regard to neuropathic pain in order to preserve neurological 
function and prevent disability. Pain modifying medications are reportedly used and 
these include; the “anti-inflammatory agents, opioids, antidepressants, anti-epileptics, 
topical anaesthetics, and capsaicin” (Gonzalez-Duarte et al., 2008), but these 
medications may also have their own adverse effects. Again, studies demonstrate that 
sustained virologic control using ART is likely to improve PN. Generally, ART benefits 
PLHIV but some ARV types still lead to PN which is a painful condition (Gonzalez-
Duarte et al., 2008). Stavudine as one the main drugs that cause PN, has been reduced 
in the ART regimens. Studies have indicated that reducing d4T dosage from 40mg to 
30mg or 20mg, resulted in a reduced PN but there was a non-significant difference in 
PN between the cohort on d4T40mg and 30mg or 20mg, dosage (Pahuja et al., 2012). 
Hence, the study by Pahuja et al., (2012) concluded that PN still persists especially 
among PLHIV who have already developed it. Moreover, d4T is still used in some 
resource-limited settings because it is easily available and cheaper than the drugs that 
can  replace it (Renaud-Théry et al., 2007; UNAIDS, 2010; Pahuja et al., 2012).  Thus, 
PN may still be prevalent with its associated functional limitations and reduced QoL, 
among PLHIV. Nevertheless, there is minimal data on function and QoL in PLHIV with 
PN, to guide rehabilitation approaches in Rwanda, and probably in other developing 
settings, particularly in the sub Saharan Africa.  
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In Rwanda specifically, there are a few studies on PN among PLHIV and these have 
largely been conducted in a few selected health facilities. One of the studies showed 
that 65% to 70% of PLHIV who are on ART reported having PN related symptoms, 
which needed treatment. Such symptoms included paraesthesia, pain and numbness 
(Uwimana and Struthers, 2007). Later on, another study by Biraguma & Rhoda (2012) 
reported the prevalence of PN as 40% in one of the rural district hospital. However, 
these prevalences may be inaccurate because both studies were carried out with small 
sample sizes, each at one site only, and the tools assessed only subjective symptoms. 
Thus, there is likely increased prevalence of PN in the in the general population of 
PLHIV on ART in Rwanda, but there are poor data on the prevalence and its related 
functional limitations. This makes it difficult to develop management strategies for PN 
in PLHIV.  
 
Therapeutic exercises have been used to manage pain related to PN and other related 
neuromuscular disorders in people with diabetes (Adeniyi et al., 2010). Again, exercises 
were successful in modifying body composition and metabolic profiles, and improving 
cardio-respiratory ability in PLHIV on ART in Africa (Mutimura et al., 2008) and studies 
have shown that exercises are safe and affordable among PLHIV (O’Brien et al, 2010). 
However, to the author’s knowledge, the effectiveness of exercise in the management 
of PN and the related functional disorders in PLHIV on ART have not been well 
described. 
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1.2 Problem statement 
Peripheral neuropathy management has been hindered by insufficient data regarding 
the prevalence of PN and how it is associated with functional limitations and QoL, 
among PLHIV in Rwanda, and in other developing countries. To obtain such data, there 
needs to be a clear definition of PN and diagnostic/assessment outcome measures that 
are locally adapted and which consider the cultural and environmental differences 
between developed and developing settings, where such tools have been validated. 
Kim et al (2007) commented that without common definitions and diagnostic 
procedures, it is difficult to define the true prevalence of PN. Therefore, as a need to 
appropriately improve the management of the effects of PN on the QoL of PLHIV in 
Rwanda, the data regarding the prevalence of PN and how it is associated with 
functional limitations and QoL, using locally adapted outcome measures, are essential.  
 
In addition, both pharmacological and non-pharmacological modalities are 
recommended in the management of PN (Nicholas et al., 2007). But it is not clear and 
there is insufficient literature on how non- pharmacological modalities, such as physical 
exercise in particular are applied and effective in the management of HIV-associated 
PN and its related functional limitations. Exercise has been considered as important 
management of PN related to diabetes (Adeniyi et al., 2010) and exercises have been 
indicated to be safe and affordable in PLHIV, but it is not known how effective exercises 
are, in managing PN and the related functional disorders in PLHIV on ART, particularly 
in Rwanda. Thus, it becomes important to test the effectiveness of non- 
pharmacological management; such as physiotherapeutic exercises using RCT 
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methodology, to understand the effects of exercises on PN and its related functional 
limitations among PLHIV on ART. Health care professionals need treatment options for 
PLHIV with established PN, irrespective of the aetiology of the PN.  
 
Research questions 
1. What is the prevalence of peripheral neuropathy among PLHIV on ART HIV in 
Rwanda?  
 
2. Does PN related to HIV and ART have an effect on the functional ability and 
quality of life, among PLHIV on ART HIV in Rwanda? 
 
3. How effective is physiotherapeutic exercise in the management of peripheral 
neuropathy and its associated lower extremity functional limitations and QoL, 
among PLHIV on ART? 
 
Aims and specific objectives 
1.4.1 Aims  
1.  To establish the prevalence of peripheral neuropathy among PLHIV on 
ART in Rwanda, 
 
2. To identify the effects of peripheral neuropathy on the functional ability 
and quality of life among PLHIV on ART in Rwanda, 
 
3. To establish the effects of physiotherapeutic exercises on peripheral 
neuropathy, its associated functional limitations and quality of life, among 
PLHIV on ART in Rwanda. 
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1.4.2 Specific objectives 
1. To pilot and adapt valid and reliable outcome measures for the assessment of 
peripheral neuropathy, it’s associated functional limitations and quality of life, 
among PLHIV on ART in Rwanda, 
 
2. To establish the prevalence of peripheral neuropathy in relation to the 
demographic and health status characteristics, of PLHIV on ART in Rwanda, 
 
3. To identify the effect of peripheral neuropathy on functional ability of PLHIV on 
ART in Rwanda, 
 
4. To identify the effect of peripheral neuropathy on quality of life among PLHIV on 
ART in Rwanda, 
 
5. To test the effects of physiotherapeutic exercise on peripheral neuropathy, its 
associated functional limitations of the lower extremities and quality of life, 
among PLHIV on ART in Rwanda, 
 
6. To identify factors associated with and influencing the effects of exercises on 
peripheral neuropathy, related lower extremity functional limitations and QoL, 
among PLHIV on ART 
 
1.5 Significance of the study 
 
The re-validating and adapting of the outcome measures may contribute to appropriate 
clinical assessment and evaluation of patients with PN and related lower extremity 
functional limitations and QoL, in Rwanda, and probably other developing countries. 
This will guide an appropriate diagnosis of PN and its related disorders, thus 
establishing data on the prevalence of PN and associated lower extremity functional 
limitations and QoL. The data on prevalence may contribute to the understanding of the 
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magnitude of the PN problem in PLHIV, which will likely be a basis on which to design 
appropriate health care strategies for PLHIV on ART, in Rwanda and probably in other 
resource-limited settings.  
 
Establishing the effects of physiotherapeutic exercises on PN may help to understand 
if the exercises can be integrated into the routine management of PLHIV on ART with 
PN and the associated lower extremity functional limitations, as a non-pharmacological 
approach to rehabilitate chronic disabling conditions related to PN. Furthermore, the 
results of the studies may serve as basis for further studies; such as an in-depth study 
to understand the mechanism of the effects of therapeutic exercises on PN in PLHIV on 
ART.  
 
1.6 The outline of the thesis 
 
The thesis consists of eight chapters and three studies;  
 Chapter 1; the introduction of the thesis that highlights the general background, 
problem statement, research questions, aims and objectives, and finally the contribution 
to be made by all three studies  
 Chapter 2; the background literature review for all three studies, 
 Chapter 3; Study one (Aim 1; specific objective 1)  
 Chapter 4; Study two; (Aim 1; specific objectives; 2, 3 & 4) 
 Chapter 5; Methodology of study three 
 Chapter 6; Results of study three; (aim 3; specific objectives; 5 & 6); an intervention 
study with  
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 Chapter 7; Discussion of the results of study three, 
 Chapter 8; Summary, conclusions and recommendations from all the three studies of 
the thesis. 
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CHAPTER 2  
2.0 LITERATURE REVIEW  
2.1 Introduction 
 
The HIV and AIDS pandemic has changed from being a terminal illness to a chronic 
manageable condition with the introduction of ART. The chronic conditions and 
disorders associated with the virus and side effects of ART, include neurological 
disorders of which PN is the most prevalent one (Wolfort and Dellon, 2012; Chen et al., 
2013; Dubey et al., 2013; Gabbai et al., 2013; Ramírez-Crescencio et al., 2013). 
Peripheral neuropathy is the main focus of this thesis and is discussed in detail and 
includes; its prevalence, types, possible risk factors with attention to the PN due to HIV 
and ART that affects the lower extremities of PLHIV. The effects of PN on the functional 
ability of the lower extremities and QoL of PLHIV on ART are highlighted. The current 
management of PN and its related chronic conditions are discussed with an emphasis 
on rehabilitation approaches and the use of exercise for the improvement of QoL among 
PLHIV on ART.  
 
The information was gathered by searching  data bases such as; PubMed, Science 
Direct, Academic Search Premier, Cochran systematic reviews, PEDro, HINARI, 
WILEY online library and searching using Google Scholar.  Keywords such as HIV and 
antiretroviral therapy; effects of HIV AND neuromuscular disorders; effects of HIV AND 
treatment; side effects AND ART OR HAART; HIV and peripheral neuropathy; ART and 
peripheral neuropathy; HIV-associated peripheral neuropathy; ART and associated 
peripheral neuropathy; types of ART associated peripheral neuropathy; ART and distal 
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sensory polyneuropathy, prevalence and HIV-associated peripheral neuropathy; 
epidemiology of peripheral neuropathy; peripheral neuropathy and pathophysiology; 
pharmacological management of HIV-associated peripheral neuropathy; non–
pharmacological management of HIV-associated peripheral neuropathy; effects of 
peripheral neuropathy on physical AND functional ability; quality of life and HIV; 
exercises and HIV AND peripheral neuropathy; quality of life and HIV; peripheral 
neuropathy AND HIV and quality of life; were all used in the search. A manual search 
was also done with related references used by other studies.  
 
2.2 An overview on HIV 
 
This section gives an overview on HIV and its prevalence globally, with a focus on sub 
Saharan Africa where the impact is more severe than elsewhere in the world. The 
treatment of HIV and its access in countries in sub Saharan Africa, including Rwanda, 
are highlighted. 
 
2.2.1 Incidence and prevalence of HIV 
 
The UNAIDS report of 2012 indicates that by the end of 2011, there were approximately 
34.0 million PLHIV globally. A year later, the prevalence of HIV increased to 35.3 million 
globally (UNAIDS, 2013). The statistics show that globally, the prevalence increased by 
17% from 2001 to 2010 (UNAIDS, 2011). The UNAIDS global report of 2013 shows that 
there has been a decrease of approximately 33% in new infections since 2001 
(UNAIDS, 2013). Though the rate of new HIV infection has decreased globally the 
overall number of PLHIV continues to increase mainly because of the ART programme 
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success. UNAIDS (2011) shows that the HIV and AIDS pandemic is found globally but 
its distribution is different with some countries having a higher distribution than others. 
More than 80% of the affected populations globally are found in developing countries.   
 
Sub Saharan African is still the region mostly affected by HIV (UNAIDS, 2013). About 
68% of all PLHIV lived in sub Saharan Africa in 2010, which has only 12% of the global 
population. Sub Saharan Africa was affected with 70% of new HIV infections in 2011. 
Women in sub Saharan Africa are more (60%) affected than men. The women in this 
region are more vulnerable than men for various reasons; such as being poor, violence 
against women such as rape, lower education levels which gives them less economic 
security, and less decision making for their protection (“WHO | Gender inequalities and 
HIV”, n.d. & Wabiri and Taffa, 2013). The age range of 15 to 35 years is the most 
affected with HIV and AIDS in sub-Saharan Africa. Around 80% of the infected group 
are aged 20 – 29 years (Onokerhoraye et al., 2012).  
 
2.2.2. Incidence and prevalence of HIV in Rwanda  
 
The HIV prevalence in Rwanda has declined over the past few years. The country’s 
national estimates for HIV prevalence decreased from 12.8% in 1998 to 5.2% in 2004 
(Kayirangwa et al., 2006), 3% in both 2005 and in 2010, according to the Rwanda 
national health demographic survey that is usually carried out every five years (2010). 
The prevalence is higher in urban areas (7.1%) than in rural areas (2.3%). The HIV 
prevalence is distributed differently between genders; 3.7 % for women and 2.2 % for 
men. Again, the widows and the divorced or separated people have the highest HIV 
prevalence of 16.6% (RDHS, 2010). The HIV prevalence also is differently distributed 
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by age groups; with highest among women aged 35 – 39 and men age 40 – 44 years. 
Kigali City also has the highest HIV prevalence of 7.3% among the adults age 15 – 49 
years.  
 
2.2.3 The HIV AND AIDS impact 
 
Globally, the HIV and AIDS epidemic had killed almost 30 million people by the end of 
2011 (UNAIDS, 2012). About 1.2 million people died in sub Saharan Africa in 2011, 
which is  equivalent to 70% of all AIDS-related global deaths (UNAIDS, 2012). UNAIDS 
(2011) reported that approximately 16.6 million children were orphaned in 2010 due to 
HIV and AIDS. The UNAIDS (2012) report shows that since 1998 about one million 
people have died annually due to HIV and AIDS in sub-Saharan Africa.  
 
However, since 2002 the deaths related to HIV and AIDS decreased steadily, as a result 
of the availability of free ART in the region (UNAIDS, 2013). Nevertheless, the impact 
of HIV still prevails. The HIV and AIDS pandemic has become a major challenge to 
health, development and humanity (UNAIDS, 2013), with more people currently living 
with HIV, largely because of increased access to HIV treatment (UNAIDS, 2013). A 
study by Hosegood (2009) indicates that the demographic impacts of HIV and AIDS in 
sub Saharan Africa are numerous such as breaking up of family and household 
structures, reduced fertility and reproduction, marriage breakdown, union instability in 
couples, as well as widow and orphan headed families. HIV in sub Saharan Africa 
continues to cause negative effects and the major challenges are the long term socio-
demographic, economic and health effects that lead compromised QoL of PLHIV 
(Hosegood,  2009).  
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Like any other developing country in sub Saharan Africa, Rwanda faces the impact of 
HIV which include the loss of active labourers (Bitran et al., 2003). This is probably due 
to the fact that HIV prevalence is higher in working than non-working men (RDHS, 
2010). The education sector has also been affected with HIV and AIDS through loss of 
teachers. Kinghorn and colleagues (2003) projected a loss of 2500 teachers in Rwanda 
during the 21st century. An increase in the number of orphans of (0 – 16) years was 
projected to increase from 64,000 in 2003, to 208,000 in 2015. Economically, the 
increase in dependants at the family, community and national levels reduces manpower 
and increases health expenses (Kinghorn et al., 2003). HIV in Rwanda also is reported 
to be higher in educated women than those without education (RDHS, 2010), which 
also impacts on employed people thus reducing work productivity (“The Effect of HIV 
and AIDS on Society,” n.d.). But the reasons to why higher educated women are more 
affected with HIV than those with less educated are not well documented. The health 
sector has been affected, more especially with challenges of managing the HIV related 
health conditions.  
 
2.2.3 HIV and treatment  
 
ART has dramatically changed the experience of PLHIV (O’Brien et al., 2010), and the 
nature of HIV illness (Ryder et al., 2012). HIV-related health conditions appear now as 
chronic ones with features of changing incidents of normal health and sickness instead 
of illness that used to end in steady advancement to death (Ryder et al., 2012).  By 
December 2012, an estimated 9.7% million PLHIV were on ART in low and middle-
income countries, with an increase of 1.6 million in 2011 (UNAIDS, 2013). As ART 
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becomes increasingly important and accessible, reduction of the long-term morbidity 
and mortality in PLHIV has become more of a focus. Accessibility and adherence to 
available ART improves the standard of care of PLHIV (Scanlon and Vreeman, 2013). 
Nevertheless, access to ART still differs in different resource-limited settings. The 
universal access is defined as 80%, or greater coverage. In some countries the access 
to treatment is above the 80%. Such countries include; Botswana, Namibia and 
Rwanda, with Rwanda having more than 90% of people eligible for ART, on it (RDHS, 
2012), while Swaziland and Zambia are reported to have reached between 70% and 
80% of ART coverage levels of the eligible people (UNAIDS, 2011). It is reported that 
the introduction of HIV treatment in sub Saharan countries has dramatically reduced 
AIDS-related mortality (UNAIDS, 2011). In general, ART has been shown to decrease 
the infection and has likely contributed to the reduced HIV new infection rate, which has 
been reduced by more than 50% in most sub Saharan African countries (UNAIDS, 
2012).  
 
2.2.4. HIV treatment in Rwanda  
 
In Rwanda, the government and donors provide support to the population through 
provision of HIV and AIDS health services, aiming to scale-up HIV and AIDS service 
provision and access to ART for all eligible PLHIV. This is purposely to give appropriate 
healthcare and treatment to those living with the infection and prevent particularly new 
infection.  
 
As mentioned earlier, more than 90% of PLHIV who are eligible for ART, are on it in 
Rwanda. The country had attained one of the highest national ART coverage level in 
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sub Saharan Africa by December 2010 (UNAIDS, 2010). ART access has increased 
progressively since 2002 in Rwanda as indicated in Figure 1 below;  
 
 
Y-axis = Number of patients, X-axis = Period in years 
Figure 1 : Progressive increase and accessibility ARVs to PLHIV in Rwanda (RBC, 2013) 
 
2.2.5 HIV treatment guidelines in Rwanda  
 
Like any other countries with limited resources, Rwanda uses most of the ART drugs 
recommended by the WHO. The WHO indicates that the most commonly used ART 
drugs in poor resource countries are those that it recommends. The drugs mainly 
comprise of; “NRTIs; AZT, 3TC, and d4T and NNRTIs; NVP and EFV” (WHO, 2006; Hill 
et al., 2007). However, d4T has been replaced with TDF recommended by the new 
WHO guidelines (WHO, n.d.). But, the d4T is one of the most potent causes of PN 
(Scarsella et al., 2002; Subbaraman et al., 2007 & Agu and Oparah, 2013), and was 
used in Rwanda before its replacement with TDF recently (RBC, 2011). Although d4T 
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has been reduced or replaced in the ART regimen, it was a first line antiretroviral in the 
Rwandan programme prior to 2011. In addition to d4T having the adverse effect of PN, 
the drug has other several adverse effects including lipoatrophy, lactic acidosis and 
hepatic steatosis (Gallant, 2012). With the cessation of the use of d4T in the first line 
ART regimen since 2011 for new eligible people, Rwanda currently uses the regimen 
combination comprised of: TDF+FTC/3TC+NVP/EFV or ABC+3TC+NVP/EFV; AZT and 
PIs are reserved for second line therapy and Etravirine + Darunavir + Raltegravir for 
third line ART regimen (Rusine et al., 2013). The ART guidelines shifted mainly from 
D4T+3TC+NVP in 2011 to TDF+3TC+EFV, as the first recommended in the first line 
regimen (RBC, 2011). 
 
2.3 Effects of HIV and ART 
 
2.3.1 General effects 
 
Previously, HIV and AIDS was a disease with progressive, weakening and fatal illness 
without applicable management and ended into sudden failing in health resulting to 
death (Gaidhane et al., 2008). But from the last two decades, HIV treatment has 
tremendously altered the survival rate of PLHIV (“Recent developments in the HIV 
neuropathies,” n.d.; Tehranzadeh et al., 2004a; Anderson et al., 2006; Louwagie et al., 
2007). PLHIV are now able to strive for fulfilling and meaningful lives (Hsiung et al., 
2005).  HIV/ AIDS is no longer an end point to death or the starting up of losses of 
employment or family life (Phaladze et al., 2005). Consequently, ART returned life 
expectancy to near normality. However, although the mortality and morbidity rates have 
been reduced with the introduction of ART, morbidity still prevails. This is because of 
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several significant adverse effects from HIV infection and its associated treatments 
(Tehranzadeh et al., 2004; Vidrine et al., 2003; Worthington and Krentz, 2005), that 
more people live with for such a long time. Living longer with HIV and AIDS and its 
numerous complications associated with both the virus as well as the drugs used to 
treat it, including the neurological ones were found to be the major causes of morbidity 
(McArthur et al., 2005).   
 
Peripheral neuropathy is reported to be the most prevalent among the neurological 
complications of HIV infection and ART (Lichtenstein et al., 2005; McArthur et al., 2005; 
Dorsey & Morton, 2006; Ferrari et al., 2006; Cherry et al., 2009; Hammersla and 
Kapustin, 2012; Cettomai et al., 2013; Chen et al., 2013; Dubey et al., 2013; Gabbai et 
al., 2013 & Theroux et al., 2013). A study conducted in Tanzania, demonstrated that the 
most reported adverse drug reactions among patients using ARVs were; anaemia, liver 
toxicity, skin rashes and PN (Minzi et al., 2009). The study indicated that PN was 
reported more frequently among participants taking d4T40mg than d4T30mg, twice 
daily, as was previously shown by a systematic review by Hill et al. (2007). Though the 
d4T dose was reduced, Pahuja et al. (2012) still reported that patients on d4T30mg 
twice daily had a high risk of developing PN which can lead to disability. The same 
authors indicated that the PN cannot be reversed in most cases unless the offending 
drug is replaced. Thus, the revised 2006 WHO guidelines recommend replacing d4T 
with TDF from first-line ART regimens (WHO, 2006). But (Walensky et al., 2010) 
showed that the implementation of the guidelines might not be possible in some poor 
resource-limited settings, suggesting that d4T is likely still used in those countries.  
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Since, PN has been indicated as the most prevalent neurological complication of HIV in 
the era of ART (McArthur et al., 2005 & Cettomai et al., 2013), this literature review 
focusses on and discusses PN in details in the following sections. 
 
2.3.2 Peripheral neuropathy and its definition  
Peripheral neuropathy is briefly defined as damage to the peripheral nerves, through 
injury, inflammation, or degeneration of the peripheral nerve fibres (Magrinelli et al., 
2013). Anatomically, the peripheral nerves denote the nerves outside the brain and 
spinal cord and comprise of motor, sensory and autonomic nerve fibres (“Central 
Nervous System Anatomy,” 2013). “Neuropathies are segmented into motor, motor and 
sensory, and pure sensory categories, depending on the fibre classes affected” 
(Magrinelli et al., 2013). Sensory neuropathies are said to be as result of sensory nerves 
being affected (Robinson et al., 2011; Kamerman et al., 2012). Mostly, the sensory 
neuropathies affect the lower extremities, and the feet and legs more, than the hands 
and arms (Cherry, Wesselingh, Lal & McArthur, 2005).  
 
2.3.3 HIV-associated PN 
Different types of PN include; “inflammatory demyelinating polyneuropathy, progressive 
polyradiculopathy, mononeuropathy multiplex, autonomic neuropathy, DSP and diffuse 
infiltrative lymphocytosis syndrome” (Wulff et al., 2000; Keswani et al., 2002). The most 
common HIV-associated PN is reported to be the DSP type. The HIV-associated DSP 
is said to occur usually in the last phases of HIV disease (Evan, et al., 2012). Symptoms 
and signs of HIV‐associated sensory neuropathies, particularly DSP and ART-ATN, are 
almost the same. These two (DSP and ATN) neuropathies are not easily distinguished 
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(McArthur et al., 2005) and are the most common types of HIV-associated neuropathy 
and commonly appear in combination in PLHIV on ART. As stated earlier in Chapter 
one ‘peripheral neuropathy’ or ‘PN’ is used to mean DSP and ATN in this review of the 
literature and in the rest of the thesis, except where differently mentioned.  
 
The symptoms of ART-associated PN, which are fundamentally indistinguishable to the 
syndrome of PN related to HIV infection, consequently puzzle the diagnosis and 
management of PN (Simpson & Cikurel, 2006). Differentiating the neuropathy related 
to HIV from PN related to ART can done by “investigating the sequential association of 
symptoms with initiation of ART, clinical or electrophysiological improvement after dose 
reduction or drug discontinuation, plus the ‘coasting effect’ from which the symptoms 
progress for two to four weeks after stopping the medication, followed by clinical 
improvement”, as reported by Simpson & Cikurel, (2006). Additionally, the ART-PN is 
likely more painful than the HIV-induced PN, has a sudden beginning, and advance very 
fast (Nicholas et al., 2007a). 
 
2.3.4 Prevalence and incidence of HIV-associated PN 
Certain contradictions exist, some studies indicate that the problem of PN has been 
reduced since the introduction of ART (Maschke et al., 2000) but others demonstrate 
that the ART-associated PN continues to be prevalent (Morgello et al., 2004; McArthur 
et al., 2005; Smyth et al., 2007; Milogo et al., 2008; Evans et al., 2011). The ART-
associated PN was mostly related to the d-drugs; ddI, ddc and d4T (Lichtenstein et al., 
2005), but it is not yet clear if the discontinuation of neurotoxic drugs such as d4T has 
reduced the prevalence of PN (Pahuja et al., 2012). In developing countries, the 
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prevalence of PN has been reported as 20%-50%, (Oshinaike et al., 2012), in some 
studies while others report 30% - 67% (Wulff et al., 2000).  
 
The prevalence of PN in African countries was shown in the 90’s to range from 15 % - 
56% (Parry et al., 1997). Recent studies demonstrate the prevalence as; 21% in 
Cameroon (Luma et al., 2012), 45% in Guinea-Bissau, (Choi et al., 2011) and a range 
of 24.4% - 57% in South Africa (Maritz et al., 2010; Wadley et al., 2011; Conradie et al., 
2014), 21.3% - 44% in Malawi (Tapsfield et al., 2011; van Oosterhout et al., 2012 & 
Kampira et al., 2013) and 21.9% - 36% in Kenya, (Mehta et al., 2010; McGrath et al., 
2012).  
 
In Rwanda, there is insufficient data on the prevalence of HIV-associated PN at a 
national level. To my knowledge, there are only two studies that were conducted by 
Uwimana and Struther (2007) and by Biraguma and Rhoda (2012). Both of these 
studies were conducted in single health centre, and with small sample sizes. However, 
the studies indicated that the prevalence of PN ranged from 65 to 70% (Uwimana & 
Struther, 2007) and 40% (Biraguma & Rhoda, 2012). This leaves a gap in the data on 
the prevalence of PN at national level and from both rural and urban settings in Rwanda. 
The gap may hinder management strategies for PN and associated co-morbidities. 
 
The following Table 1 indicates a summary of some studies done from different 
settings and reported PN prevalence. 
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Table 1 : A summary of prevalence of HIV-associated PN in adults; by different studies  
 
Study areas, participants and the sample Definition, methods of 
assessment tool 
Prevalence   Reference  
A cross sectional study among 187 
outpatient PLHIV attending one rural district 
hospital of Rwanda 
PN symptoms were screened with 
Subjective Peripheral Neuropathy 
Screen. Was not clear of how 
diagnosis of PN was confirmed.    
40.5% Biraguma & 
Rhoda, 2012 
A cross sectional study among 295 adult 
PLHIV patients at Douala general hospital 
in Cameroon  
Used BPNS to screen HIV – SN, 
where by the neuropathy was 
defined as presence of 
neuropathy symptoms and at 
least an abnormal perception of 
vibration sense or reduced ankle 
tendon reflex 
21% had HIV 
– SN 
Luma et al., 
2012 
Participants in an ART – naïve who initiated 
ART were annually screened for symptoms 
and signs of PN: USA 
Brief Peripheral Neuropathy 
Screen (BPNS) was used to 
screen at least mild loss of 
vibration in the both great toes 
and hypoactive ankle reflex 
bilaterally. 
32.1% after 
three years on 
ART 
Evans et al., 
2011 
Cross sectional data of 1539 PLHIV in USA Neurological clinical signs and PN 
diagnosed with at least one sign 
with BPNS 
57% with 
signs and 
61% with 
signs and 
symptoms 
Ellis RJ et al., 
2010 
A cross sectional PN screening of 102 
Patients receiving ART in Mombasa, Kenya 
PN was determined with a 
combination of at least one 
symptom grade > 0 and one 
bilateral sign, assessed with 
BPNS 
36% Mehta et al., 
2010 
In a large randomised controlled trial of 775 
PLHIV, from 12 sites in USA  
Peripheral neuropathy was 
examined wit revised signs and 
symptoms checklist  
44% Nicholas et 
al., 2010 
A 2 week cross sectional comparative study 
using a convenient sample of 100 adults with 
HIV in Melbourne, Australia 
One or more PN symptoms 
together with at least one sign; 
either reduced vibration sense or 
42%  Smyth et al., 
2007 
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reduced ankle jerk, screened with 
BPNS  
A cross sectional data was analysed from 
PLHIV on ART (d4T, 3TC and NVP), in a 
home-based AIDS care program in rural 
Uganda 
Assessment tool not clearly 
mentioned 
36 % had PN Forna et al., 
2007 
101 adults with advanced HIV were 
evaluated for DSP over 48 weeks  
Screening done with BPNS  52 % with 
DSP 
Simpson et 
al., 2006 
2515 HIV Outpatients were tested for 
symmetrical peripheral neuropathy, in 7 
cities of USA. 
Clinical evaluation in a cohort 
sample; Tools used not 
mentioned 
13.1%  Lichtenstein et 
al., 2005 
49 HIV positive adult patients in Brazil were 
clinically evaluated over a period of 17 
months 
Isolated or combined impaired 
sensory, absent deep tendon 
reflex were assessed 
69.4% Zanetti et al., 
2004 
Clinical examinations were performed 
among randomly selected PLHIV at 
different stages of the disease, in Zimbabwe  
Nerve conduction with 
electrophysiological procedures 
44% to 56% Parry et al., 
1997 
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2.3.5 The pathophysiology, causes, and risk factors of HIV-associated PN 
 
The pathogenesis of PN is reported to be multifactorial, and is still unknown (Nicolas et 
al., 2007b). The pathophysiology is mentioned to have “three specific mechanisms; 
dying back or axonal degeneration of long axons in distal regions, loss of unmyelinated 
fibres, and an adjustable degree of macrophage infiltration in peripheral nerves and 
dorsal root ganglia” (Pardo, McArthur and Griffin, 2001; Laast et al., 2011).  
 
According to Simpson & Cikurel (2006a), the ART drugs particularly the NRTIs are 
reported to restrict the DNA synthesis and cause mitochondrial defects which are 
connected to the demonstration of the PN symptoms. The driving force for the 
occurrence of PN is said to be the mitochondrial toxicity and its powerful pathogenic 
responsibility in various organ system toxicities (Simpson et al., 2006b), in PLHIV on 
ART. But this has been reported as a hypothetical theory which is still a subject of 
discussion, according to the same authors. However, Kallianpur and Hulgan, (2009) in 
their study on the pharmacogenetics of NRTI-associated PN, confirmed that there is 
evidence of ART-associated PN partly as a result of the drug induced mitochondrial 
dysfunction. Additionally, a review by Kamerman et al. (2012) reported that the 
sequence of those events of the mitochondrial dysfunction that results in 
hypernociception,   is still not clear. Nonetheless, the neurotoxicity of some of the NRTIs 
affecting the mitochondria function has been implicated (Kamerman et al., 2012). 
Conclusively, the ART-associated PN is increasingly demonstrated as a result of the 
toxic effect of drugs that possibly cause mitochondrial injury and dysfunction (McArthur 
et al., 2005; Kamerman et al., 2012). On the other hand, PN can be caused directly from 
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the HIV-infection to the neurons, and opportunistic infections of neurons due to 
generalized immunosuppression (McArthur et al., 2005;  Keswani et al., 2006; 
Kamerman et al., 2012; Moss et al., 2012 & Mangus et al., 2014) 
 
Generally, PN frequently is reported as the most common complaint among PLHIV 
receiving ART in resource limited settings (van Oosterhout et al., 2005; Boulle and Ford, 
2007; Forna et al., 2007). Various studies indicate these risk factors for PN as; old age 
and neurotoxic ARV drugs (Smyth et al., 2007; Shurie and Deribew, 2010; Wadley et 
al., 2011). Other factors reported as predisposing include; diabetes mellitus, 
malnutrition, isoniazid exposure, ethnicity and increased height (Kamerman et al., 
2012). In addition, Robinson-Papp et al. (2012) showed that substance or drug abuse 
and long periods of HIV infection are influencing factors for PN.  
 
Peripheral neuropathy is said to be the most prevalent adverse effect leading to the 
regimen changes among PLHIV in sub Saharan Africa, (Mehta et al., 2010). The same 
authors showed that though d4T has been known to be the most common risk factor for 
developing PN in PLHIV on ART, there are likely other factors that contribute to the 
presence of PN among PLHIV. These factors are said to include; nutritional deficiency, 
toxic effects of anti- tuberculosis medication, alcoholism, diabetes, and HIV-infection 
itself (Mehta et al., 2011). The pre-ART studies indicate that advanced 
immunosuppression, shown by reduced CD4+ cell counts and increased HIV viral load 
increased the risk and severity of neuropathy in PLHIV (Lichtenstein et al., 2005). ART 
reduces viral load and increases CD4+ cell counts (Iwuji et al., 2013). Controversially 
however, ART has been found to lead to an increased prevalence of neurologic 
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conditions particularly ART-associated PN in long-term survivors of HIV disease (Evans 
et al., 2011). There is a pool of evidence that PN has not declined in frequency, even in 
the ART era, particularly in recipients of d-drug ARV regimens (Smyth et al., 2007); 
Oshinaike et al., 2012). PLHIV have an improved life expectancy because they are on 
ART, and in some cases have long periods of PN, and this has increased the prevalence 
of PN (Evans et al., 2011).  
 
Peripheral neuropathy has become the main neurological adverse effect of ART, and 
people at any stage of HIV can be affected. Peripheral neuropathy was demonstrated 
to appear throughout the range of HIV disease and its occurrence has been augmented 
because of extended survival rates and the development of ART (Dorsey & Morton, 
2006). Contrarily, Schiftto et al. (2005) indicated that ART reduces disease 
advancement, improves  immunity, and extends the proportion of therapeutic to toxic 
effects of individual ARVs, causing a lower possibility of evolving PN, but PN has not 
decreased since ART was introduced (Simpson et al., 2006). Such conflicting findings 
probably suggest the presence of other influencing factors that enhance or prevent the 
development of PN. People are probably living longer, and have more time to develop 
PN, whether associated to viral, ART or other factors.  
 
Dalakas (2001) indicated that ddC is one of the medications that increase the risk of PN 
in PLHIV. However, recent studies have also indicated that PN has remained 
unchanged even in the reduction of all d-drugs from the ART regimens (Oshinaike et 
al., 2012). This generates research questions such as whether PN is mainly associated 
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with HIV itself and or with most of the ARV types in the ART regimens, rather than d-
drugs alone.  
 
The prevalence of PN rises as CD4 cell count drops (Lichtenstein et al., 2005). A similar 
relationship was confirmed in the study by Evan et al. (2012) in which patients with PN 
at ART initiation presented more progressive HIV disease than those without PN. Such 
associations suggest that a patient with low CD4 counts may not suffer from PN related 
to HIV alone, but also from neurotoxicity or other associated conditions. Hence, the risk 
of developing PN increases at starting stages of ART, and more specifically when 
therapy is initiated in patients with low CD4 counts (Lichtenstein et al., 2005).  
 
2.3.6 Symptoms, signs and progression of PN 
 
Peripheral neuropathy manifests symptomatically with pain and paraesthesia in a “stock 
and glove distribution” and dysaesthesia in the feet, as demonstrated by Hung et al. 
(2008). The studies by Dalakas (2001); Simpson and Cikurel (2006), highlight that 
PLHIV experiencing PN can present with various complaints; such as the earliest 
symptoms of PN that include; “pain, numbness, and tingling in the hands and feet in the 
classic ‘stocking and glove’ distribution”. In their study on controlling neuropathic pain 
in HIV, Verma et al. (2005) showed that neuropathic pain comprised of about 25% to 
50% of all visits at their pain clinic. The study further explained that some people 
express changed “sensation when picking up objects, as if their fingers are made of 
‘plastic’, or feeling as if their hands and feet are ‘falling asleep’. Furthermore, the 
patients may also complain of their feet “throbbing or cramping at night or of stumbling” 
30 
 
when they try to walk. Additionally, the symptoms are said to be largely symmetric, even 
though are likely to be more severe on one side. In cases of severe neuropathy, it is 
described that touching the affected extremity can feel like “an open wound is being 
touched”. Additionally, the study by Simpson & Cikurel (2006) found that several 
patients have no any symptoms or PN mild at start. One of the studies conducted at 
one of the ART clinics in Rwanda, by Uwimana & Struthers (2007) found that the 
numbness and paraesthesia in the hands and feet were the most common symptoms 
among PLHIV. Other reported clinical features of PN were increased vibratory 
thresholds, reduced pinprick, and sense of temperature in the stock and glove 
distribution.  
 
The PN symptoms are shown to advance constantly, or can be worse very fast within a 
time frame of days or weeks (Schifitto et al., 2002; Evans et al., 2012). Altered 
sensations and pain progress in a pattern starting with the toes and soles of the feet; 
then, the symptoms may spread to the ankles, as nerve injury continues, in most PLHIV 
(Evans et al., 2011). Progressed PN symptoms are mostly characterised by painful 
sensation, which can easily be elicited with any touch to the affected part of the limb. 
Such touch may include socks, bed sheets, or shoes, and this usually results into 
embarrassment. In the most advanced stages of PN, the upper extremities may also be 
affected with involvement of the fingers, hands, and wrists. When PLHIV with PN are 
asked to explain their symptoms, it is said that the most common descriptor used is 
pain, then numbness, tingling, burning, and stinging (Nicholas et al., 2002). Muscle 
strength and joint position sensation are reported usually to be normal. Symptomatic 
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weakness occurs late during the disease and is largely restricted to the distal intrinsic 
foot muscles (Schifitto et al., 2002).  
 
2.4 Effects of PN on lower extremity functional ability 
 
HIV and its treatment are known to have complications and effects on body systems 
and particularly on the neuro-musculoskeletal system (McGuire, 2003; Luciano et al., 
2003 & McArthur, 2005). The chronic conditions as side effects and complications of 
HIV and ART have resulted in functional limitations or difficulties with mobility, impaired 
self-care and pain which are commonly reported in various studies (Rusch et al., 2004; 
O’Brien and Nixon 2010).  
 
The study by Van As et al. (2009) indicated a significant association between pain 
related to PN of the lower extremities in PLHIV, and functional activity limitations. The 
sensory loss and pain; which are commonly major symptoms and signs of PN, were the 
most common (71%) of the impairments identified by Van As et al. (2009), among 
PLHIV. The same authors described the impairments of sensation and pain as strong 
predictors of the mobility problems affecting PLHIV. Similarly, the neuropathic pain as 
one of the symptoms of PN was found to be strongly associated with limitations of daily 
activities and thus a major influencing factor for disability among PLHIV (Ellis et al., 
2010). The functional limitations as a result of PN among PLHIV are various and 
therefore may point to the need to concentrate on individualized efforts in dealing with 
the problem (Sandoval et al., 2013).  
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2.4.1 Relationship between PN, lower extremity functional limitations and QoL 
 
HIV and its associated health conditions are now increasingly viewed as chronic, long 
term conditions with functional limitations rather than as a terminal illness (Worthington 
et al., 2005; Mkanta and Uphold, 2006). These functional limitations likely result in 
disability if not dealt with. However the understanding of the limitations is still a 
challenge. O’Brien, et al. (2008) stated that disability is conceptualised by PLHIV, as 
being multi-dimensional and occasionally with features of irregular phases of normal 
health and sickness. Consequently, HIV infection and its treatment have potentially 
resulted in a variety of functional limitations which may be the patient’s primary problem 
(Zonta et al., 2003), which likely influence poorer QoL. A study conducted in Brazil 
among PLHIV to evaluate functional disabilities confirmed that the majority of patients 
(91%) presented with some degree of functional limitations that predicted poorer QoL 
(Zonta et al., 2003) 
 
Improvements in functional ability and wellbeing are essential outcomes of the 
management of HIV and should be measured regularly (Hsiung et al., 2005; Jelsma, 
2009). The demand on the management will place greater emphasis on maximizing 
patients’ individuality, diminishing the functional limitations and improving the patient’s 
functional ability thus contributing to their improved QoL (Anderson, 2006). Health care 
professionals are challenged in assisting PLHIV to adapt to the living longer with HIV 
and AIDS and its complications (Phaladze, et al., 2005). This is because living longer 
with HIV and AIDS has associated disabling conditions. The involvement and 
empowering of the community to develop management strategies, using affordable 
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approaches, is essential. The preventive measures for such disabling conditions like 
PN that is common with the chronicity of HIV should be the goal in the rehabilitation of 
PLHIV. Thus, the potential to enhance QoL is increased through providing interventions 
that will meet the essential functional needs to ensure reasonable QoL of PLHIV 
(SOWELL et al., 1997; Crystal et al., 2000). 
 
2.5 Quality of life of PLHIV with PN  
2.5.1 An overview on QoL 
 
Various studies have defined and described QoL in terms of being both objective and 
subjective. The objective QoL has been shown to include; “income, living situations and 
physical functioning while subjective QoL includes individual’s perception of important 
life domains and satisfaction with those domains” (Njoki et al., 2007). Furthermore, a 
study by (Casado et al., 2004) described an operational definition of QoL as a complex 
and multidimensional concept which is difficult to define and measure. Casado (2004) 
continued to describe the QoL as a term which is universally used to give an overall 
sense of wellbeing and that includes aspects such as happiness and satisfaction with 
life as a whole. The QoL in clinical settings may be defined as a condition with specific 
symptoms; “body discomfort, social and role functioning, overall perception of health, 
cognitive status, and general well-being”. While in research, the QoL tools give new 
understandings into the nature of disease by measuring how disease weakens or 
influences the subjective well-being of a person throughout entire range of daily 
activities (Hakuzimana, 2005). There are other influences including demographics, 
personality, economic status, environment, and social relationships that impact on QoL 
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(Hakuzimana, 2005). Thus, the negative results of the disease and its treatment 
represent a single category of influences, but there other many influences or factors of 
QoL.  
 
2.5.2 Quality of life and HIV AND AIDS 
 
PLHIV are found to have lower scores on QoL which deteriorates along with a 
cumulative number of symptoms (Herrmann et al., 2013). Extensive studies on QoL 
among PLHIV have been done, and some have attempted to both assess QoL and 
determine predictors for good or poor QoL (Mweemba et al., 2009). PLHIV are not only 
concerned with a treatment’s ability to extend life but also with the QoL they are able to 
lead (Basavaraj et al., 2010). Quality of life for PLHIV is increasingly becoming 
important, as therapy should not only be concerned with suppressing the virus, reducing 
symptoms and extension of survival but also be concerned with improving QoL 
(Oguntibeju, 2012). PLHIV experience numerous symptoms due to the disease, side 
effects of medication and co-morbidities and have severe symptoms. Thus, the QoL of 
PLHIV is associated with disease stage and disease symptoms, hence with proper 
management of HIV and AIDS symptoms, improves the QoL (Gakhar et al., 2013). 
 
The concept of QoL in PLHIV has received increased attention in the literature, and it is 
recognized that HIV illness impacts on all aspects of patients’ lives (Worthington and 
Krentz, 2005). As stated by (Yen et al., 2004), QoL levels of PLHIV are different 
according to the method used to measure it. The same authors found that male 
outpatients who presented fewer HIV symptoms had medium QoL levels using the 
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WHOQOL-BREF. Higher QoL scores are found among asymptomatic PLHIV compared 
with symptomatic ones and with an AIDS diagnosis (Imam et al., 2011).  
 
There are various results on the relationship of ART and QoL in different studies 
regarding improvements made (Oguntibeju, 2012; Wen et al., 2013; Gakhar et al., 
2013). The long-term use of ART has positive effects on controlling the disease, 
prolonging survival, reducing incidence and mortality rates (Oguntibeju, 2012), 
moderating the symptoms due to HIV-infection, and slowing the development of AIDS, 
and hence improving the QoL. Therefore, considerable improvements in the QoL of 
symptomatic HIV subjects have been noted on QoL measures following ART (Margalho 
et al., 2011). However, some consequences of ART on the QoL were reported by some 
studies such as direct toxicity (Oguntibeju, 2012) that is highlighted to likely cause PN. 
This is likely to result in more morbidity consequences of the PN if appropriate 
management approaches are not put in place. 
 
2.5.2.1 Factors affecting QoL of life among PLHIV 
 
Differing results has been reported, particularly when determining predictors of poor 
QoL. Variables, such as; female gender, older age, close family members or friends, 
stigma and marital status are among the sociodemographic and psychosocial, variables 
that have been associated with lower QoL in PLHIV (Subramanian et al., 2009), while 
higher income and employment have been associated with better QoL (Viswanathan et 
al., 2005). Also, studies have found that employed PLHIV, have significantly higher 
overall QoL than unemployed PLHIV (Rueda et al., 2012).  
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In regard to gender as a socio-demographic factor, low performance for women in some 
aspects of QoL is documented (Vigneshwaran et al., 2013) and married women are said 
to be more vulnerable than men to interruptions in their QoL (Thomas et al., 2009). 
Married women are likely to have more sexual disruptions over time than men and also 
sexual relationship discontinuation in women is documented more frequent than in men 
(Thomas et al., 2009).  
 
Younger age is reported to be related to better QoL, as opposed to old age (Skevington, 
2012).  It is reported that adult people of 35 and above years are likely to suffer from 
more depression and other psychological symptoms that compromise their QoL, than 
the young (Basavaraj et al., 2010). When comparing educated and less educated 
groups, the findings show that those with low levels of education have significantly 
poorer QoL than those with higher levels of education (da Silva et al., 2013). 
Nevertheless, few studies have documented the QoL of PLHIV who have PN. The few 
that are available on QoL and PN, according to the domains of QoL, are discussed 
below.  
 
2.5.2.2 Physical health domain of QoL 
 
The physical health domain of QoL is described to assess the effects of disease on the 
daily living activities, dependence medications, deficiency of energy and creativity, 
mobility limitations and work capacity (Skevington et al., 2004; Wig et al., 2006). 
Physical health gives an individual the ability to perform and adapt to the environment. 
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The domain is estimated by an individual’s perceptions of “energy and fatigue, pain and 
discomfort, sleep and rest”. There is a confirmed association found between the 
physical health domain and overall QoL. In cases where physical status with high levels 
of physical activity, perceptions were that physical health and QoL were more positive 
(Pucci et al., 2012).  
 
HIV infection affects various domains associated with physical health since frequent 
illness and increasing fatigue affect the individuals’ ability to perform employment 
related and routine activities (Kohli et al., 2005). Jenkin et al. (2006) demonstrated that 
fatigue is common in PLHIV and may affect one’s functional activity level. As a result, 
symptoms of fatigue and pain often lead to limitations in leisure time and physical 
activities (Harmon et al., 2008). PLHIV experience problems with physical function and 
activity limitations (Van As et al., 2009). However, there are few studies on the QoL of 
PLHIV with PN; it is likely that their QoL is worse than those without PN. One of the 
studies conducted in one district hospital in Rwanda demonstrated that PLHIV with PN 
had lower physical health QoL (Biraguma and Rhoda, 2012).  
 
2.5.2.2.1 Factors affecting the physical health QoL 
 
Certain factors such as occupation and education were shown to affect the physical 
health domain in some studies on QoL of PLHIV (Wig et al. 2006; Adewuya et al., 2008). 
Active workers and business persons scored better in physical health domain in relation 
to others, meaning that people with good occupations likely have better physical health 
(Basavaraj et al., 2010).  
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Other factors regarding ART and physical QoL have been established. It is mentioned 
that adherence to ART reduces viral loads and allows the immune system to improve 
(Cambiano et al., 2010) yet, non-adherence of ART ranges from 22% to 47% (Naidoo 
et al., 2013; Pefura-Yone et al., 2013). Some reasons for non-adherence to ART have 
been identified to include depression and poor QoL associated with ART adverse 
effects such as neuropathy (Uzochukwu et al., 2009; Bhat et al., 2010; Chen et al., 
2013). In comparison, some studies indicate improved overall QoL with the use of ART 
(Wang et al., 2009), while others observe a decreased physical QoL with the use of 
ART (Gill et al., 2002; Chen et al., 2013). 
 
2.5.2.3 Psychological health 
 
Wig et al. (2006) describes that the psychological domain incorporates the “patient’s 
own thoughts about body image and appearance, negative feelings, positive feelings, 
self-esteem and personal beliefs”. Psychological health parameters that include the 
level of depression and anxiety, have been found by (Mitro et al., 2008), to be a source 
of resilience against stress and becoming ill, thus an individual’s positive psychological 
well-being influences having good QoL. HIV infection does not only affect the physical 
health of PLHIV, but also morbidity which commonly leads to weakening of the 
psychological domain of QoL, as indicated by Liu et al. (2006).  
 
Depression is reported as the most commonly observed mental health disorder among 
18% to 81% of PLHIV (Arseniou et al., 2014). The disorder is reported as the major 
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predictor of poor QoL in PLHIV (Hou et al., 2014). The comprehensive study on how 
depression relates to QoL in PLHIV in Nigeria by Adewuya et al. (2008) demonstrated 
a strong relationship between the depression diagnosis and poorer QoL. Reductions in 
depression has been observed with ART management in PLHIV (Wagner et al., 2012). 
However, despite the positive effects of ART, significant psychological challenges have 
been noted for both people who respond positively to treatment and those who do not 
(Sherr et al., 2007). Thus, the HIV infection causes psychological disorders and some 
are as a result of ART side effects such as PN that may still be challenge for PLIHV 
(Chen et al. 2013). Again the study by Biraguma and Rhoda (2012) indicated lower 
psychological health QoL as result of PN due to HIV infection and or ART in Rwanda. 
 
2.5.2.4 Social relationships 
 
According to Wig et al. (2006) the social domain examines the personal relationships, 
social support and sexual activity. Social support is one of the identified mediators to 
reduce the impact of stigma among PLHIV with depression and symptomatology (Rao 
et al., 2012). The QoL is mostly and negatively affected by social relationships 
compared to other health domains of QoL (Imam et al., 2011). This is likely because 
social relationships are one of the main areas affected in PLHIV and includes being 
stigmatised by society, and this impacts on other aspects of QoL (Greeff et al., 2010). 
It makes PLHIV to often experience social isolation, stigmatization, discrimination and 
marginalization, as put forward by (Greeff et al., 2010). Stigmatization has been found 
to be a major barrier to improved QoL for PLHIV (Mahajan et al., 2008; Jin et al., 2010) 
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2.5.2.5 Environmental health 
 
Environmental factors are among others that have a main role in determining health 
situations of people. According to Wig et al. (2006) the environmental domain examines 
the effects of factors such as “financial resources, the work environment, accessibility 
to health and social care, freedom, security, participation and opportunities for leisure 
activities on QoL”. In daily life people would like to have the financial resources that they 
need to meet their daily needs and this gives life satisfaction (Xiao et al., 2009), and is 
thus a predictor for positive QoL.  
 
As mentioned previously, physical safety and security are important aspects of the 
environment as they give the individual emotional freedom. It is also considered 
essential to access good quality health and social care that provide chances for 
obtaining new information and skills. A safe and secure environment that enable 
participation opportunities for recreation and leisure, and hence promotes a high level 
of QoL (Arcury et al., 2012). 
 
According to (Misfeldt et al., 2014), financial support such as giving incentives delivers 
more benefits in addition to financial, and also structures for social support, role identity 
and personal meaning, for working individuals. The impact of employment on QoL and 
psychological functioning among employed PLHIV, results in significantly higher overall 
QoL than unemployed individuals with HIV (Blalock et al., 2002).  
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A study on the influence of HIV on the QoL by Skevington (2012) found that the support 
from the family, and occupation, are important factors that affect the QoL in the 
environmental domain among PLHIV. The same study demonstrated family as the most 
significant element of the direct environment of the individual. The family is considered 
as the main backing, not only for financial support, but also for security and safety, 
noting that decent and helpful home surroundings may assist PLHIV to feel healthier. It 
is also shown that expert workers and business persons scored better in environment 
domain (Wig et al., 2006). The same authors concluded that improving surroundings of 
PLHIV can give them a better QoL. 
 
2.5.3 Relationships between PN and QoL 
 
Most literature indicates that PLHIV experience different neurological complications 
associated with clinical manifestations of the epidemic, related opportunistic conditions 
and side-effects from medication, such as the neurocognitive disorders (Alfahad and 
Nath, 2013) and PN (Chen et al., 2013; Conradie et al., 2014; Dubey et al., 2013; Scott 
R. Evans et al., 2011; Forna et al., 2007; Gabbai et al., 2013; Hahn et al., 2010; Luma 
et al., 2012; Maritz et al., 2010; Mehta et al., 2010; Nicholas et al., 2007a; Simpson et 
al., 2006; Wadley et al., 2011; Wolfort and Dellon, 2012; Wulff et al., 2000). The 
neurological complications are reported to be the most challenging among HIV 
researchers (Alfahad and Nath, 2013), and PN is said to be the most common among 
the neurological co-morbidities (Luma et al. 2012; Chen et al. 2013; Dubey et al. 2013; 
Gabbai et al. 2013; Conradie et al. 2014). Peripheral neuropathy is reported to impact 
on daily activities of PLHIV and their relationship with the external environment, and can 
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greatly affect their QoL (Padua et al., 2005). Worsening QoL of affected individuals may 
increase their disability (Hogan and Wilkins, 2011).  
 
However the data available regarding QoL and PN in PLHIV is not sufficient to guide 
the rehabilitation approach for the PLHIV with PN. Most information on QoL and PN is 
about diabetes associated PN. Like any other chronic pain the PN related to diabetes 
has a significant negative effect on QoL of the affected person. One study by (Gore et 
al., 2005) demonstrated that QoL was strongly lower in patients with diabetes with 
severe pain related to PN than among patients with diabetes without the severe pain 
related to PN. It was further noted that people with diabetes and chronic pain, have 
reductions in sleep, walking and ability to perform domestic duties and hence such 
painful PN has been shown to have severe adverse effect in physical, psychological 
functioning and the overall QoL of people with diabetes (Bouhassira et al., 2013; Vinik 
and Casellini, 2013). Similarly, one of the few studies on PN in PLHIV, indicated that 
neuropathic pain was strongly associated with the sleep disturbances which impacted 
on the mobility functioning (Sandoval et al., 2013). Thus, the PN related to HIV is 
characterised by painful symptoms as demonstrated with PN related to diabetes. The 
same effects of PN related to diabetes on the QoL are likely to be similar to the ones in 
HIV-associated PN. Biraguma & Rhoda (2012) indicated that PN was significantly 
associated with QoL, among PLHIV in one of the district hospital in Rwanda. However, 
the sample size of this study was small and the study was done in one setting. Hence, 
it is important to conduct other studies with a bigger sample size and in more settings, 
to improve surveillance for PN. This may facilitate in developing an appropriate data 
base to enable better understanding of the effects on PN on the QoL of PLHV, as well 
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as for the development of early interventions to improve QoL and prevent disabling pain 
and the associated functional limitations. The study by Griswold et al. (2005) assessed 
the coping approaches of PLHIV with PN and discovered that the approach strategies 
can vary depending on age, gender and the ethnic background of PLHIV. It is therefore, 
important to conduct studies with interventional methodologies among PLHIV on ART 
who have associated PN. 
 
In conclusion, despite all the progress in HIV care and treatment, there is minimal data 
related to HIV–associated PN and the related functional limitations and rehabilitation 
approaches in Rwanda. It is an issue of concern as there is a need to improve and 
maintain the QoL of PLHIV on ART in the region. 
 
2.6 Management of HIV-associated PN, related functional limitations 
and QoL 
 
2.6. 1 Introduction  
This section highlights the identified and suggested management strategies of PN, the 
related functional limitations of the lower extremities and the QoL.  
 
2.6.2 Treatment of HIV-associated peripheral neuropathy 
Peripheral neuropathy management aims at relieving painful neuropathic symptoms 
and to educate patients regarding prevention and care of PN-related disorders that 
affect people’s lives (Brix Finnerup et al., 2013). However, the management is still a 
challenge for the health care professionals of these patients because of lack evidence 
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based data on the management approaches. There is a need to develop effective 
management for PN as highlighted by (Phillips et al., 2010) 
 
The management of PN incorporates pharmacological and non - pharmacological 
approaches (Nicholas et al., 2007; Dworkin et al., 2007; Phillips et al., 2010). There is 
enormous evidence based on the pharmacological management of painful neuropathy. 
In this evidence, systematic literature reviews, RCTs, and existing guidelines were 
evaluated by Dworkin et al. (2007). In the systematic literature review, the same authors 
found and recommended that the first-line treatments for the PN, which contain some 
antidepressants such “(tricyclic antidepressants and dual reuptake inhibitors of both 
serotonin and norepinephrine), and calcium channel α2-δ ligands (i.e., gabapentin and 
pregabalin), and topical lidocaine”. They then indicated that opioid analgesics and 
tramadol be recommended usually for second-line treatments, but further mentioned 
that could be used for first-line in chosen clinical conditions (Dworkin et al., 2007). The 
authors demonstrated that there are other drugs that would be used as third-line 
treatments but might also be applied in the second-line treatment in some conditions. 
These included some of the antiepileptic and antidepressant medications, such as 
“mexiletine, N-methyl-d-aspartate receptor antagonists, and topical capsaicin” as 
indicated by Dworkin et al. (2007). Similarly, gabapentin and pregabalin that were added 
to the management of PN in patients with diabetes have been effective and lowered the 
costs of health care (Sicras et al., 2013). The pregabalin is reported as safe and 
effective in reducing pain associated with diabetic PN (Deli et al., 2013), and also 
improves mood, sleep disturbances, and QoL (Vinik et al., 2013). However, when 
pregabalin was tested for the same effect on PN in PLHIV, it was not superior to 
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placebo. The authors concluded that the pregabalin did not show a significant difference 
on being effective than placebo for the management neuropathic pain PLHIV (Simpson 
et al., 2010).  
 
Furthermore, a systematic review and a meta-analysis of RCT’s was conducted by 
Phillips et al. (2010), with the objective of evaluating the clinical effectiveness of 
analgesics in treating painful PN. The conclusions from the review were that an 
evidence of efficacy exists only for capsaicin 8%, smoked cannabis and rhNGF. 
However, the rhNGF could not be available for clinic purpose and the smoked cannabis 
could not be commended as routine therapy (Phillips et al., 2010). The same authors 
recommend that assessment of new management approaches for the PN associated 
with HIV is urgently essential (Phillips et al., 2010). Contraliry, a double – blind RCT 
carried out by Clifford et al. (2012), did not indicate a significant effect of the capsaicin 
8% patch in the treatment of HIV – DSP. But some improvement in the pain were felt 
as reported by the same study. Earlier, Simpson et al. (2003) and later Titlic et al. (2008) 
had showed that lamotrigine was effective in treating the HIV-associated neuropathic 
pain among PLHIV on neurotoxic ART.  
  
It has also been shown that there is no dramatic improvement of PN with ART-related 
reductions in HIV viral load, as the neuropathy damage is likely irreversible due to the 
virus, or the ongoing damage with ART. This may mitigate the benefit of viral control 
(Evans et al., 2011; Oshinaike et al., 2012). The non-improvement of PN with ART 
management indicates a definite need for the supplemental treatment management and 
could include non-pharmacological management. 
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Non-pharmacological management of PN generally, has also been tried. Exercise 
programme and lifestyle changes were both recommended (Ahmad and Goucke, 2002). 
The same authors emphasised that such management approaches are important to 
maintain mobility and independence, particularly of elderly patients with PN, because 
old age is susceptible to PN. This was mainly to avoid the adverse effects of drug – 
treatment in this group.  
 
Thus, diet control and exercises are some of the lifestyle interventions used in pre - 
diabetic neuropathy to prevent pain. Most of the non-pharmacological management for 
PN has been reported in patients with diabetes (Smith et al., 2007). In some studies, it 
has been highlighted that management of the neuropathic pain among the people with 
mild PN symptoms, can be managed through lifestyle changes such as avoiding; 
wearing limiting shoes, standing for long time and walking long distances (Nicholas et 
al., 2007a). The same authors further indicated that nutritional supplements, putting feet 
in warm water, rest, elevation of limbs, rubbing the feet with cream, and exercises, are 
some of the approaches that have been mentioned to help people with PN (Nicholas et 
al., 2002 & 2007a). Additionally, Nicholas and the colleagues (2007a) showed that 
complementary modalities are supportive to help people in prevention and reducing of 
the ART side effects as well as managing the PN symptoms. The modalities which are 
commonly used include but not limited to; yoga, meditation, physical modalities such as 
heat, whirlpool, and massage, traditional Chinese medicine such as; acupuncture and 
tai chi (Galantino et al., 1999; Phillips et al., 2004; Meyer-Hamme et al., 2012). Again, 
Dorfman et al. (2013) found that brief hypnosis interventions may give a useful and a 
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well-torelated management of HIV – PN but further investigations are needed. All such 
modalities aim at long term improvement and have less adverse effects (Meyer-Hamme 
et al., 2012). 
 
There are a variety of treatment modalities available for PN, but preferences should be 
made based on the safety and the adverse effects of the modalities, and should depend 
on the individual. The lifestyle changes and complimentary approaches were preferred 
to be added to the health care of people with PN (Nicholas et al., 2007a). The same 
author stated emphasised that the pharmacological remedies can only be used in the 
management of the PN if the lifestyle changes and complementary approaches are not 
able to control the pain associated with PN. Yet, the patient usually request the 
symptomatic treatment with the pharmacologic agents but there are no precise features 
of the pain that can estimate what kind of remedies would work better for the relief of 
the symptoms, as described by Nicholas et al. (2007a). The selection of the drug is said 
to be centred on how severe the symptoms are, and the likely adverse effects known 
from the drug (Dworkin et al., 2007; Phillips et al., 2010). 
 
Improvements in QoL of PLHIV has been obtained through the treatment of PN, with 
relief their neuropathic symptoms and depression levels (Dorfman et al., 2013). Thus, 
effective treatment of symptoms is essential for improving QoL. According to Lorenz et 
al. (2001), most persons living with chronic illnesses appraise their QoL, at least in part, 
according to the symptoms (including treatment side effects) they experience. 
Nevertheless, few studies have investigated the management of physical and functional 
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impairments as a result of PN, for the purpose of early rehabilitation so as to prevent 
patients remaining prone to disability (Myezwa et al., 2009) 
 
It is not yet clear if there standard treatments for PN available, but the ones available, 
are oriented to relief of the symptoms (Verma et al., 2005). But the rehabilitation of the 
function that may have been affected by PN is not probably described in the treatment 
strategies available for the purpose of preventing functional limitations and improving 
the QoL of the affected PLHIV. 
 
2.6.3 The rehabilitation needs for PN-related functional limitations 
 
There is a dearth of literature on PN-related functional limitations to inform rehabilitation 
professionals. However, there is literature that highlights the association or a link 
between PN and functional limitations, specifically of the lower extremities. The study 
by Ellis et al. (2010) found that PN impairments; specifically for neuropathic pain was 
strongly related to limitations of activities of daily living, unemployment and reduced 
QoL. Vinik et al. (2013) showed that PN related to diabetes is found to be associated 
with both impairments and functional limitations and that PN is closely associated with 
functional limitations which finally result in reduced QoL if not dealt with appropriately. 
This shows the need for rehabilitation of the impaired function with PN.  
 
The study by Myezwa et al. (2009) found that it is necessary for rehabilitation 
professionals to be familiar with the impairments and rehabilitation diagnosis for 
appropriate treatment plans, identification of patients and outcomes. The authors 
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emphasised that rehabilitation professionals such as physiotherapists need to identify 
appropriate patients themselves and primary care physicians should understand the 
subsequent disabilities seen in AIDS for proper referral to rehabilitation (Myezwa et al., 
2009). Regardless of the evidence that there is an important role for rehabilitation 
providers to play in the health care of PLHIV, there is a potential gap between the 
documented rehabilitative needs of PLHIV and services provided by rehabilitation 
professionals (Worthington et al., 2008).  
 
 
2.7 Effects of exercises on PN, related functional limitations and QoL 
 
2.7.1 An overview of the effects of exercise interventions in HIV-related 
disorders 
 
Exercise is known to have positive effects in various conditions and in particular in 
rehabilitation of chronic illness, including those in PLHIV. In this section, different 
exercise approaches and interventions in the common HIV related conditions are 
highlighted. As the focus of this study is on PN, the available exercise interventions for 
PN, related functional limitations and QoL are also demonstrated in the following sub-
sections.  
 
The literature includes various studies that have tested the effectiveness and safety of 
exercises among PLHIV. The effects of some exercise intervention studies among 
PLHIV were highlighted in a systematic review by O’Brien et al. (2010). The authors 
conducted the systematic review with the objective of examining the “safety and 
effectiveness of aerobic exercise interventions on immunologic and virologic, 
cardiopulmonary, psychological outcomes, strength, and weight and body composition” 
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in adult PLHIV. The review included RCT’s with comparisons of the aerobic exercise 
interventions against interventions without aerobic exercise or any other exercise or 
treatment approaches. According to their criteria of study selection, the exercise must 
have been done at a frequency of at least three sessions per week and for at least a 
period of four weeks with adults PLHIV of 18 years old and above. Altogether, 14 studies 
fulfilled the authors’ set requirements and were included in the review. From the results 
of the studies examined, the authors concluded that exercises are safe and that they 
may be helpful for adult PLHIV (O’Brien et al., 2010). However, the same authors further 
commented that the findings had limitations with smaller sample sizes and high rates 
withdrawal identified from the studies evaluated. They suggested that further studies 
would use participants’ follow-up and intention-to -treat analysis (O’Brien et al., 2010).  
 
Supervised aerobic exercise done at sub-maximal age predicted maximal heart rate 
levels of 70% and resistance exercise programmes in PLHIV has been shown to be 
safe and is known to improve cardiovascular fitness (O’Brien, et al., 2010). Specifically, 
one of the studies by Mutimura et al. (2008) demonstrated that the exercises are safe 
and efficient in improving metabolic profiles and cardiovascular fitness, in ART treated 
PLHIV in Rwanda. Most exercise intervention studies found no effect of exercises on 
the immune indices, specifically, changes in CD4 count (Baigis et al., 2002; Driscoll et 
al., 2004; Dolan et al., 2006; Terry et al., 2006; Mutimura et al., 2008). Contrary, a single 
study by Perna et al. (1999) showed that adherent exercisers improved their CD4 count 
by 13% while the non-adherent exercisers diminished CD4 count by 18%. The 
participants in the control in the same study indicated a decrease trend of CD4 count 
by 10% (Perna et al., 1999). The authors concluded that aerobic exercises significantly 
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increased CD4 count among symptomatic PLHIV. The non-adherence might be 
associated with quicker CD4 decline because of numerous probable mechanisms 
(Perna et al., 1999).  
 
Similarly, some of the exercise interventions indicate that exercise improves strength 
outcomes (O’Brien et al., 2010). However, most of the studies in the review did not 
assess strength outcomes (Baigis et al., 2002; Terry et al., 2006; Mutimura et al., 
2008b), probably because the muscle weakness is not considered as the primary effect 
of the HIV and or ART-associated complications. Muscle strength in most cases is 
included during rehabilitation.  
 
Generally, the benefits of exercise intervention among adult PLHIV are demonstrated 
in almost all exercise intervention studies, whereby exercises are safe and affordable. 
However, the studies differed in the objectives of the interventions, types of exercises 
or approach used. For the purpose and focus of this thesis, the following sections 
highlight the effects of exercise interventions on PN, functional ability of lower extremity 
in particular and the QoL, of PLHIV.  
 
2.7.2 Effects of exercise intervention on PN 
 
The exercise interventions for PLHIV with PN seem not to have been conducted yet. 
The available literature is mostly on the effect of exercise on PN in other health 
conditions such as diabetes. The effects of exercises in these other conditions may be 
beneficial to PLHIV with PN, as well. This is because the exercise have been approved 
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and shown to be safe and beneficial for the population with HIV (Nixon et al., 2002; 
Nixon et al., 2005; Mutimura et al., 2008b; O’Brien et al., 2010). 
 
Therapeutic exercise that includes progressive resisted exercise, aerobic exercise, 
individualised exercise programmes, and generalised home programmes, are 
commonly used in the management of PN in patients with diabetes (Ward, 2005). Taylor 
et al. (2007) stated that “therapeutic exercise is defined as the prescription of a physical 
activity or programme where the client carries out voluntary muscle contraction and or 
body movement with the aim of relieving symptoms or improving, retaining or slowing 
deterioration of health”. The same authors carried out a systematic review on 
therapeutic exercise studies published from 2002 to 2005, that conducted exercise 
interventions among participants with neurological, musculoskeletal, cardiopulmonary, 
and other conditions. The outcomes of interest in the systematic review were to “identify 
the effect of therapeutic exercise in terms of impairments, activity limitations or 
participation restriction” as stated by the authors. The review on the therapeutic exercise 
in neurological physiotherapy yielded six reviews but only one managed to meet the 
standard criteria and described the effect of exercise on PN. This is likely an indication 
that very few studies have been conducted with standard methodologies that test the 
effect of therapeutic exercise on peripheral neuropathies. But the review concluded that 
therapeutic exercise was extensively effective throughout the big range of 
physiotherapy treated conditions (Taylor et al., 2007) and these include neurological 
ones, specifically peripheral neuropathies.  
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A systematic review by White et al. (2004) included three trials which examined the 
effect of exercise in people with PN but the three studies had small sample sizes  The 
authors of the systematic review concluded that there is little evidence from the RCTs 
to assess the effect of exercise on the ability of function among people with PN. 
Nevertheless, the same authors pointed out an evidence of muscle strength as result 
of exercises among people with PN. The implication for future research was that there 
is a deficiency of quality evidence, which can guide assessment of the effect of exercise 
on the ability of function among people with PN. The implication supports a strong need 
to develop further research with high quality sufficiently powered trials (White et al., 
2004).  
 
Furthermore, a study was conducted to examine the “feasibility and effectiveness of a 
supervised, moderately intense aerobic and resistance programme” in people with PN 
related to diabetes (Kluding et al., 2012). The study used a pre-test post-test design and 
the assessment was done on 17 people after 10 weeks of participation in an aerobic 
and strengthening exercise programme. The findings from the study indicated 
significant improvements of pain, neuropathic symptoms, and increased intra-epidermal 
nerve fibre branching. The authors pointed out that the study indicated an improvement 
in neuropathic symptoms and cutaneous nerve fibre branching following supervised 
exercise in people with PN related to diabetes. Despite the fact that the findings were 
promising the study was for a short time and lacked a control group. The authors further 
recommended comparison with a control in futures studies (Kluding et al., 2012).  
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2.7.3 Aerobic exercise in people with PN 
 
An aerobic exercise regimen is reported to include; physical activity done at frequency 
of at least three times per week for at least four weeks, according to O’Brien et al. 
(2010). In their meta-analysis, O’Brien, et al. (2010) demonstrated results of different 
clinical trials that an effective exercise regimen must ideally be at least six weeks long. 
Studies on aerobic exercises have been documented by various systematic reviews, 
and their results indicated that the exercises are safe and beneficial for PLHIV (Nixon 
et al., 2002; Nixon et al., 2005; O’Brien et al., 2010). Conversely, to my knowledge, 
there is a paucity of aerobic exercise interventions for PLHIV with PN. Nonetheless, 
strengthening and balance training exercises incorporated into aerobic exercise 
programmes have been shown to be beneficial for people with PN related diabetes 
(White et al., 2004; Tofthagen et al., 2012; Kluding et al., 2012). In their study, Balducci 
et al. (2006) suggested that aerobic exercise training done for long-term may be 
beneficial in preventing the onset or change nature of PN related to diabetes. The 
aerobic exercise with less intensity such as brisk walking, were identified as beneficial 
and relevant for management strategy, like preventing the start or adapt the nature of 
PN in diabetes (Balducci et al., 2006). Strength training with isometric exercises done 
against maximal resistance, with no associated joint movement in people with PN, was 
recommended by White et al. (2004).  
 
2.7.4 Effects of exercise on functional limitation and QoL among PLHIV with PN  
 
The functional activity limitation and participation restriction, which commonly result in 
deteriorated QoL, are frequently identified in PLHIV with PN (Wong and Sagar, 2006). 
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Exercises are consistently documented as one of the greatest common self-therapies 
(Ciccolo et al., 2004). Studies to identify the effects of exercise on functional limitations 
and the QoL among PLHIV, with HIV-related co-morbidities, indicate improvements in 
functional limitations and QoL (O’Brien et al., 2010).  
 
 A study by Galantino et al. (2005) tested the effect of group aerobic exercise and tai 
chi on functional outcomes and QoL in patients with HIV. The study considered thirty 
eight (38) subjects with advanced HIV and AIDS who were randomised to one of the 
three groups; tai chi, aerobic exercise, or control. The two exercise treatments were 
carried out at each research site, twice weekly for 8 weeks. The overall goal of the study 
was to improve strength, flexibility, balance and endurance without using sophisticated 
equipment (Galantino et al., 2005). The results of the study demonstrate that the tai chi 
and aerobic exercises improve physiologic parameters, functional outcomes, and QoL, 
compared to controls. Specifically, the functional improvements were seen in the 
balance for functional activity that requires balance, balance in sitting and standing and 
endurance after the intervention. Improved flexibility was one of the main achievements 
reported by the participants, in addition to improved stair climbing and all the functional 
measures tested. Tai chi exercise includes balance activities and is likely to improve 
balance. There were significantly enhanced psychological coping; specifically 
bewilderment and tension- anxiety among the participants. The participants also 
reported qualitatively on improvements in the overall health related perceptions in the 
subscales that measure QoL. Specifically, participants mentioned feeling better after 
exercising with improved social interactions with their peers which encouraged them to 
exercise harder (Galantino et al., 2005). 
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Home exercise programmes have been demonstrated by (Ruhland and Shields, 1997) 
to as essential in the rehabilitation of people with chronic PN in diabetes. In their study, 
they assessed the effects of home exercise programme by looking at differences in the 
changes of impairments and QoL between an exercise and control group. The 
relationships between the QoL and measures of impairment were also examined. The 
authors compared the QoL of people with chronic PN and the general population. In the 
study, the exercise group comprised of 14 participants and exercised for 6 weeks in a 
home exercise program, while the control group of 14 participants did not exercise. The 
participants in the intervention improved their muscle strength and walking time that was 
associated with the physical function, compared to the controls that did not. Finally, the 
study concluded that the home exercise programme is an essential constituent of the 
management of chronic PN. In comparing with the general population, people with 
chronic PN had lower QoL, but some areas appeared to improve after the programme 
of the home exercise (Ruhland and Shields, 1997). 
 
However, despite all the exercise interventions described above, to my knowledge none 
so far have indicated the effectiveness of exercises on PN and related functional 
limitations among PLHIV. It is therefore worthwhile to note that testing the effectiveness 
of exercise in PN and related functional limitations for the promotion of QoL in PLHIV is 
essential.  
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2.7.5 Adherence to exercise  
 
The adherence to exercise is an important consideration in an intervention study 
because it can influence the actual results of a study (Petroczi et al., 2010). The 
perception of well-being, lifestyle and cultural beliefs are major contributors to 
adherence. According to O’Brien et al. (2008) the withdrawal rates in the studies they 
reviewed ranged from 0 - 76 % and different reasons included; employment, illness, 
relocation, loss of interest, transportation difficulties, personal issues, lack of 
motivation, lack of time, and economic reasons. 
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Table 2 Summary of effects of exercise interventions on PN, lower extremity functional limitations and QoL  
 
Study design and 
sample size and 
participants  
Type of exercise intervention    Main results on PN, LEFLs, QoL and 
conclusions 
Authors and 
date   
A RCT among 160 PLHIV 
in selected health 
facilities in Zimbabwe 
Progressive resisted exercises 
(PRE) were given to 80 participants 
twice a week for 12 weeks, were 
compared to 80 control group that 
walked un supervised at home   
The finding of the study did not show a 
difference of the effects of PRE on 
performance oriented mobility in PLHIV with 
PN when compared to advice to exercise at 
home but showed a positive effect on the QoL 
of the group that had supervised exercise. The 
PRE programme may be extended to PLHIV as 
a home programme exercise was the author’s 
conclusion 
Mkandla, 2013 
Pre-test and post-test 
design among 17 
participants with Diabetic 
peripheral neuropathy 
(DPN) 
10 – week aerobic and 
strengthening exercise  
Significant reduction in pain, neuropathic 
symptoms, and increased intra-epidermal 
nerve fibre branching. 
Authors’ conclusions:  That was first study to 
describe improvements in neuropathic and 
cutaneous nerve fibre branching following 
supervised exercise in people with diabetes 
PN. Findings were promising given the short 
duration of the intervention and recommended 
a validation with comparison of a control group 
in future studies 
Kluding et al., 
2012 
A RCT of 100 PLHIV (50 
participants at baseline 
and 48 participants at 
study completion for the 
exercise group). And 50 
at baseline and 49 at 
completion for non-
Supervised aerobic exercise was 
given for Six month. Aerobic 
Exercise included: proper warm up, 
stretching, and 15 minutes of brisk 
walking, followed by 45-60 minutes 
of jogging, running, stair climbing, 
low-back and abdominal 
stabilization and strengthening 
Significant improvements in quality of life 
(QOL) on the psychological, independence, 
social relationships, HIV+ HAART-specific 
domains of QOL, and overall QOL score as 
measured by the World Health Organization 
Quality of Life HIV Instrument (WHOQOL-
BREF) for exercisers compared with non-
Mutimura et al., 
2008 
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exercising control group, 
in Rwanda.  
exercises, followed by a 15 minute 
cool down and stretching exercises.  
Duration and Frequency: 3X per 
week, 1.5 hour per session, 
alternating days for 24 weeks (6 
months). 
For non-exercising control group; 
No intervention was given. 
exercisers. No difference between groups on 
the physical QOL domain score. 
Author’s Conclusions: 
Results imply that exercise training is a safe, 
inexpensive, practical and effective treatment 
for evolving metabolic and cardiovascular 
syndromes associated with HIV and HAART 
exposure in resource-limited settings such as 
Su-Saharan Africa 
Cross sectional 
identification of 
symptoms management 
and self-care strategies 
for PN in 1217 PLHIV in 
USA 
Reported symptoms management 
and self - care strategies  
About 20 self-care behaviours including 
complementary therapies, use of medications, 
exercise and rest and/or elevation of 
extremities were identified.  
Nicholas et al., 
2007 
A RCT with three groups 
of PLHIV (advanced 
HIV), and tai chi for 38 
participant: USA 
Tai chi was compared to aerobic 
exercise and the control groups. 
Both exercise regimens were 
conducted twice weekly, for 8 
weeks. 
Tai chi and aerobic exercises improve 
physiologic parameters, functional outcomes, 
and QoL, compared to the control group. 
Galantino et al., 
2005) 
A RCT of 123 participants 
at baseline 
 
 
Supervised exercise among 68 (at 
baseline) and 35 (study completion) 
participants exercised on Ski 
machine. 40 minutes total: 5 minute 
stretching, 5 minute warm-up on 
machine, 20 minutes constant 
aerobic exercise at 75-85% HRmax 
followed by 5 minutes cool-down 
and 5 minutes stretching. 
Duration and Frequency: 3X per 
week for 15 weeks. Constant 
aerobic versus non-exercising 
Significant improvement in overall health 
subscale of the MOS-HIV found among 
exercisers compared to non-exercisers 
Author’s Conclusions: Exercise appeared to 
be safe in HIV-infected individuals 
 Baigis et al., 
2002 
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control of 55 participants at baseline 
and 34 at study completion.  
RCT of home programme 
exercises, among 28 
participants; with chronic 
PN 
14 participants were given home 
based exercises and were 
compared with 14 other participants 
without exercises and also were 
compared with the general 
population 
Study indicated an increase in the average 
muscle score in the exercise group compared 
with the control group after the intervention. 
Also the exercise group improved the scores 
on the role limitation. The authors concluded 
that the home exercise programme appears to 
be an important component of the treatment of 
persons with chronic PN  
Ruhland and 
Shields, 1997 
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2.8 Summary 
Chapter two highlights that the HIV pandemic is still a burden around the globe and 
more especially in sub Saharan Africa. The burden of the pandemic has shifted from a 
death threatening condition to a chronic lifelong condition often with disabling 
complications such as PN. The prevalence of PN in different regions of the world has 
been demonstrated in this chapter, and is still relatively high. In addition, the effects of 
PN in HIV, specifically on lower extremity function and related QoL have not been clearly 
demonstrated. The chapter reviewed the existing management strategies for PN and 
HIV related QoL, which include more pharmacological than non-pharmacological 
interventions. Finally, the available management strategies of PN and the associated 
effects on function and QoL, have been demonstrated. Of particularly interest are 
exercise interventions as a strategy in this era of ART, to minimise or even prevent the 
disabling chronic PN and related functional limitations. 
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CHAPTER 3 
3.0 STUDY 1 
 
THE OUTCOME MEASURES TO ASSESS PERIPHERAL NEUROPATHY, 
RELATED LOWER EXTREMITY FUNCTIONAL LIMITATIONS AND QUALITY OF 
LIFE IN PLHIV ON ART IN RWANDA 
 
 
3.1 Introduction  
This chapter describes the various outcome measures which were used in the data 
collection of the three studies for the thesis. The outcome measures used were to 
assess; PN, the related lower extremity functional limitations and the QoL in PLHIV on 
ART, in Rwanda. Additionally, a checklist for identification of demographic and health 
status characteristics and included the one for differential diagnosis of the neuropathic 
pain.  
 
Several outcome measures were available in the literature, such as the Brief Peripheral 
Neuropathy Screen (BPNS) to assess HIV-associated PN (Cherry et al., 2005), DN4- 
questionnaire (Bouhassira et al., 2005) for assessing neuropathic pain, and the World 
Health Organisation (WHO) quality of life HIV instrument-short form (WHOQOL-BREF) 
(Skevington et al., 2004) to assess the QoL. Furthermore, an outcome measure to 
assess lower extremity functional activity performance called the Lower Extremity 
Functional Scale (LEFS) was also available.  
 
However, the LEFS had not been tested to assess the lower extremity functional activity 
performance limitations related to PN in PLHIV on ART. The scale was originally 
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developed to assess the functional activity performance limitations in patients with 
disorders of one or both lower extremities particularly, in old people. The scale also 
could be applied to screen people with the lower extremity limitation over time and would 
evaluate treatment intervention effectiveness (Binkley et al., 1999).  
 
The main aim of study 1 was to re-establish the validity, reliability and adapt outcome 
measures to assess PN and the related functional limitations of the lower extremity 
among PLHIV in Rwanda, so that the measures could be used in the rest of the studies 
of the thesis. The exception was the WHOQOL-BREF which had already been adapted 
through its translation into Kinyarwanda (Hakuzimana, 2005), and had been used in 
other studies such as by Mutimura et al. (2007), in Rwanda. It was therefore, not re-
adapted in this study.  
 
3.2  Specific objectives of study 1 
 
3.2.1 To describe the outcome measures used this study 
3.2.2 To adapt the BPNS for assessing PN in PLHIV on ART in Rwanda  
3.2.3 To re-establish the validity and reliability of LEFS in Rwanda;  
3.2.3.1 To translate the LEFS into Kinyarwanda   
3.2.3.2 To pilot and test the translated LEFS for clarity  
3.2.3.3 To modify and rectify unclear items found in LEFS for specific Rwandan 
cultural activities of daily living 
3.2.3.4 To re-establish the intra and inter -assessor reliability of the modified 
LEFS 
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3.2.1 Description of the outcome measures  
 
The checklist, neuropathic diagnostic tool (DN4), and WHOQOL-BREF, outcome 
measures are described in this section. 
 
3.2.1.1 Checklist (Appendix 1: section A)  
 
The design of the checklist used in this study was based on related studies conducted 
among PLHIV on ART (Bouhassira et al., 2005; Hsiung et al., 2005). The content 
analysis was undertaken by two clinician experts in HIV and AIDS and infectious 
diseases at the former Treatment, Research and AIDS Centre (TRAC) in Rwanda. The 
checklist included demographic characteristics such as age, gender, marital status, 
level of education, and the health status information such as duration since the 
participant was diagnosed with HIV, the ART regimen the participant is taking, duration 
on ART, the participant’s history of other pathologies (such as diabetes, central 
neuropathy, alcoholism, kidney disorders, for exclusion purposes when screening HIV-
associated PN). The CD4 cell count levels, presence of PN symptoms and if the 
symptoms commenced before or after starting on ART, were also identified. The 
checklist was used to collection information from the participants and from their medical 
records. It was completed by the author with assistance when needed by the medical 
practitioner working at the respective outpatient ART clinic included in the two following 
studies. 
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3.2.1.2: Neuropathic pain diagnostic outcome measure: DN4 (Douleur 
Neuropathique 4 questions) (Appendix 1 section B) 
 
The DN4 is an outcome measure used to differentiate between pain syndromes related 
to neuropathic pain and somatic component that are non-neuropathic (Bouhassira et 
al., 2005). DN4 is a validated and researcher/clinician administered outcome measure 
to score the responses from participants regarding neuropathic pain. It has 
psychometric properties of; sensitivity (83%), specificity (90%), internal consistence 
reliability (rho=0.7), inter-rater (rho = 0.68 – 0.79), and intra-rater (rho=0.92 – 0.95), 
(Bouhassira et al., 2005). The tool was translated into Kinyarwanda and cross checked 
by experts for the correct use of the terminologies. Thereafter, the scale was piloted to 
familiarise the assessors about the use of the scale. The DN4 is constituted with 
altogether 10 items that are in four sections. The first seven items assess the pain 
quality, that is “burning, painful cold, electric shocks” and how the pain is related with 
abnormal sensations; “tingling, pins and needles, numbness, itching”. The rest three 
items are associated with the neurological assessment of the painful area; “touch 
hypoaesthesia, pinprick hypoaesthesia, tactile allodynia”. It is shown that each positive 
score is given 1 for every item, and each negative score is given 0 for every item. The 
sum of all scores of the items is counted out of 10, and the minimal number for the 
neuropathic pain diagnosis is 4/10 (Bouhassira et al., 2005). 
 
3.2.1.3 Quality of life – questionnaire (Appendix 1 section E). 
 
There are various outcome measures for assessing QoL in PLHIV but the one which 
was most relevant for these studies was the short form of the WHOQOL-BREF. It is a 
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short form of the WHOQOL-BREF outcome measure which was developed and 
validated, based on a well-classified definition of QoL and encompasses physical, 
psychological, social and environment domains. WHOQOL-BREF is recommended as 
a useful instrument in patients with HIV infection (Jang et al., 2004; Hsiung et al., 2005) 
and it has been validated in multi-cultural settings including African countries. The 
instrument has the psychometric properties tha include; internal consistence of α=0.74-
0.85 and test – retest reliability of rho=0.64-0.79, (Jang et al., 2004). This instrument 
had already been translated and re-validated in Rwanda among PLHIV (Mutimura et 
al., 2007). The outcome measure facets in each of the following four domains (physical, 
psychological, social and environmental) have scores measured on a five point Likert 
interval scale from one to five. One indicates low and five indicates high perception 
(Jang et al., 2004; Hsiung et al., 2005). The WHOQOL-BREF for the measure of QoL 
contains items/facets asking about how a “person feels about different aspects of their 
life in the previous four weeks”.  
 
3.2.2.2 Description and adaptation of the BPNS for PLHIV in Rwanda  
3.2.2.2.1 Description 
 
The BPNS (Appendix 1 section C) is both a self-report and objective PN screening tool, 
which is a valid and reliable instrument for diagnosis of PN specifically DSP, (Cherry et 
al., 2005), with psychometric properties of; specificity (88%) and sensitivity (78%), 
(Evans et al., 2005). The BPNS examines subjective and objective outcomes constant 
with PN. It has been used in several clinical trial protocols; in particular by the AIDS 
Clinical Trial Group (ACTG) (Cherry et al., 2005) and evaluated in large-scale studies. 
It was identified to precisely discover PLHIV who have the highest grade of peripheral 
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nervous system dysfunction and pathology. The study by Cherry et al. (2005) concluded 
that the presence of both symptoms and signs on the BPNS provides a useful 
operational criterion for HIV- associated PN in the era of ART. One of the studies by 
Mehta, et al. (2010) implemented the validated BPNS in patients receiving ART in 
Mombasa, Kenya and the study recommended that the tool can easily be integrated 
into routine care by general practitioners in an outpatient HIV clinic with limited 
resources. The tool was therefore, a more realistic one to use in a resource limited 
country like Rwanda due to the high cost and lack of specialized instruments for nerve 
conduction such as, electromyography or sural nerve testing and electrophysiological 
changes. However, the tool was still piloted for adaptation to assess PN among PLHIV 
on ART in Rwanda. 
 
3.2.2.2.2 Adaptation of BPNS in Rwanda 
The adaptation of the BPNS was done together with piloting and re-validation of LEFS 
in study 1 with 50 participants. The procedures of adaptation of the BPNS Included; 
translating the scale into Kinyarwanda and cross checked by experts for the correct use 
of the terminologies. Thereafter, the scale was piloted to familiarise the assessors about 
the use of the scale, and estimate the duration of administration and use of the scale 
for the assessment of PN  
 
3.2.2.3 Procedure of piloting and adaptation of BPNS 
BPNS is a researcher/clinician administered scale. The author (assessor 1) and two 
other assessors (2 & 3), who were senior physiotherapists, did the assessments. A two 
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hour training session was conducted by assessor 1 for the other two assessors to 
familiarise them on using the scale to assess PN symptoms and signs.  
 
A sample of 50 participants was randomly selected from all the PLHIV on ART 
registered at an outpatient ART clinic at Biryogo health centre, commonly known as 
“Kwa Nyiranuma” in Kigali city. The sample was 10% of the approximate total sample 
size ≥ 500 estimated for the prevalence study (Study 2). The health centre attends to 
more than 50 PLHIV on ART on each day of the five working days of the week. Ten 
participants were systematically randomly selected from each list of 50 plus PLHIV 
attending the centre per day. The sample of 50 participants was obtained in one week.  
 
3.2.3 Ethical consideration 
An ethical clearance certificate (protocol number M080812) for all the three studies in 
this thesis was obtained from the Human Research Ethics Committee at the University 
of the Witwatersrand and the research protocol was approved by the Faculty of Health 
Sciences at the University. As the research data were collected in Rwanda, national 
clearance was also obtained from the Institutional Review Board at the former Kigali 
Health Institute and scientific approval by the National Commission for control of HIV 
and AIDS, in Rwanda. Also authorisation letters were obtained from all the health 
facilities where the studies were conducted. A letter containing information describing 
the details of the study was given to the participants to invite them to participate, before 
they were recruited into the study. Participants, who agreed to participate and gave 
permission to use their medical records, signed a consent form. Confidentiality and 
anonymity were ensured to all participants’ given information and the participation was 
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voluntary. Participants were informed of their rights to stop the participation from the 
study at any time.in case one deemed to discontinue.  
 
3.2.4 Data collection 
The author and the two assessors administered and assessed the selected participants 
with the BPNS, for PN, using the procedure described in the original validation of the 
scale by Cherry et al., (2005). This was done after obtaining the informed consent from 
each participant before commencing the data collection on each working day of the 
week; from Monday to Friday.  
 
The participants were requested to score the “presence and severity of symptoms, using 
a scale of 1 (mild) to 10 (severe) for each leg separately”. The symptoms assessed 
were; “pain, aching, or burning in feet and/or legs; pins and needles in feet and/or legs; 
and numbness in feet and/or legs”. The single highest score of the six scores (three for 
each leg) was transformed to a “subjective PN grade as follows: symptoms absent = 
grade 0, score of 1–3 = grade 1, score of 4–6 = grade 2, and score of 7–10 = grade 3”. 
Symptoms had to be bilateral to be graded as ≥ 1. “Objective findings (signs) included 
in the BPNS are the loss of the sense of vibration and abnormal ankle deep tendon 
reflexes”. The vibration sense perception was assessed with a 128-Hz tuning fork, 
“maximally struck and applied at the great toe distal interphalangeal joint of each foot”. 
The vibration sense was defined as “normal for a vibration felt for > 10 seconds, mild 
loss for a vibration felt for 6 –10 seconds, moderate loss for a vibration felt for ≥ 5 
seconds, and severe loss for no feeling of vibration”. The ankle tendon reflexes were 
defined as “absent, hypoactive, normal, hyperactive, or clonus”. For testing of the ankle 
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reflex, the participant was in a sitting position and the assessor used one hand to push 
up the foot of the participant into dorsiflexion at 90 degrees. Holding the reflex hammer 
in the other hand, the assessor struck the ankle tendon. The tendon reflex was felt in 
the assessor’s hand as a planter flexion of the participant’s foot.  
 
As the above position was found to be too difficult for the patients and thus difficult to 
get an accurate reading, a modification was made accordingly. In addition, the intra 
assessor Spearman’s rank correlation coefficient for this assessment on reflex 
responses was weak. Therefore, the position was modified; from sitting to kneeling on 
a soft cushioned chair or bench or plinth/bed (whichever was available at the site), with 
the foot hanging over the edge of the chair/bench or plinth/bed. The assessment was 
repeated in a second pilot study after the above modifications of the starting position.  
 
With this changed position the assessors repeated the assessment of all items in BPNS, 
using the same instructions as before. Planter flexion was seen and felt through the 
assessor’s hand. The reflex response was recorded as, hypoactive, normal, 
hyperactive, or clonus, accordingly. The intra correlation coefficient calculated after the 
second pilot was good and the modified position was adopted to be used in the rest of 
the studies’ assessments. This was the only item modified in the BPNS, and hence the 
tool was adapted to be used for PLHIV on ART in Rwanda.  
 
The primary outcome of interest in this measure was the presence of PN, which was 
defined as the combination of at least one subjective neuropathy grade greater than 0 
and either reduced or none sense of vibration and, or reduced/none ankle deep tendon 
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reflex, bilaterally, as has been defined and used in previous studies (Cherry et al., 2005; 
Mehta et al., 2010).  
 
3.2.5 Re-establishing validity and reliability of Lower extremity functional scale 
in Rwanda 
 
3.2.5.1 Lower extremity functional scale description 
LEFS assesses the subjective functional activity performance of daily living, in the lower 
extremities. It was developed and validated for various lower extremity conditions 
centred on the WHO model of impairment, disability and handicap (Hsiung et al., 2005), 
specifically for the elderly. The sensitivity to change of LEFS is expected to accurately 
measure even the small effects of impaired activity performance experienced by 
participants. It has the psychometric properties of; internal consistency (α=0.96), test – 
retest reliability (rho=0.86), and minimal detectable change of 90%, (Binkley et al., 
1999). The scale comprises 20 items which assess the level of difficulty in performing a 
variety of activities of daily living (ADL). Each item may be scored by the participant as 
0 = “unable to perform activity”, 1 = “quite a bit of difficulty”, 2 = “moderate difficulty”, 3 
= a little bit of difficulty”, and 4 = “no difficulty”.  The scale scores vary from 0 (none) to 
80 (normal) (Binkley, et al., 1999) (Appendix 1 section D). Function is defined as follows: 
“extreme difficulty or unable to perform activity (0–19 points), quite a bit of difficulty (20–
39 points), and moderate difficulty (40–59 points), a little bit of difficulty (60–79 points), 
and no difficulty” (80 points) (Schep et al., 2009)  
 
LEFS was validated in the developed world, specifically in the United States of America 
(USA) where the culture and environment are quite different from the resource limited 
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world, specifically in Africa, and Rwanda in particular. To my knowledge, there is no 
validation of this tool that has been done in most, if not all of the African countries. It 
was therefore, important that such a scale be adapted and re-validated when used in 
an African context and specifically in Rwanda.  
 
3.2.5.2 Procedure to re-establish validity and reliability of LEFS in Rwanda 
The following procedure was used to re-validate and adapt the LEFS in Rwanda.  
 
3.2.5.2.1 Forward and backward translation of English and Kinyarwanda 
languages 
 
The scale was translated from English to Kinyarwanda, (the local language spoken in 
Rwanda). Two independent professional language translators from the Language 
Centre at the University of Rwanda, College of Medicine and Health Science 
(specifically at former Kigali Health Institute), translated the scale from English to 
Kinyarwanda. Susequently, two independent professional translators translated the 
scale back to English, to ensure content validity. The translation was assessed by a 
consensus workshop of a panel of two physiotherapists and two medical doctors 
working at the former Treatment, Research and AIDS Centre in Rwanda (TRAC), 
together with all of the four translators, and the author. Changes and modifications were 
made for some scientific terms and functional activities in the scale (Table 4). The 
modifications in the activity performance were based on the activities of daily living that 
are culturally applicable and used in daily life in Rwanda; an example being a question 
that asked about having difficulty “getting in and out of a car”. Most people in Rwanda 
and in other African countries, travel in public taxi/buses (for those who manage to travel 
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in vehicles). When participants were asked about having diificulty getting in and out of 
a car, some mentioned, “I have never moved with a car” or “I seldom move with a car” 
So, the item/activity “getting in and out of a car” was modified as having any difficulty of 
“getting in and out of the car/public taxi/bus”  
 
3.2.6 Intra assessor reliability of LEFS prior its modification 
Two pilot studies were carried out to collect data for intra and inter assessor reliability.  
 
3.2.6.1 Pilot 1 procedure 
In pilot 1, the aim was to pilot the LEFS and establish intra assessor reliability of the 
scale by the author. The translated and content re-validated LEFS was administered to 
a sample of 50 PLHIV on ART; (the sample for study 1 has been described in section 
3.2.2.2.1 above). The author administered the translated and professionally scrutinised 
LEFS to the selected participants. Two assessments for each participant were 
conducted with a one week interval between the two assessments. Participants were 
assessed in the first week and were given an appointment to come in the following week 
from Monday to Friday respectively, for the second assessment. The day for each 
participant’s appointment for the second assessment corresponded with the day of the 
first assessment so as to ensure there was a one week time interval between the two 
separate assessments. Transport costs for the participants who came for the second 
assessment were compensated for, by the author. 
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3.2.6.2. Data collection:  
 
LEFS was self-administered by the participants to assess their lower extremity 
functional activity performance. All participants who knew how to read and write were 
given the scale to complete individually. However, the author was nearby to give any 
clarification or assistance wherever needed. The author administered the scale for the 
participants who did not know how to read. He read each question/item to an individual 
participant and the participant gave an individual response. The author assisted 
interview took place in a well prepared private room. In the latter cases, the author 
recorded the responses accordingly.  
 
3.2.6.3 Modification of the functional activities in the LEFS 
 
Following the analysis of the intra assessor correlation between the first and second 
assessment in pilot 1, all activities were classified as; strong [rho ≥ 0.8], moderate [rho 
< 0.8 and ≥ 0.5] and weak [rho < 0.5] (Black, 2011). In addition, during pilot 1, some 
activities in LEFS were unclear to the Rwandan participants and needed precise 
examples, forming the basis for the subsequent modifications. All such activities were 
modified and made clearer with specific examples, without changing the concepts and 
context of the original LEFS. The modification was done in consultation with a team of 
three health professional experts; two physiotherapists and a medical doctor, who were 
experienced in rehabilitation services, and two participants. The purpose of the team 
consultation was to establish appropriate activities that are commonly and culturally 
done by people living in Rwanda and similar to the activities that define LEFS. The 
activities and their common examples were identified.   
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3.2.6.4 Intra and inter assessor reliability after modification of LEFS 
  
Again pilot 2 aimed at testing the clarity of the LEFS after modifying unclear, moderate 
and weak correlated activities in the scale, and also to carry out intra and inter 
assessor reliability among the author (assessor 1), and the two other assessors. 
 
 
3.2.6.4.1 Procedure 
A sample of 12 participants was randomly selected from PLHIV attending the ART clinic 
at Rwanda Military Hospital in Kigali. Two assessments with a one week interval in 
between were carried out to test the intra and inter assessor reliability after the 
modifications. A two hour training session was conducted for the two assessors to 
familiarise them on using the scale. The three assessors administered the scale piloted 
and modified in pilot 1. Each assessor carried out the assessment of each participant 
independently, and was blinded to the other assessors’ assessment outcomes and 
participants’ scores. The order of the assessors was random to reduce the possible 
learning effect by the participants across the series of the assessments.  
   
3.2.7 Data analysis 
 
The statistical analysis was carried out using STATA (version 11, Stata Corp, College 
Station, Texas, USA). The variables (activities) in the LEFS were categorical and ordinal 
in nature. Spearman’s rank correlation coefficient was used to measure the strength of 
statistical dependence between the same functional activities at the two assessments 
done at two intervals for the same participants. The activity correlation coefficients were 
76 
 
classified according to the levels of strength; as strongly (rho ≥ 0.7), moderately (rho < 
7 ≥ 0.5), and weakly (rho < 0.5) correlated activities (Black, 2004). All activities with 
moderate and weak correlation coefficients (rho), according to the classification, in pilot 
1 were considered for modification (Table 4).  
 
3.2.8 Results of intra and inter assessor reliability testing  
 
Out of 50 (100%) participants who were assessed in the first week, 42 (84%) returned 
in the second week for the second assessment, in pilot 1. Test-retest analysis for intra 
assessor reliability included 42 participants who were able to undergo two assessments 
with a one week time interval between the two assessments. The Spearman’s rank 
correlation coefficient values between the first and the second assessments for each 
activity indicated that 90% (18/20) of the activities were  were moderately (rho ≥ 0.5 ≤7) 
and only 10% (2/20) were weakly correlated (rho ≤ 0.5). Table 3 below describes the 
results. 
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Table 3: The intra assessor reliability done by the author in pilot 1 (n=42) 
 
Activities                                     rho p-value      
Doing daily home activity 0.57 <0.01 
Recreational activity 0.63 <0.01 
Bath limitation 0.69 <0.01 
Walking between rooms 0.54 <0.01 
Putting on shoes & socks *0.44 0.02 
Squatting           0.61 <0.01 
Lifting small object 0.53 <0.01 
Doing light activity at home 0.61 <0.01 
Doing  heavy activity at home 0.52 0.01 
Getting into & out of car 0.53 <0.01 
Walking across from one building to 
another 
*0.47 <0.01 
Walking a km 0.66 <0.01 
Walking up stairs (10 stairs)  0.63 <0.01 
Standing for  1hr 0.63 <0.01 
Sitting for  1hr   0.65 <0.01 
Running on even ground 0.62 <0.01 
Running on uneven ground 0.60 <0.01 
Making sharp turn while running 0.62 <0.01 
Hopping  0.65 <0.01 
Roll over in bed 0.68 <0.01 
*Weak correlation coefficient  
 
Table 3 above indicates that most functional activities that define the LEFS were 
moderately correlated with Spearman’s correlation coefficient in each activity as; doing 
daily home activity (rho=0.57), recreational/leisure activities (rho=0.63), walking 
between rooms (rho=0.54), squatting (rho=0.61), lifting small objects (rho=0.53), doing 
light activity at home (0.61), doing heavy activity at home (rho=0.52), getting into & out 
of car (rho=0.53), walking a km (rho=0.66), and sitting for an hour (rho=0.63), while the 
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weakly correlated activities were only “putting on  shoes & socks” (rho=0.44) and 
walking across from one building to another (rho=0.47). The last two activities which 
were weakly correlated are not commonly undertaken, in most of the Rwandan 
population. Such activities and others with moderate correlations were considered for 
modification.   
 
The Table 4 below indicates the modifications which were made for these activities, with 
specific examples applicable to the Rwandan population. 
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Table 4 Modification of weak and moderate correlated activities with pilot 1 
coefficient results 
Activities     rho p-value Comments and Suggested modifications 
Moderately correlated activities and their modifications 
Doing daily usual 
activity 
0.57 <0.02 Specific examples related to activities the person does 
daily, such as those done at work/employment, going 
to/coming from work, etc   
Recreational/leisure 
activity 
0.63  <0.01 Most people are not involved in traditionally defined 
recreational/leisure activities; related activities were given 
as an example, such as attending weddings and visiting 
friends, going to church, etc 
Bath limitation 0.69 <0.01 Examples included taking a shower or bath 
Squatting           0.61 <0.01 Giving specific example like squatting on pit latrine  
Doing light activity at 
around home 
0.61 <0.01 Examples like, preparing a meal, cleaning a 
the house, making a  bed  
Walking a km 0.66 <0.01 Examples such as going to market/shops, church, or 
other social activities, were given 
Walking up stairs 
(10 stairs) 
     0.63    0.001 For those who might not experience walking up stairs, 
additional examples included; walking on  relatively steep 
irregular ground 
Standing for 1hr      0.63     
0.001 
Examples included standing doing some work, e.g. 
digging, standing in long  service lines, shopping 
Sitting for 1hr 0.65 0.001 Sitting for 1 hour,  like  in church, public bus/taxi, or 
meetings 
Walking between 
rooms    
0.54 <0.01 Specific examples, such “walking from bed room to 
toilet”, bathroom etc 
Lifting an object like 
a bag of groceries  
0.53 <0.01 Examples like lifting a small container full of water (5 litre 
container),  basket of potatoes, etc 
Doing  heavy activity 
at home 
0.52 <0.01 Examples of heavy activities like digging, lifting a heavy 
bag of potatoes, 20 litre container of water, shifting big 
items, etc 
Getting into & out of 
car 
0.53 <0.01 Added on public taxi/bus which is a common mode of 
transport for the majority of people 
Running on an even 
ground 
0.62 0.00 Fast walking on even ground 
Running on uneven 
ground 
0.60 0.00  Fast walking on uneven ground 
Making sharp turn 
while running 
0.62 0.00 Making sharp turns while walking fast at your pace   
Hopping  0.65 0.00 Standing up very fast from squatting as needed 
Roll  over in bed 0.68 0.00 Turning in bed 
Weakly correlated variables and their modifications 
Putting on  shoes & 
socks 
0.44 0.02 Some people hardly put on socks or even closed shoes. 
Question rephrased as “...problems with putting on any 
kind of shoes, including sandals, etc.” 
Walking 2 blocks 0.47 0.01 A specific distance of 100m, or walking from his/her 
home to neighbour’s, a distance of not more than 200m 
away.  
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Table 4 above indicates that the activities that were moderately (rho ≥ 0.5 ≤7) and 
weakly (rho ≤ 0.5) correlated were modified with specific examples of activities which 
are culturally and commonly practiced/used in Rwanda.   
 
Table 5 Activities in the original LEFS versus the activities in LEFS-Modified 
 
Original LEFS activities Modified LEFS Activities 
Any of your usual work, housework, or school 
activities.  
Any of your usual work, (e.g. work that earns you income, or any 
other work you do) housework, or school activities 
Your usual hobbies, recreational or sporting 
activities.  
Your usual hobbies, recreational or sporting activities, eg 
attending weddings, church or visiting friends 
Getting into or out of the bath.  Getting into or out of the bath/taking a bath. 
Walking between rooms.  Walking between rooms  (such as walking from your room to 
toilet, bath room, kitchen,  etc)  
 Putting on your shoes or socks. Putting on any kind shoes or socks, including slippers or open 
shoes, if applied. 
Squatting. Squatting (e.g. squatting on pit latrine/doing any squatting 
activity) 
Lifting an object like a bag of groceries from 
the floor. 
 Lifting an object, like a bag of groceries or a small container like 
5 litres container full of water,  basket of potatoes, etc, from floor 
Performing light activities around your home.  Performing light activities around your home(such as preparing a 
meal, cleaning the house, making a bed, or any other light 
activity at home)   
Performing heavy activities around your 
home. 
Performing heavy activities around your home (digging, lifting a 
heavy bag of potatoes, 20 litre container of water, shifting big 
items, etc 
Getting into or out of a car.  Getting into or out of a car/public taxi/bus. 
 Walking 2 blocks.  Walking across from your home to neighbours or walk l 100m  
Walking a mile.  Walking a km, such as going to market, church or any other 
place  
Going up or down 10 stairs (about 1 flight of 
stairs). 
Going up or down 10 stairs (about 1 flight of stairs) or walking up 
steep and irregular ground 
 Standing for 1 hour. Examples including standing doing some work, e.g. digging, 
Standing in  long  service lines, shopping, etc. 
Sitting for 1 hour.  Sitting for 1 hour,  like  in church, public bus/taxi, or meetings 
Running on even ground. Fast walking on even ground  
Running on uneven ground. Fast walking/running on uneven ground 
Making sharp turns while running fast. Making sharp turns while walking/running very fast    
Hopping.  Standing up fast from squatting as needed  
Rolling over in bed. Turning in bed 
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The modified – LEFS was piloted in pilot 2 to test intra and inter assessor reliability. 
The following tables 6 to 7 indicate the results of study part 2.
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Table 6 Intra-assessor reliability of functional activity in LEFS – Modified, in both assessment1 and assessment 2 
 
*Moderately correlated 
 
Functional Activities  Assessor 1 Assessor  2 Assessor  3 
rho p-value Rho p-value rho p-value 
Any of your usual work, (e.g. work that earns you income, or any other work you do) 
housework, or school activities 
0.9 <0.01 0.75 0.03 0.91 0.02 
Your usual hobbies, recreational or sporting activities, e.g. attending weddings, church 
or visiting friends 
0.7 0.02 0.82 <0.01 0.83 0.05 
Getting into or out of the bath/taking a bath. 1.00 <0.01 0.99 <0.01 0.73 0.03 
Walking between rooms  (such as walking from your room to toilet, bath room, 
kitchen,  etc)  
1.00 <0.01 0.97 <0.01 0.7 0.05 
Putting on any kind shoes or socks, including slippers or open shoes,  0.9 <0.01 0.80 <0.01 1.0 0.01 
Squatting (e.g. squatting on pit latrine/doing any squatting activity) 0.7 0.04 0.76 0.02 0.76 0.04 
Lifting an object, like a bag of groceries or a small container like a 5 litre container full 
of water,  basket of potatoes, etc, from floor 
0.72 0.03 0.81 0.03 0.86 0.03 
Performing light activities around your home(such as preparing a meal, cleaning the 
house, making a bed, or any other light activity at home)   
0.8 0.04 0.72 <0.01 0.7 0.05 
Performing heavy activities around your home (digging, lifting a heavy bag of 
potatoes, 20 litres container of water, shifting big items, etc 
0.7 0.03 0.77 0.03 0.95 0.02 
Getting into or out of a car/taxi. 0.8 0.02 0.75 0.04 0.84 0.03 
Walking across from your home to neighbours or walk 100m  0.7 0.05 0.88 0.02 0.75 <0.01 
Walking a Km, such as going to market, church or any other place  0.9 <0.01 0.84 0.02 0.85 <0.01 
Going up or down 10 stairs (about 1 flight of stairs) or walking up steep and irregular 
ground 
0.78 0.05 0.78 <0.01 0.73 0.04 
Standing for 1 hour,  0.9 <0.01 0.83 0.03 0.84 0.03 
Sitting for 1 hour,  like in church, taxi, or meetings 0.8 0.02 0.70 0.04 0.7 0.03 
Fast walking on even ground  0.7 0.04 0.71 0.03 1.0 <0.01 
Fast walking/running on uneven ground 0.76 0.02 0.90 <0.01 0.78 0.03 
Making sharp turns while walking/running very fast    0.75 <0.01 0.82 <0.01 *0.62 0.05 
Standing up fast from squatting as needed  1.00 <0.01 0.90 <0.01 1.00 <0.01 
Turning in bed 0.8 <0.01 0.88 0.02 0.8 0.02 
Total score 0.79 <0.01 0.85 0.03 0.8 0.02 
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Table 6 above presents the results of all the three assessors. The results indicate that almost all the weak and moderate 
correlated variables were improved to rho ≥ 0.7, only one “Making sharp turns while walking/running very fast” rho=0.62 
(p=0.06)  remained moderately  correlated. 
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Table 7: Inter- assessor reliability obtained for a pair of assessors, for each functional activity in LEFS – Modified 
 
*Moderately correlated 
Functional Activities  Assessor  1 &  
Assessor  2 
Assessor 1 &  
Assessor 3  
Assessor 2 &  
Assessor  3 
rho p-value rho p-value rho p-value 
Any of your usual work, (e.g. work that earns you income, or any other work you do) 
housework, or school activities 
0.8 0.01 0.8 0.01 0.8 0.02 
Your usual hobbies, recreational or sporting activities, e.g. attending weddings, 
church or visiting friends 
0.75 0.01 *0.68 0.04 0.9 0.01 
Getting into or out of the bath/taking a bath. 1.0 <0.01 1.00 <0.01 1.00 <0.01 
Walking between rooms  (such as walking from your room to toilet, bath room, 
kitchen,  etc)  
1.0 <0.01 1.00 <0.01 1.00 <0.01 
Putting on any kind shoes or socks, including slippers or open shoes,  0.7 0.01 0.69 0.03 0.7 0.02 
Squatting (e.g. squatting on pit latrine/doing any squatting activity) 0.74 0.02 0.72 0.04 0.8 0.01 
Lifting an object, like a bag of groceries or a small container like 5 litre container full 
of water,  basket of potatoes, etc, from floor 
0.82 0.01 0.67 0.05 1.00 <0.01 
Performing light activities around your home(such as preparing a meal, cleaning the 
house, making bed, or any other light activity at home)   
0.72 0.02 0.71 0.03 1.00 <0.01 
Performing heavy activities around your home (digging, lifting a heavy bag of 
potatoes, 20 litres container of water, shifting big items, etc 
0.71 0.03 0.9 0.01 1.0 <0.01 
Getting into or out of a car/taxi. 0.8 0.01 0.7 0.01 0.7 0.05 
Walking across from your home to neighbours or walk  100m  0.7 0.01 1.00 <0.01 1.00 <0.01 
Walking a Km, such as going to market, church or any other place  0.7 0.02 0.83 0.02 1.0 <0.01 
Going up or down 10 stairs (about 1 flight of stairs) or walking up steep and irregular 
ground 
0.8 0.01 0.7 0.03 1.0 0.01 
Standing for 1 hour,  0.86 0.01 0.9 0.05 0.71 0.03 
iioasSitting for 1 hour,  like when in church, taxi, or meetings 0.73 0.02 0.81 0.01 1.0 0.01 
Fast walking on even ground  0.86 0.01 0.7 0.03 1.0 <0.01 
Fast walking/running on uneven ground 0.73 0.03 0.74 0.03 1.0 <0.01 
Making sharp turns while walking/running very fast    0.9 <0.01 0.85 0.02 1.0 <0.01 
Standing up fast from squatting as needed  0.9 0.01 1.0 0.01 1.0 0.05 
Turning in bed 0.81 0.01 0.82 0.02 1.00 <0.01 
Total score 0.74 0.01 0.91 0.03 0.95 0.01 
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The second intra assessor analysis showed that the weak and moderate correlated 
variables were improved to r ≥ 0.7, very few remained moderately and none were 
weakly correlated. The improved correlation coefficients were due to the modification of 
including precise examples of activities as applied in Rwanda and in most African 
developing countries.  
 
3.3 Discussion 
This study demonstrates the first validation of the LEFS in PLHIV on ART, from English 
(Binkley et al., 1999) into Kinyarwanda and adapted to an appropriate cultural context. 
HIV-associated functional limitations have been associated with decreased physical 
functioning and have numerous impacts on daily activities of living (Cade et al., 2004; 
Cacchio et al., 2010). The identification of functional activities of the lower extremity is 
crucial for rehabilitation of patients with chronic illness such as those living with HIV and 
on ART (Dudgeon et al., 2004). 
 
This study tested the LEFS to assess the functional activities of the lower extremity for 
rehabilitation purposes in Rwanda. The tested scale can likely be adapted for a similar 
purpose in Africa and other developing countries. LEFS in the developed world has very 
high correlation coefficients of about rho=0.94. It was developed and validated for the 
purpose of identification and evaluation of lower extremity functional activity among the 
elderly (Binkley et al., 1999). Studies suggest that there might be important differences 
in health related activities between high-income and middle/low-income countries 
(Karlsson et al., 2010). Scales may not identify the activities among the population in a 
developing environment (Miranda et al., 2008). The same author pointed out that 
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“research findings from developed settings are not necessarily appropriate to other 
contexts; thus, local knowledge is important”. The results of this study confirm this, with 
most of the activities in the original LEFS only moderately correlated and a few weakly. 
This was probably attributable to the fact that some of the activities in LEFS were not 
familiar to most of the population living in Rwanda. In addition, the language and cultural 
differences might be reasons for such differences seen in the re-validated LEFS. Also 
the methodological differences such the clinical behaviour of participants, may 
contribute to the differences, as commented by Perez et al. (2007) in their study which 
tested the reliability of the Spanish DN4 version from the original French version. The 
results of this study are similar to the results by Perez, et al. (2007) which indicated that 
testing of reliability and validity when a tool is used in another language from that in 
which it was originally validated is crucial. This suggests that it is important that outcome 
measures used in an environment different from the one in which they were originally 
developed and validated are re-validated. The validity and reliability of the adapted 
Kinyarwanda version of the LEFS- Modified tool was good. 
 
3.4. Limitations of the study 
 
Although the DN4 and BPNS were translated into Kinyarwanda and crosschecked by 
experts for the correct use of the terminologies in the Kinyarwanda language, it was not 
necessarily re-tested statistically for re-validation in Rwanda. This would be an 
important consideration for further research.  
87 
 
3.5 Conclusion 
The modified, translated LEFS performed well, with very few remaining moderately and 
no weakly correlated functional activities. Modifications to take into account local 
conditions are critical for evaluations of similar tools that were validated in developed 
world contexts.  
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CHAPTER 4 
4.0 STUDY 2 
 
PREVALENCE OF PERIPHERAL NEUROPATHY, RELATED LOWER EXTREMITY 
FUNCTIONAL LIMITATIONS AND QUALITY OF LIFE, IN PEOPLE LIVING WITH 
HIV ON ART FROM SELECTED ART CLINICS IN RWANDA 
 
4.1 Introduction 
This chapter describes the study on the prevalence of PN, the related lower extremity 
functional limitations and QoL, in PLHIV from selected ART clinics in Rwanda. The 
existing data on the prevalence of PN in Rwanda is limited, and is likely a barrier to 
rehabilitation of PLHIV with PN. The aim of this study was therefore, to document the 
prevalence of PN, its related lower extremity functional limitations and QoL, across 
urban and rural settings in Rwanda. The specific aims were to;  
1.  Establish the overall prevalence of PN, its distribution with demographic and 
health status characteristics,  
2. Identify the association of lower extremity functional limitations with PN, 
3. Assess the association of QoL with PN,  
4. Compare lower extremity functional limitations among PLHIV in urban with rural 
settings and, 
5. Compare QoL among PLHIV in urban with rural settings, in Rwanda. 
 
4.2 Study design, setting, participants and selection 
4.2.1 Design and setting 
The study was a cross sectional quantitative design. It was carried out at eight simple 
randomly selected public outpatient ART clinics clustered into provinces; the western, 
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eastern, northern and southern provinces, and Kigali city, in Rwanda. The lists of all the 
public ART clinics in each province and Kigali city were availed from the former 
“Treatment and AIDS research centre” (TRAC) that is currently a unit in the Rwanda 
Biomedical Centre (RBC), in Rwanda. The list included 186 public ART clinics in 
Rwanda as per the end of 2011. The list was availed in February 2012 when selection 
of the settings was carried out. Private ART clinics were not included in this study 
because of their uniqueness, namely; different medical care protocols and attendance 
by “a high socioeconomic” class of people and which number is very low (RDHS, 2010), 
and who might not be true representatives of the general population. Eight (8) clinics 
(Table 9 below) were selected for this study. Four clinics were simple randomly selected 
from Kigali city (an urban setting) and the other four from the four provinces; one clinic 
per province. The provinces of Rwanda are mostly rural and the population there has a 
homogeneous life style. Kigali city is the only place in Rwanda that has a population 
with an urban life style; therefore, the selection of four clinics from the provinces and 
four from Kigali city had a twofold purpose; 
1. To ensure representative data from both urban and rural settings in this study. 
2. To ensure an appropriate sample for study 3; which was an intervention that was 
planned to be carried out in Kigali city 
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Table 8: The number of participants from each selected ART clinics  
 
No.  ART clinics Province Average number 
attending clinic 
in two weeks (10 
days) 
Number of 
participants 
invited in two 
weeks (10 
days) 
Eligible number 
of participants 
for the study 
1 Biryogo Health Centre Kigali City 490 98 76 
2 Byumba Hospital Northern 360 72 62 
3 Gisenyi Hospital Western 400 80 73 
4 Kabgayi Hospital Southern 370 74 62 
5 Kacyiru Health Centre Kigali City 420 84 66 
6 Kicukiro Health Centre Kigali City 400 80 62 
7 Kimironko Health 
Centre 
Kigali City 390 78 
54 
8 Nyamata Hospital Eastern 350 70 52 
 Total  3180 636 507 
 
4.2.2 Participants and selection 
The study participants were adult men and women aged 18 and above, PLHIV on ART 
who were attending ART clinics for routine health care and management that included; 
receiving ARV medication, health care consultations, counselling services and other 
advice concerning ART in particular, laboratory testing; such as CD4 cell counts. A 
systematic random sampling of 20% of the PLHIV on ART attending each day at each 
of the selected clinics was used in this study, to invite volunteers for participation. A list 
of participants attending at each clinic for a period of two weeks was made available 
prior to the selection of volunteers at every visit. The total number of the participants on 
the list made for each visit (denoted by N) was multiplied by 20% to get the number (n) 
of volunteers for selection on that day; (n=N*20%). The study population was 
considered as a homogeneous population, thus the systematic random selection was 
done by taking the every Kth number; where Kth was a sampling interval on the ordered 
list made for a day. The Kth was calculated by dividing the total number of the 
participants on the list (N), by the number of sample to be selected for the day (n); (Kth 
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= N/n), (Black, 2011). The procedure was repeated for a period of two weeks (10 
working days) which was the maximum period designated for data collection at each 
ART clinic. A total number of 3180 PLHIV were registered to have attended the eight 
selected ART clinic services within the two week period of the study. Using the 
procedure described above, a sample of 636 potential participants was systematically 
invited from the total registered number (3180). The whole process of data collection at 
the eight selected ART clinics took 16 weeks (two weeks at each clinic).  
 
4.2.3 Inclusion Criteria  
I. All people living with HIV on ART from the selected public outpatient ART clinics 
in Rwanda 
II. Aged 18 and above; both females and males 
III. No active opportunistic infection such as TB or others 
 
4.2.4 Exclusion Criteria 
I. PLHIV with known disorders of the central nervous system 
II. PLHIV with a known history of diabetes, Vitamin B12 deficiency, TB, renal failure, 
hypothyroidism and other pathologies that may be associated with neuropathy 
 
4.3 Outcome measures 
Validated and reliable outcome measures were used in this study. The outcome 
measures used in this study were described in chapter 3.  
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4.3.1. Identification of demographic and health status characteristics  
The checklist was used to assess the bio-demographics such as age, gender, level of 
education, marital status, and health status information such as duration the participant 
had been diagnosed with HIV, the type of ARV’s the participant was on, duration on 
ART, other pathologies and behaviour that commonly has PN related disorders (such 
as diabetes, Vitamin B12 deficiency, TB, renal failure, hypothyroidism and others, to 
identify the exclusion criteria), the CD4 cell count level, and PN symptoms (PNS) and if 
the symptoms commenced prior to starting on ART or afterwards. The PN 
characteristics of neuropathic pain were assessed with DN4 (also described in chapter 
3 and in appendix 1 C). The checklist was used to gather the information from the 
participants and from their medical records. It was completed by the researcher with 
assistance when needed from the physician working at the respective outpatient ART 
clinic. 
 
4.3.2 Assessment of peripheral neuropathy 
Peripheral neuropathy was assessed with an adapted (described in chapter 3) validated 
measure, the BPNS tool (McArthur et al, 2005) (appendix 1). The BPNS tool assessed 
subjective and objective measures of PN. The author and two research assistants, who 
are senior physiotherapists with MSc (physiotherapy) degrees, did the assessments. 
Training of the research assistants was conducted by the researcher over one day 
before starting the assessments. Again as mentioned in Chapter 3, the same procedure 
of administering the BPNS to the participants was used. The participants were 
requested to score the “presence and severity of symptoms, using a scale of 1 (mild) to 
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10 (severe) for each leg separately”. The symptoms assessed were; “pain, aching, or 
burning in feet and/or legs; pins and needles in feet and/or legs; and numbness in feet 
and/or legs”. The single highest score of the six scores (three for each leg) was 
transformed to a “subjective PN grade as follows: symptoms absent = grade 0, score of 
1–3 = grade 1, score of 4–6 = grade 2, and score of 7–10 = grade 3”. Symptoms had to 
be bilateral to be graded as ≥ 1. “Objective findings (signs) included in the BPNS are 
the loss of the sense of vibration and abnormal ankle deep tendon reflexes”. The 
vibration sense perception was assessed with a 128-Hz tuning fork, “maximally struck 
and applied at the great toe distal interphalangeal joint of each foot”. The vibration sense 
was defined as “normal for a vibration felt for > 10 seconds, mild loss for a vibration felt 
for 6 –10 seconds, moderate loss for a vibration felt for ≥ 5 seconds, and severe loss 
for no feeling of vibration”. The ankle tendon reflexes were defined as “absent, 
hypoactive, normal, hyperactive, or clonus”. The primary outcome of interest in this 
measure was the presence of PN, which was defined as the combination of at least one 
subjective neuropathy grade greater than 0 and either abnormal vibratory sense or 
ankle deep tendon reflex, bilaterally, as has been defined and used in previous studies  
(Cherry et al., 2005;  Mehta et al., 2010).  
 
4.3.3 Assessment of lower extremity functional limitations 
The lower extremity functional limitations were assessed with the LEFS tool piloted and 
modified LEFS; described in chapter 3). The modified LEFS was self-administered by 
the participants. All participants who knew how to read and write were given the scale 
to complete individually. However, the author and the assistants were nearby to give 
any clarification or assistance wherever needed. The author and the assistants 
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administered the scale for the participants who did not know how to read by reading 
each question/item to an individual participant and the participant gave an individual 
response. The researchers’ assisted interviews took place in a well prepared private 
room. In these cases, the author recorded the responses accordingly. The LEFS 
comprises of 20 items which assess the level of difficulty in performing a variety of ADLs. 
Each item was scored by the participant as 0 = “unable to perform activity”, 1 = “quite a 
bit of difficulty”, 2 = “moderate difficulty”, 3 = “a little bit of difficulty”, and 4 = “no 
difficulty”. 
 
4.3.4 Assessment of quality of life  
The QoL was assessed with the WHOQOL-BREF (described in chapter 3) and in 
appendix 1 E. The outcome measure was self-administered to the participants and they 
completed their perceptions and feeling responses for facets assessing QoL, as 
instructed in the outcome measure. 
 
4.5 Data collection procedure 
4.5.1 Recruitment of participants 
The participants, who were selected according to the procedure described in section 
4.2.2 of this chapter, were asked for their consent to volunteer for the study. Participants’ 
medical records were consulted to get the following data; treatment history such as the 
type of ARVs the participant was on, the duration on ART and to check if the participant 
had any other pathology commonly associated with PN (such as the ones mentioned in 
the exclusion criteria above) apart from HIV and ART. Data from the medical records 
also included information on all relevant laboratory tests such as CD4 cell count and 
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blood counts. In addition, the checklist was used to screen for participants’ eligibility for 
the study. The participants who mentioned having pain were further assessed with the 
DN4 questionnaire to screen for neuropathic pain from other kinds of pains. The 
checklist was used to compliment clinical data extracted from the patients’ record. The 
screening was followed by the assessment for peripheral neuropathy using the BPNS 
tool described above in section 4.3.2. All selected participants completed the rest of the 
questionnaires namely the LEFS and WHOQOL-BREF, to establish lower extremity 
functional ability and QoL, respectively.  
 
4.6 Data analysis 
Descriptive analyses such as tabulations for frequencies and percentages for 
categorical variables and measures of central tendency (means) and measures of 
variability (standard deviations) for continuous variables were done. A bivariate analysis 
using Pearson’s Chi – square and Fisher’s exact tests were used when analysing the 
prevalence distribution of PN and its association with categorical demographic and 
health status variables. The demographic variables included gender, level of education, 
occupation, marital status and place of residence. Health status variables included; the 
period since the diagnosis of HIV, current CD4 count, current ARV regimen 
combination, period since the start on ARVs, presence of PN symptoms, start of PN 
symptoms; if before or after start on ARVs, and the period since start of PN symptoms. 
The student’s t-test (or Mann Whitney for non-normally distributed data) was used for 
pairs of continuous variables. Univariate and multivariate logistic regression analysis 
were used to establish associations, and magnitude (odds ratio) of demographic and 
health status and influence on occurrence of PN. The same test was used to determine 
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the association of settings (in terms of urban or rural) of participants, on the lower 
extremity functional limitations and QoL outcomes. A multivariate regression was 
carried out to determine the presence of PN as a predictive factor on the domains of 
QoL, among PLHIV on ART in Rwanda. The analysis was done using STATA (version 
11, Stata Corp, College Station, Texas, USA).  
 
4.7 Results 
4.7.1 Introduction 
This section describes the results of study 2 namely the prevalence of PN, related lower 
extremity functional limitations and QoL, among PLHIV on ART in Rwanda. The results 
are presented in sections namely;  
 Response rate and the overall prevalence of PN, 
 Prevalence of PN and its association with  demographic characteristics, 
 Prevalence of PN and its association with  health status characteristics,  
 The demographic and health status characteristics predicting the prevalence of PN. 
 The association between PN and lower extremity functional limitations 
 The association between PN and  QoL 
 The association between the participants’ settings and lower extremity functional 
limitations 
 The association between the participants’ settings and QoL 
 
 4.7.2 Response rate  
 
The data collection in this study was done over a period of two weeks at each of the 
selected ART clinics. A total number of PLHIV attending the ART services at the eight 
ART selected clinics was registered as three thousand, one hundred and eighty (3180) 
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within the two week data collection period. Out of this number; 636 who attended the 
clinics in the two week period were randomly invited to participate in the study. Five 
hundred and seven (507), equivalent to 80% of the invited volunteers were eligible 
according to the set selection criteria, fully completed the outcome measures and their 
data were analysed. Therefore, the response rate in this study is 80%.  
 
4.7.3 Prevalence of peripheral neuropathy 
Of the analysed sample of 507, three hundred (300/507) equivalent to 59% [95% CI 
(54%, 63%)] were diagnosed with PN according to the definition of PN given in Chapter 
3. The sections below illustrate the prevalence of PN and its association with different 
characteristics and measured outcomes of the participants in the sample.  
 
4.7.3.1 Prevalence of PN and its association with demographic characteristics 
The prevalence of PN is presented with respect to the demographic characteristics; age, 
gender, level of education, occupation, marital status, and the place of residence 
whether urban or rural. The associations between PN and the demographic 
characteristics are presented in Table 9 below.  
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Table 9: Prevalence of PN and its association with demographic characteristics 
 
  PN n (%) n=507   
Variable  Without 
PN 
(n=207) 
With PN 
(n=300) 
p-value All 
Age (mean±SD)  37(±8.8) 42(±9.2) <0.001* 39.8(±9.2) 
Gender  Female 156 (43) 210 (57)  
0.402 
366 (73) 
 Male 51 (37) 87 (63) 138 (27) 
Education  None 39 (35) 73 (65)  
 
0.002* 
112 (22) 
 Primary 123 (49) 128(51) 251 (50) 
 >=Secondary 45(31) 99 (69) 144 (28) 
Occupation  Employed  13 (31) 29 (69)  
 
<0.001* 
 
42 (8) 
 Peasant/Farmer  118 (53) 106 (47) 224 (44) 
 Self employed  33 (37) 56 (63) 89 (18) 
 Unemployed  43 (28) 109 (72) 152 (30) 
Marital status  Single   17 (49) 18 (51)  
 
0.003* 
35 (7) 
 Married 119 (52) 112 (48) 231 (46) 
 Divorced/Separated 18 (22) 63(78) 81 (16) 
 Window/Widower 53 (33) 107 (67) 160 (31) 
Setting/Residence  Urban  58 (22) 200 (78)  
<0.001* 
258 (51) 
 Rural  149 (60) 99 (40) 248 (49) 
* Denotes significant association between the PN and the demographic characteristic  
 
The prevalence of PN and its association with the demographic characteristics is shown 
in Table 9 above, with the mean age of the participants being 39.7 (SD ±9.2). Half of 
the participants; 251 (50%) had a primary level of education. Participants with PN were 
slightly older than those without PN; [42(SD±9.2) vs 37 (±8.8) (p<0.001)]. There were 
more males (63%), than females (57%) with PN but the difference was not significant 
(p=0.402). The prevalence of PN was significantly different (p<0.01) among the 
participants with different levels of education whereby PN was more prevalent (69%) 
among participants with a higher level of education; secondary school and above. A 
high number (244; 44%) of participants were peasants or involved in farming activities 
on a small scale. There was a statistically significant (p<0.001) difference in the 
prevalence of PN among the participants with different occupational activities, in which 
the PN appeared most in unemployed (72%), followed by employed (69%), self-
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employed/business (63%) and least among the farmers (47%). Almost half (46%) were 
married and PN appeared to be more prevalent among those who were 
divorced/separated (78%), followed by widow/widowed (67%). This difference in 
prevalence of PN with marital status was significant (p=0.003). Peripheral neuropathy 
was highly prevalent among the participants living in the urban setting with 78% 
compared to 40% among those living in rural settings (p<0.01).  
  
4.7.3.2 Prevalence of PN and its association with the health status 
characteristics  
Health status characteristics included the CD4 cell count levels, duration of HIV 
infection, the current ARV regimens the participants were on, duration on ARVs, ARV 
regimen changes the participant had undergone, and the ARV regimen the participant 
had started with; in terms of containing d4T. Table 10 below illustrates the findings.  
Table 10 Prevalence of PN and its association with health status characteristics 
 
  PN n (%) n=507   
Variable  Without  
PN (n=207) 
With PN 
(n=300) 
p-value All 
CD4 cell count <=350 63 (51) 91 (49)  
0.98 
154 (30) 
 >350 144(41) 209 (59) 353 (70) 
Duration since 
HIV diagnosis  
0 – 3 years ago 72 (46) 84 (54)  
<0.001* 
156 (31) 
4 – 6  years ago 91(49) 96 (51) 187 (37) 
 7 and above years 44 (27) 120 (73) 164 (32) 
Current ARV 
regimen  
Non d4T containing 156 (39) 247 (61)  
0.056 
403 (79) 
d4T containing  51 (49) 53 (51) 104 (21) 
Duration on 
ARVs (in years) 
0 – 1 71 (58) 52 (42)  
 
 
<0.001* 
123 (24) 
1 – 3 58 (36) 101 (64) 159 (32) 
4 – 6 61 (30) 108 (70) 169 (33) 
7 and above 17 (41) 39 (59) 56 (11) 
ARV regimen 
changes  
None 44  (43) 48  (57)  
0.045 
102 (20) 
Once 120 (44) 150 (56) 270 (53) 
 Two and more 43  (32) 92  (68) 135 (27) 
ARV started with  Non D4T containing 62 (37) 104 (63)  
0.27 
166 (33) 
 D4T containing  145 (43) 196 (57) 341 (67) 
* Denotes significant p-value for the association between the PN and the health status characteristic  
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The majority (70%) of participants had CD4 cell counts of 350ml/m3 and above. There 
was no significant difference (p=0.98) in the prevalence of PN among participants with 
different CD4 cell count levels. A statistically significant difference (p<0.001) was found 
in the prevalence of PN among participants with different durations of HIV infection; 
whereby PN was more prevalent (73%) among participants who had the infection for 
the last seven and above years. Similarly, an association (p<0.001) was observed 
between PN and the duration on ARVs, in which PN was most prevalent with a duration 
of (4 – 6) years (70%), followed by (1 – 3) years (64%). In addition to the level of CD4 
cell count, other characteristics such as the current ARV regimens and the regimen 
started with, in terms of containing d4T, did not show differences in PN prevalence. 
 
4.7.3.3 The demographic and health status characteristics, predicting PN  
Various demographic and health status characteristics were identified as being 
associated with PN and were likely predictors of its occurrence. Further analysis with 
logistic regression models with separate univariate and multivariate analyses were done 
to determine the magnitude of the association of the characteristics with, and as 
predictors of PN. Only variables with significant associations on univeriate were 
included into the multivariate models. Table 11 below illustrates the results with the 
univariate and multivariate models. 
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Table 11 Demographic and health status, characteristics associated with PN 
*Denotes significant p-value for the association of the characteristics with PN in a multivariable model 
 
Peripheral neuropathy appeared to be associated with demographic characteristics 
such as; age [OR=1.1; 95% CI(0.1, 1.1); p<0.001], education level [OR = 0.6; 95% Cl 
(0.4, 0.9); p<0.01], occupation [OR=0.4; 95% CI(0.2, 0.8); (p<0.01], rural or urban 
setting [OR=0.2; 95% CI(0.1, 0.3); p<0.001], and with health status characteristics that 
Characteristics   Univariate Models Multivariate Models 
 Odds Ratio 
(OR)(95% CI) 
p-value 
 
Adjusted 
Odds Ratio 
(aOR) (95% CI) 
p-value 
Age   1.1 (1.0, 1.1) <0.001 1.1 (1.0, 1.1) <0.001* 
Gender Female    
0.25 
  
 Male  1.3 (0.8, 1.9) 
Education None  1.0 (ref) 
0.6(0.4, 0.9) 
1.2(0.7, 2.0) 
 
0.01 
0.55 
1.0 (ref) 
0.6(0.3, 1.0) 
0.6(0.3, 1.3) 
 
0.04* 
0.2 
 Primary  
 >=Secondary  
Occupation Employed  1.0 (ref) 
0.4(0.2, 0.8) 
 
0.01 
0.5 
0.74 
1.0 (ref) 
0.9 (0.3, 2.2) 
0.3(0.1, 0.9) 
0.6(0.2, 1.4) 
 
 Peasant/Farmer  0.76 
 Self employed  0.8(0.3, 1.7) 0.03 
 Unemployed  1.1(0.5, 2.4) 0.22 
Marital status Single  1.0 (ref) 
0.9 (0.4, 1.8) 
3.3 (1., 4) 
1. 9 (0.9, 4.) 
 
0.75 
<0.01 
0.09 
  
 Married  
 Divorced/Separated  
 Window/Widower    
 Setting/Residence Urban   
0.2(0.1, 0.3) 
 
<0.001 
 
0.1(0.06, 0.3)  Rural  <0.001* 
CD4 cell count <=350      
 >350  1.0(0.7, 1.5) 1.008   
Duration since 
HIV diagnosis 
0 – 3  years ago  1.0 (ref) 
0.9(0.6, 1.4) 
2.3(1.5, 3.7) 
 
0.60 
<0.001 
1.0 (ref) 
0.6(0.3,1.1) 
1.4 (0.7, 3.0) 
 
0.08 
0.33 
4 – 6  years ago  
7 and above yrs  
Current ARV 
regimen 
Non D4T containing   
1.0(0.4, 1.0) 
 
0.06 
  
D4T containing    
Duration on 
ARVs (in years) 
0 – 1  1.0 (ref) 
2.4(1.5, 3.8) 
2.4(1.5, 3.9) 
 
<0.001 
<0.001 
1.0 (ref)  
1 – 3  2.6 (1.4, 4.8) 0.001 
4 – 6                                  2.0 (10, 4.1)           0.05 
 7 and above     3.1(1.6, 6.1) 0.001 2.2 (0.8, 5.9) 0.1 
ARV regimen 
changes 
None  1.0 (ref)    
Once  0.9(0.6, 1.5) 
1.6(1.0, 2.8) 
0.80 
0.08  Two and more  
ARV started with Non D4T containing      
 D4T containing  0.8(0.6, 1.2) 0.27   
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include; duration of HIV infection [OR=2.3; 95% CI(1.5, 3.7); p=0.001], and the duration 
on ART [OR=2.4; 95% CI(1.5, 3.8); (p<0.001)]. Although, these characteristics were 
associated with the prevalence of PN in the univariate analysis, some characteristics 
were not independently associated with PN in the multivariate analysis. Only the age 
[aOR = 1.06, 95% CI (1.03, 1.08), p<0.001], the education level [aOR = 0.6, 95% Cl 
(0.3, 1.0), p = 0.04] and urban or rural setting [aOR=0.1, 95% CI (0.06, 0.3), p<0.001], 
were independently and statistically associated with the prevalence of PN. Thus, age, 
education level and setting predominantly predicated the prevalence of PN in this study.  
 
4.7.4 Association of PN with lower extremity functional limitations 
The association of PN and the lower extremity functional limitations of the participants 
with HIV on ART were assessed. The mean and standard deviations of the scores of 
each activity for all participants were calculated. Table 12 below illustrates the results 
of the activity mean and standard deviation scores and the association with PN.  
 
 
4.7.4.1 The status of functional activity performance and its association with PN 
 
Table 12 below indicates the results of the test.  
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Table 12: Functional activity performance and its association with PN 
 
 PN mean(±SD)   (n=503) 
Functional limitation measures Without PN 
(n=205) 
With PN 
(n=298) 
p-value All participants 
Doing any of your usual work  3.4(±1.0) 2.4(±1.2) <0.001 2.8(±1.2) 
Hobbies, recreational and sporting 3.5 (±1.0) 2.5(±1.3) <0.001 2.9(±1.3) 
Getting into or out of the bath  3.8(±0.7) 3.2(±1.1) <0.001 3.4(±1.0) 
Walking between rooms    3.9(±0.5) 3.3(±1.0) <0.001 3.5(±0.9) 
Putting on any kind of shoes or socks  3.9(±0.5) 2.9(±1.3) <0.001 3.3(±1.1) 
Squatting  3.7(±0.9) 2.7(±1.3) <0.001 3.1(±1.2) 
Lifting an object  3.7(±0.7) 2.9(±1.2) <0.001 3.2(±1.1) 
Doing light activities around home 3.8(±0.7) 3.2(±1.1) <0.001 3.4(±1.0) 
Doing heavy activities around home  3.6(±0.8) 2.7(±1.3) <0.001 3.1(±1.1) 
Getting into or out of a car/taxi.   3.8(±0.8) 3.1(±1.1) <0.001 3.4(±1.0) 
Walking between buildings  3.8(±0.6) 3.2(±1.1) <0.001 3.4(±1.0) 
Walking a Km  3.7(±0.7) 2.9(±1.2) <0.001 3.2(±1.1) 
Going up or down 10 stairs  3.7(±0.7) 2.7(±1.3) <0.001 3.1(±1.2) 
Standing for 1 hour  3.6(±0.8) 2.5(±1.3) <0.001 3.0(±1.3) 
Sitting for 1 hour  3.7(±0.6) 2.8(±1.2) <0.001 3.2(±1.1) 
Fast walking on even ground  3.7(±0.8) 2.6(±1.3) <0.001 3.1(±1.2) 
Fast walking on uneven ground  3.6(±1.0) 2.5(±1.4) <0.001 3.0(±1.3) 
Making sharp turns while walking  3.7(±1.0) 2.6(±1.4) <0.001 3.1(±1.3) 
Standing up fast from squatting  3.7(±0.8) 2.5(±1.4) <0.001 3.0(±1.3) 
Turning in bed  3.8(±0.7) 3.3(±1.0) <0.001 3.5(±0.9) 
Data expressed as mean± standard deviation 
 
There were statistically significant differences (p<0.001) in all of the functional activity 
performance scores between the participants with PN and those without PN. The 
participants with PN had lower mean functional ability scores than those without PN.  
 
4.7.4.2 Association of settings with lower extremity functional limitations 
Urban and rural settings of the participants indicated differences in terms of association 
with PN, as indicated in the demographic characteristics and its association with PN, 
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section. Further testing was done to identify if the settings are also associated with lower 
extremity functional limitations. Table 13 below illustrates the results.  
 
 
Table 13: Level and association of Lower extremity functional limitations with 
participants’ settings 
 
 LEFLs mean(±SD)   (n=506) 
Functional limitation measures Urban (n=258) Rural (n=248) p-value All settings  
Doing any of your usual work  2.8(±1.2) 2.8 (±1.3) 0.55 2.8(±1.2) 
Hobbies, recreational and sporting 3.0 (±1.3) 2.8 (±1.3) 0.22 2.9(±1.3) 
Getting into or out of the bath  3.4(±1.0) 3.4(±1.0) 0.87 3.4(±1.0) 
Walking between rooms    3.8(±1.0) 3.6(±1.9) 0.14 3.5(±0.9) 
Putting on any kind of shoes or socks  3.1(±1.3) 3.5(±1.0) <0.001* 3.3(±1.1) 
Squatting  3.0(±1.3) 3.2(±1.1) 0.08 3.1(±1.2) 
Lifting an object  3.3(±1.1) 3.2(±1.0) 0.26 3.2(±1.1) 
Doing light activities around home 3.3(±1.1) 3.6(±1.1) 0.02* 3.4(±1) 
Doing heavy activities around home  3.2(±1.1) 3.0(±1.2) 0.17 3.1(±1.1) 
Getting into or out of a car/taxi.   3.3(±3.3) 3.5(±1.1) 0.12 3.4(±1.1) 
Walking between  buildings  3.4(±1.1) 3.5(±1.0) 0.35 3.4(±1.1) 
Walking a Km  3.2(±1.1) 3.3(±1.0) 0.86 3.2(±1.1) 
Going up or down 10 stairs  3.1(±1.1) 3.2(±1.1) 0.68 3.1(±1.2) 
Standing for 1 hour  2.8(±1.3) 3.0(±1.2) 0.38 3.0(±1.3) 
Sit for 1 hour  3.1(±1.2) 3.3(±1.0) 0.10 3.2(±1.1) 
Fast walking on even ground  3.0(±1.2) 3.2(±1.0) 0.04* 3.1(±1.2) 
Fast walking on uneven ground  2.8(±1.4) 3.2(±1.0) 0.03* 3.0(±1.3) 
Making sharp turns while walking fast 2.8(±1.4) 3.3(±1.1) <0.001* 3.1(±1.3) 
Standing up fast from squatting  2.8(±1.5) 3.2(±1.1) <0.01* 3.0(±1.3) 
Turning in bed  3.5(±1.0) 3.6(±0.8) 0.73 3.5(±0.9) 
* Significant values 
 
From Table 13 above, it is observed that participants from urban and rural settings were 
not different in terms of their lower extremity functional performance abilities. Significant 
differences were likely in the more complex activities, in which participants from the 
urban setting demonstrated lower activity performance scores compared to their 
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counterparts from rural, settings. These activities included (urban vs rural); fast walking 
on even ground [3.0(±1.2) vs 3.2(±1.0) p=0.04], fast walking on uneven ground 
[2.8(±1.4) vs 3.2(±1.0) p=0.03], making sharp turns while walking fast, [2.8(±1.4) vs 
3.3(±1.0) p<0.001], and getting up from squatting [2.8(±1.4) vs 3.3(±1.1) p<0.01]. Some 
of the lighter activities that were different between the participants in rural and urban 
settings were (urban vs rural); putting on socks [3.1(±1.3) vs 3.5(±1.0) p<0.001], and 
doing light activities around home [3.3(±1.1) vs 3.6(±1.1), p=0.02]. Lower levels of 
performance ability were seen in participants from the urban setting.  
 
4.7.5 The association of QoL with PN among PLHIV on ART 
 
The level and association of QoL of PLHIV on ART with PN were assessed using the 
QoL facet scores and domains, as defined in the WHOQOL-BREF tool for assessing 
the QoL in PLHIV; (as described in chapter 3). The results for each facet score with 
categories of PN (with PN and without PN) are given (Table 14 below), the computed 
domain scores (Table 15), and the association of QoL according to the urban and rural 
settings, were all assessed (Table 17). 
 
4.7.5.1 Rating of QoL facets and association with PN  
The level and association of QoL facets among all participants with HIV on ART with 
PN were computed for mean and standard deviation scores of each facet against the 
PN categories. Mean and standard deviations were appropriate measures to report the 
results of QoL scores. These measures  are recommended for the calculation of QoL 
health domain scores as described in the validation and calculation of scores using 
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WHOQOL-BREF; the tool to assess QoL in PLHIV (Hsiung et al., 2011). Table 14 below 
illustrates the results of the facet mean and standard deviation scores and the 
association with PN.  
 
Table 14: Quality of life facet scores and association with PN 
 
*Denotes Non significant association between the PN and the quality of life facet  
 
PN mean(±SD) (n=507)  
Quality of life facets in domains Without PN With PN p-value Combined 
Overall quality of life     
Rating of quality of life 3.1(±0.9)      2.9(±1.0) <0.01 3.0(±1.0)  
Satisfaction with general health    3.2(±1.0)        2.9(±1.0) <0.01 3.0(±1.0) 
Physical health domain     
Physical pain and discomfort  3.9(±1.2)          3.7(±1.1) 0.02 3.8(±1.0) 
Dependence on medication to function  3.7(±1.4)        3.5(±1.3) 0.24 3.6(±1.4) 
Energy  and fatigue    3.8(±1.0)         3.2(±1.1) <0.001 3.4(±1.1) 
Ability to get around   3.6(±1.1)        3.3(1.1) <0.01 3.4(±1.1) 
Sleep and rest   3.7(±1.1)        3.5(±1.1) 0.02 3.7(±1.1) 
Ability  to perform your daily activities  3.6(±1.1) 3.2(±1.1) <0.001 3.4(±1.1) 
Capacity for work   3.6(1.1) 3.2(±1.1) <0.001 3.3(±1.1) 
Psychological health domain     
Positive feeling of life 3.4(1.1) 3.1(±1.1) <0.01 3.2(±1.1)       
Spirituality or personal beliefs  3.3(±1.1) 3.0(±1.0) <0.01 3.1(±1.0)         
Thinking, memory and concentration  3.7(±1.0) 3.2(±1.0) <0.001 3.4(±1.0)          
Bodily image and appearance 3.7(±1.0) 3.4(±1.1) <0.001 3.5(±1.0)         
Self esteem   3.7(±1.1) 3.5(±1.1) <0.05 3.5(±1.0)          
Negative feelings   3.6(±1.3) 3.5(±1.2) 0.58* 3.5(±1.2)        
Social relationship domain      
Personal relationships  3.9(±1.0) 3.5(±1.1) <0.001 3.6(±1.1)           
Sexual activity   3.1(±1.4) 2.7(±1.4) 0.002 2.9(±1.4)          
Social support  3.7(±1.1) 3.3(±1.1) <0.01 3.6(±1.1)        
Environmental domain     
Physical safety and security  3.6(±1.1) 3.2(±1.1) 0.001 3.5(±1.1)           
Financial resources   2.2(±1.3) 2.1(±1.2) 0.41* 2.2(±1.3)           
Healthy physical environment  2.1(±1.3) 24(±1.2) <0.01 2.2(±1.2)         
Opportunity for acquiring new information and skills   2.9(±1.2)     2.7(±1.1) 0.01 2.8(±1.1)         
Participation and opportunity for leisure activities  3.3(±1.4) 2.8(±1.4) <0.001 3.0(±1.4)         
Home environment conditions  3.7(±1.0) 3.4(±1.1) <0.001 3.5(±1.1)       
Access to health services  3.5(±1.3) 3.0(±1.5) <0.001 3.2(±1.5)         
Transport   3.6(±1.2)        3.2(±1.3) <0.01 3.3(±1.3) 
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Table 14 above demonstrates statistically significant differences (p<0.05) for most of 
the facet scores between participants with PN and without PN. The mean scores among 
the participants with PN were lower than those without PN. However, there were facets 
in which the differences between participants with and without PN did not differ 
significantly; namely one from the physical health domain which is the “dependence on 
medication to function” (p=0.24), one from the physiological health domain; the 
“negative feelings” (p=0.58), and one from the environmental domain; “financial 
resources” (p=0.41). The general rating of QoL and life satisfaction was significantly 
better (p<0.01) among the participants without PN than with PN. 
 
4.7.5.2 Rating of QoL domains and the association with PN  
 
For the purpose of knowing the association of QoL health domains and PN, further 
computations and analysis as described in the WHOQOL-BREF tool, were done for the 
domains scores, against PN groups. Table 15 below illustrates the results. 
  
Table 15: Quality of life domain scores and the association with PN among 
PLHIV 
 
 PN mean(±SD)   
Domains Without PN With PN p-value 
Physical 14.6(±5.5) 13.4(±5.6) <0.001 
Psychological 14.1(±4.8) 12.9(±3.2) <0.001 
Social relationship 14.0(±2.9) 12.5(±3.1) <0.001 
Environmental 12.2(±6.6) 11.5(±6.7) 0.02 
General QoL and health satisfaction 12.4(±1.8) 11.6(±2.0) 0.03 
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Table 15 above illustrates higher mean scores among PLHIV without PN compared to 
those with PN, in all the domains of QoL. The differences were statistically significant at 
p<0.001 for physical, psychological, and social relationship, health domains and at 
p<0.05 for environmental health, general QoL and health satisfaction.  
 
4.7.5.3 Peripheral Neuropathy as a predictor of PN health domain scores 
 
In previous sections on the association of PN with QoL scores, the observation was that 
PN is associated with lower QoL scores among participants with PN. Further analysis 
with a multiple linear regression model to establish PN as a predictive factor for the 
lower QoL domain scores, among PLHIV on ART was undertaken. Table 16 below 
illustrates the results. 
Table 16: Association of PN with QoL domain 
 
Each of the QoL domain scores remained significantly different between PLHIV with PN 
and those without PN, at p<0.001; for physical, psychological and social relationships, 
while environmental and general QoL and health satisfaction were significant at p<0.05, 
after adjusting for other domains.  
QoL health 
Domains 
Univariate 
Models 
Multivariate Models 
Unadjusted coef. 
(95% CI) 
p-value 
 
Adjusted coef. 
(95% CI) 
p-value 
Physical  2.1(1.2, 3.1) <0.001 
<0.001 
2.1(1.2, 3.1) 
1.8 (0.9, 2.6) 
<0.001 
<0.001 Psychological  1.8 (0.9, 2.6) 
Social relationship   1.2(0.7, 1.7) 
1.5(0.3, 2.7) 
0.4(0.09, 0.8) 
<0.001 
0.01 
0.01 
1.2(0.7, 1.7) 
1.5(0.3, 2.7) 
0.4(0.09, 0.8) 
<0.001 
0.01 
0.01 
Environmental 
General QoL & 
health satisfaction 
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4.7.5.4 Rating of QoL among urban and rural participants, in association with PN 
 
Peripheral neuropathy has been identified in this study, to be more prevalent among 
urban than rural participants. The influence on the QoL of the participants from the two 
different settings was assessed; in terms of rating the QoL facets and health domains. 
The following Tables 17 and 18 illustrate the results for the facets and health domains, 
respectively. 
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Table 17: Quality of life facets scores and the association with urban and rural 
settings 
 
* Denotes Non significant association between the PN and the quality of life facet  
 
Most of the QoL life facets scores were not significantly different between the 
participants from urban and rural settings. However, some significant differences were 
PN mean(±SD)  (n=507)  
Quality of life facets   Urban Rural p-value Combined  
Overall  quality of life     
Rating of quality of life 3.0 (±1.0) 2.9 (±1.0) 0.14 3.0(±1.0)  
Satisfaction with general health    3.0 (±1.0) 2.9 (±1.0) 0.28 3.0(±1.0) 
Physical health domain     
Physical pain and discomfort  3.8 (±1.1) 3.7 (±1.2) 0.21 3.8(±1.0) 
Dependence on medication to function  3.5 (±1.4) 3.7 (±1.3) 0.08 3.6(±1.4) 
Energy  and fatigue    3..5 (±1.1) 3.4 (±1.0) 0.44 3.4(±1.1) 
Ability to get around   3.5 (±1.0) 3.3 (±1.1) 0.11 3.4(±1.1) 
 Sleep and rest   3.7 (±1.1) 3.5 (±1.2) 0.15 3.7(±1.1) 
Ability  to perform your daily activities  3.4 (±1.1) 3.3 (±1.1) 0.64 3.4(±1.1) 
Capacity for work   3.4 (±1.2) 3.3 (±1.1) 0.48 3.3(±1.1) 
Psychological health domain     
Positive feeling of life 3.2 (±1.1) 3.2 (±1.1) 0.46 3.2(±1.1)       
Spirituality or personal beliefs  3.1 (±1.0) 3.2 (±1.1) 0.43 3.1(±1.0)         
Thinking, memory and concentration  3.4 (±1.1) 3.4 (±1.1) 0.76 3.4(±1.0)          
Bodily image and appearance 3.5 (±1.1) 3.5 (±1.0) 0.98 3.5(±1.0)         
Self esteem   3.5 (±1.1) 3.5 (±1.0) 0.80 3.5(±1.0)          
Negative feelings   3.6 (±1.1) 3.4 (±1.3) 0.09 3.5(±1.2)        
Social relationship domain      
Personal relationships  3.6 (±1.1) 3.7(±1.0) 0.69 3.6(±1.1)           
Sexual activity   2.9 (±1.4) 2.8(±1.4) 0.65 2.9(±1.4)          
Social support  2.5 (±1.1) 3.4(±1.1) 0.70 3.6(±1.1)        
Environmental domain     
Physical safety and security  3.4 (±1.1) 3.3(±1.2) 0.65 3.5(±1.1)           
Financial resources   3.3 (±1.2) 2.0(±1.2) <0.001* 2.2(±1.3)           
Healthy physical environment  2.3 (±1.1) 2.2(±1.1) 0.08 2.2(±1.2)         
Opportunity for acquiring new information and 
skills   
2.9 (±1.1) 2.7(±1.1) 0.01* 2.8(±1.1)         
Participation and opportunity for leisure 
activities  
3.2 (±1.4) 2.9(±1.4) 0.02* 3.0(±1.4)         
Home environment conditions  3.5 (±1.1) 3.5(±1.1) 0.44 3.5(±1.1)       
Access to health services  3.2 (±1.5) 3.2(±1.4) 0.79 3.2(±1.5)  
Transport   3.4 (±1.3) 3.3(±1.2) 0.24 3.3(±1.3) 
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seen with better scores in urban versus rural. The facets with differences included; 
financial resources; [3.3 (±1.2) vs 2.0(±1.2), p<0.001], opportunity for acquiring new 
information and skills; [2.9(±1.1) vs 2.7(±1.1), p=0.01] and participation and opportunity 
for leisure activities; [3.2(±1.4) vs 2.9(±1.4), p=0.02].  
  
Table 18 Quality of life health domain scores and the association participants’ 
settings 
 
*Significant value at p<0.05 
 
The QoL health domains did not show differences between the urban and rural 
participants. The only significant difference was in the environmental health domain 
where participants from the urban setting had better scores on the QoL in this domain 
than participants from the rural setting, [urban; 12.2 (±6.8) vs rural; 11.5 (±6.7)], at 
p=0.02. 
 
4.8 Discussion  
HIV has changed from being a terminal illness to a chronic condition in the ART era 
(Theroux et al., 2013) and PLHIV are now living longer. However,  living with a chronic 
health condition such as HIV and on ART, has its own complications of which some are 
 Settings 
Health domains Urban Rural p-value 
Physical  14.1(±5.7) 13.8(±5.6) 0.30 
Psychological 13.5(±5.0) 13.5(±5.1) 0.84 
Social relationship  13.3(±3.1) 13.2(±3.0) 0.88 
Environmental  12.2(±6.8) 11.5(±6.7) 0.02* 
General QoL and health satisfaction 12.2(±1.9) 11.8(±1.9) 0.20 
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disabling (Oshinaike et al., 2012). Peripheral neuropathy has been reported as one of 
the common neurological complications of HIV infection and in the ART era (Kamerman 
et al., 2012; Harrison and Smith, 2011). HIV-associated neuropathy is reported as a 
persistent cause of morbidity among PLHIV due to its effects on their quality of life (Ellis 
et al., 2010; Theroux et al., 2013). This study identified the prevalence of PN and its 
association with demographic and health status characteristics, related lower extremity 
functional limitations and QoL among PLHIV on ART from selected rural and urban ART 
clinics in Rwanda. 
 
4.8.1 Prevalence of peripheral neuropathy 
 
The overall prevalence of PN was as high as 59%, compared to previous study 
conducted in Rwanda. A previous study in Rwanda, by Biraguma and Rhoda, (2012) 
indicated a prevalence of 40.5% from one rural district hospital. The difference in the 
prevalence between the two studies may be due to the difference in the study setting 
coverage, in that this study was carried out in various rural and urban health facilities 
while the former was conducted in only one rural district hospital. However, both studies 
show similarities in the prevalence in the rural settings. The prevalence in the rural 
setting in this study is 40% which is the same as the one (40.5%) in the previous study 
conducted in one hospital in the rural setting. The prevalence in the urban setting in this 
study is 78%, which eventually contributes to the overall prevalence being high, that is 
59%.  
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Furthermore, the prevalence in this study is higher than other studies carried out in 
Africa, such as by Luma et al., (2012)  in Cameroon with 28%, Mehta et al., (2010) in 
Kenya with 36%, Oshinaike et al., (2012) in Nigeria with 39% and Maritz et al., (2011) 
with 49% in  South Africa. Almost similar prevalence of PN is found between this study 
and the study by Wadley et al. (2011) done in South Africa. On the contrary, the 
prevalence of PN in this study is slightly lower than that found in  the study in Brazil by 
Zanetti et al. (2004) where the prevalence was 69.4%. There might be various reasons 
for the differences, and these may be due to different methodologies such as study 
populations, the study area, risk factors of PN; examples being age, types of ARV 
regimens, disease stages, and different procedures to control PN, different 
environmental factors and many others. Despite the fact that the prevalence of PN 
differs from that in other studies in Africa, the prevalence falls into the range of the 
general reported prevalence of HIV-associated PN that has been identified to range 
from 30% - 67% (Wulff et al, 2000; Evans et al., 2011; Kamerman et al., 2012). Even 
so, it is important to note that as about 90% of PLHIV in Rwanda who are eligible for 
ART are on it, and some ARVs are likely to influence the development of PN (Theroux 
et al., 2013), the prevalence of PN is likely to continue increasing. This implies that 
PLHIV with PN are and will likely live longer which has a negative impact on their quality 
of life (Venkataramana et al., 2005; Ellis et al., 2010; Oshinaike et al., 2012). Thus, 
efforts need to be made to develop cost effective strategies to reduce the high 
prevalence that impacts on the QoL of PLHIV on ART. 
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4.8.2 Association of peripheral neuropathy with demographic characteristics  
 
An older age was associated with PN, those with PN were older (42 years old) than 
their counterparts without PN (37 years old). This is similar to other studies in which age 
has been consistently identified as a risk factor for developing PN (Cherry et al., 2009; 
Oshinaike et al., 2012). It is known that aging is susceptible to various neuromuscular 
disorders (Hyldahl and Hubal, 2013) including PN. Identifying and monitoring PN 
occurrence is important for possible early detection and appropriate management of PN 
in this group.  Haanpää et al. (2009) and colleagues highlighted that early identification 
and management of the neuropathic pain symptoms is important in primary care to 
improve the quality of life.   
 
There is a high prevalence of PN in PLHIV on ART living in urban compared to rural, 
settings in Rwanda. The very big difference between rural and urban prevalence rates 
is puzzling. A possible reason for the difference may be that people living in an urban 
setting are more likely to be physically inactive and physical inactivity has been reported 
as a risk factor for neuromuscular conditions (which may include PN) in PLHIV 
(Masterson Creber et al., 2010; Schuelter-Trevisol et al., 2012). Similarly, increased 
body weight which is usually common among people who are physically inactive has 
been identified in one of the studies conducted in Rwanda, as a risk factor for 
neuropathy (Mutimura et al., 2007), although weight was not measured in this study. 
Again, the literature shows that physical exercise reduces weight and other co-
morbidities (Botros et al., 2012), such as lipodystrophy which is a potential mediator for 
PN in HIV (Jayakumar et al., 2012). Despite the fact that this study did not assess weight 
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and lipodystrophy, Mutimura et al. (2007) indicated that lipodystrophy was more 
prevalent among PLHIV in urban than rural settings in Rwanda. Routine monitoring and 
assessment of PN with its association with physical inactivity and body weight would be 
useful so as to advise on the appropriate strategies for the management of PN among 
PLHIV, particularly in urban settings.  
 
4.8.3 Association of PN and health status characteristics  
 
The CD4 cell count was not associated with PN. Similar findings of non-associated CD4 
cell counts with PN have been demonstrated in the studies by Morgello et al. (2004), 
Schifitto et al. (2005) and Oshinaike et al. (2012). This implies CD4 cell count might not 
be a measure of risk once on ART (Ellis et al., 2010). The results are contrary to what 
has been found in other studies done in Africa, such as the study by (Millogo et al., 
2008) in Burkina Faso, and the study by Luma et al., (2012) in Cameroon. Possible 
reasons for the differences might include that this study was cross sectional and all 
participants were outpatients and most of them (70%) had CD4 cell counts of 350m//m3 
and above. Yet, decreased CD4 cell count has been shown to be associated with co-
morbidities including PN in PLHIV (Ances et al., 2009).  
 
Likewise, the d4T containing regimen was not associated with PN, which is contrary to 
the findings in the  study by Forna et al. (2007), but is similar to the study by Luma et 
al. (2012) which showed no association of d4T use with PN. A possible reason being 
that people who experience PN as a result of d4T usually experience it in the initial 
stages of the therapy (Hung et al., 2008; Kampira et al., 2013). In their study, Hung and 
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colleagues (2008) demonstrated that the continuation of the use of the so called “d-
drugs” such as d4T among patients who persist with PN from the initial stages did not 
show a significant difference with  the use of non d-drugs, in worsening the neuropathy. 
It is common practice that in cases of PN suspected to occur as a result of d4T, the 
medication is usually discontinued. The experience of PN at later stages of therapy is 
likely attributable to factors other than d4T.  
 
The time since HIV diagnosis and duration on ART, did not independently predict the 
occurrence of PN after adjusting for other confounders in a multivariate model with the 
exception of the duration of 1 – 3 years that appeared as a predictor of PN. To the 
author’s knowledge, it is not yet clear as to why being on ART in the first three years 
predicts PN rather than longer periods of 4 – 6 or 7 and above years. Possible reasons 
might be that  people who experience PN as a result of ART particularly regimens 
containing toxic “d” drug usually experience it in the initial stages of the therapy (Hung 
et al., 2008; Kampira et al., 2013). Additionally, individual susceptable to develop PN, 
regardless of the cause, they do so early. However, further investigation into this with 
longitudinal studies to identify the trend should be done. Otherwise, similar findings in 
other studies in Africa such as by Oshinaike et al., (2012) indicated the same trend of 
ART duration and non - association with PN. Conversely,  studies such as the one by 
Robinson-Papp et al  (2012), highlighted the duration of HIV infection as a risk factor for 
PN. It is important to note that there is a likelihood that the duration the patient has been 
HIV positive and on ART, may influence the occurrence of PN, but different intervals of 
the duration need to be specifically identified.  
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4.8.4 The lower extremity functional limitations and the association with PN 
 
Pain and its associated body functional disturbances or limitations are common in 
PLHIV (Sandoval et al., 2013). The common cause of  chronic pain in HIV is  sensory 
neuropathy (Robinson-Papp et al., 2010), and the pain usually affects the physical, 
psychological,  social, and functional abilities of the affected person (Van As et al., 
2009). Sensory neuropathy in HIV, of which the common one is DSP (Luma et al., 
2012), affects the lower and upper extremities (Robert P. Fellows et al., 2012). This 
study assessed the lower extremity functional limitations and their association with PN. 
 
The findings demonstrated that the functional ability of the lower extremity among 
PLHIV with PN was lower than those without PN. The differences between the two 
groups were observed in all of the functional activities of the lower extremities assessed.  
It is noted that having peripheral neuropathy likely caused limitations in mobility of the 
lower extremities in the group with the neuropathy. Such limitations in mobility 
eventually impacted on the functional activities of the lower extremities of the affected 
participants. For example, participants with PN had difficulties in walking fast, standing 
and sitting for a period of an hour and squatting in toilets (as many people particularly 
in rural areas still use pit latrines), compared to their counterparts without PN. It is 
obvious that PN specifically the neuropathic pain such as burning pain, tingling 
sensations and paraesthesia limit movements that later result in tight muscles, stiff joints 
and spasms and hence limited mobility. This is likely to cause muscle weakness of the 
affected lower extremity due to inactivity. These findings are similar to the study by Van 
As et al., (2009) which found body impairments including neurological, in PLHIV as 
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“predictors of mobility”. Physiologically, neurological impairments influence the daily 
physical functional activities and have been demonstrated as the common cause of 
mobility dysfunction among PLHIV (Meholjić-Fetahović, 2005; Harrison and Smith, 
2011). It is important therefore to note that most cases of HIV related physical body 
impairments affect mobility, and because PN affects the lower extremity, thus the 
functional activities of the lower extremity are more affected.  
 
The lower extremity functional performance abilities of the participants from the urban 
and rural settings were mostly the same. Only significant differences were observed in 
some of the more difficult physical activities, in which there were lower activity 
performance scores, among participants from the urban setting compared to the rural 
one. Physical activities are common in the daily activities of the Rwandans living in rural 
settings because they earn their living through doing hard physical work. Their work 
usually include activities such as farming, cultivation, walking long distances to fetch or 
gather food, firewood, and water, socialisation and other public activities like attending 
church, and going to market. Although such activities are hard, it is likely that they help 
people keep strong physically maintain their flexibility and hence are protective against 
some of the effects of PN on their functional ability. Physical activity or exercise has 
been shown to improve physical functioning and reduce functional limitations (Graham 
et al., 2007), but this was not specifically tested in this study. Further studies could look 
into this relationship. Additionally, the literature indicates that physical activity has a 
protective effect on neurodegenerative disorders (Foster et al., 2011), which might 
result in reduced effects of PN thereby reducing functional limitations among the 
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physically active rural population. The latter might be one of the reasons for having less 
PN related functional limitations among the rural dwellers compared to the urban ones.  
 
The urban participants also had more difficulty in some of the lighter activities namely; 
“putting on socks” and “doing light activities around the home”, than the rural 
participants. The difficulty in putting on socks may have been due to superficial sensory 
pain that is a  common symptom in  PN (Cettomai et al., 2013). The difficulty of putting 
on socks is one of the functional activities related to the sensory hypersensitivity 
disorders among PLHIV with PN assessed in this study. But there are other related 
difficulties faced by PLHIV with PN which likely affect their daily living. For instance, 
people with allodynia encounter problems with sleep difficulties whereby a light touch 
with a bed sheet, for example causes pain, and the person feels as if “there is a touch 
on a wound” (Verma et al., 2005).  
 
4.8.5 The association of PN with QoL 
 
Quality of life is a measure of people’s wellbeing and any disruption of QoL affects their 
wellbeing. It was found that PLHIV with PN have a lower quality of life compared to 
those without PN. However, the participants did not differ in some facets of QoL; as all 
participants equally demonstrated that they depend on the medication such as ARVs, 
experience negative feelings and are financially poor. Poverty, and their dependency 
on medication sometimes result in negative feelings which impact on their quality of life 
(Skevington, 2012). This implies that in addition to the effects of PN for some PLHIV, 
there are other life challenges that impact on them, as demonstrated equally by  both 
groups of participants; those with and without PN.  
120 
 
 
Generally, the rating of QoL and life satisfaction was lower among participants with PN 
than without. The low rating of QoL and life satisfaction might have been in this group 
with PN simply because the QoL is generally affected with functional activity limitations 
as a result of compromised mobility, pain and discomfort (Hughes et al., 2004) of which 
all have been identified among PLHIV with PN. People with limited mobility are unable 
to do most of their daily activities and this affects their QoL and life satisfaction (de 
França et al., 2013). A person with limited mobility may have difficulty doing active work 
that usually earns an income in environments like in this study. Activities like sitting or 
standing for at least an hour, lifting loads, walking long distances, were identified in this 
study to be limited in PLHIV with PN. These findings are similar to the study conducted 
in one district hospital in Rwanda by Biraguma and Rhoda (2012) which showed a lower 
QoL with PLHIV with PN compared to a group of people without PN symptoms in the 
physical and psychological domains. But the studies differ in the study area and 
participant coverage. This study was conducted among both urban and rural 
participants, while the previous one considered only rural participants. To my 
knowledge, this study is the first of its kind to identify the relationship between PN and 
quality of life at a national level coverage of eight health facilities in Rwanda. The results 
from this study may thus be generalised to Rwanda and possibly to other resource 
limited countries, particularly in Africa where some of the social and environmental 
influences are  similar (Conn, 2012).  
 
Peripheral neuropathy was a predictor of low QoL among PLHIV in all QoL domains. 
The domains of QoL include; physical and psychological health, social relationships and 
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environmental domains. Peripheral neuropathy which is described with symptoms that 
include neuropathic pain, numbness, tingling and, “pins and needle” sensations, and 
signs such as reduced or no vibration sense, and ankle tendon reflex, are all likely to 
affect all the domains of QoL. This is one of the reasons that people with PN confirmed 
low QoL compared to those without. The results  are similar to those of Ellis et al. (2010) 
except that Ellis and colleagues tested PN as a predictive factor of QoL among  pre-
ART participants. Furthermore, the study by Ellis et al. (2010) used neuropathic pain as 
a measure for PN, and the effects of PN on physical and mental subscales of the 
measure of the QoL, were assessed.  
 
On the other hand, PLHIV with PN in urban areas showed better financial resources, 
opportunities for acquiring new information and skills, and participation opportunities for 
leisure activities, compared to their counterparts from rural areas. This difference is 
likely to be related to environmental factors rather than to the PN. For example in the 
urban areas there is easy access to information through radio and TV, opportunities to 
access recreational centres, good road networks and easy public transport. 
Furthermore, it is possible that some people in the urban areas were employed, 
although this was not assessed. These factors might have contributed to the urban 
dwellers having better accessibility to information, recreational services and having 
better financial resources than those in the rural areas. The Rwanda Demographic and 
Health Survey [RDHS] (2010) has reported that households in  urban areas are 
wealthier by 12% than those in the rural areas. This also might have resulted in the 
reporting of better financial resources in the urban dwellers. It has been reported that 
financial resources are one of the most common facets in the environmental domain 
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that influences lower QoL (de França et al., 2013). A study conducted in Singapore 
highlighted that the financial resources were “intimately linked to environmental and 
living conditions” and impacted on the QoL (Leow et al., 2013).  
 
4.8.5.1 Importance of understanding PN in relation to QoL 
 
Although the introduction of ART has improved the QoL in PLHIV by reducing the impact 
of HIV, the adverse effects of ART including PN, still affect the QoL of PLHIV (Abdella 
et al., 2011). The QoL is affected in its various domains that include; physical, 
psychological and environmental and this may interfere with the benefits of ART, hence 
impacting on ART adherence (Abdella et al., 2011). It is important therefore to have 
initiatives for complementary management of the neuropathy, particularly in Rwanda 
and other resource limited countries, where the PN prevalence is high.  
 
4.8.6 Strengths and limitations of the study 
 
The strength of this study is demonstrated in the large sample size and inclusion of 
randomly selected ART clinics. The use of a rigorous PN assessment tool ensured 
reliable data to determine the prevalence of PN in Rwanda. The data can be used in 
developing strategies for the comprehensive management of the condition, particularly 
among urban and in the older, PLHIV on ART in Rwanda. In addition, the findings can 
be generalized for both rural and urban dwellers in Rwanda and possibly poorly 
resourced nations where the lifestyle of the populations is similar. 
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The study’s major limitation is that it is cross sectional and participants were outpatients 
who were likely not in the advanced stages of HIV, which might have influenced the 
level of CD4 cell count in the sample. Additionally, few participants in the sample were 
on d4T containing regimens which may have limited the associations tested for d4T and 
PN. Occupational activities were used to identify the lifestyle of the participants but a 
more rigorous assessment procedure to identify the lifestyle activities, and demonstrate 
the influence of the lifestyle activities on occurrence of PN could be done. Also the study 
recruited participants from public ART clinics, which is a limitation on generalisation of 
results to the private PLHIV, though the number of people who attend the private ART 
services is likely very low.  
 
4.8.7 Conclusions  
 
This study identified a high prevalence of PN in Rwanda and this can form the basis for 
designing strategies for managing the problem and to prevent or minimise the effects of 
PN that compromise the quality of life of PLHIV. Older PLHIV and those living in urban 
settings and on ART should have their PN status monitored so as to maintain and 
improve their quality of life appropriately. However, further investigation into lifestyle 
behaviour and other factors that may influence the occurrence of PN need to be 
assessed in a longitudinal study. 
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CHAPTER 5 
 5.0 STUDY 3: METHODOLOGY OF THE EXERCISE INTERVENTION 
(RCT) 
 
THE EFFECTS OF PHYSIOTHERAPEUTIC EXERCISES ON PERIPHERAL 
NEUROPATHY, RELATED FUNCTIONAL LIMITATIONS OF THE LOWER 
EXTREMITY AND QUALITY OF LIFE, AMONG PLHIV ON ART IN RWANDA 
 
5.1 Introduction 
The aim of study 3 was to establish the effects of physiotherapeutic exercise (PTEx) on 
PN, its related lower extremity functional limitations and QoL, among PLHIV on ART in 
Rwanda. The study was a RCT and this chapter describes the methodology used. The 
methodology includes; the objectives participants and their selection, the randomisation 
process, exercise programme protocol, assessment procedures and finally the data 
analysis tests done. 
 
5.2 Objectives  
1. To test the effects of PTExs on PN, related lower extremity functional limitations 
and QoL, in PLHIV on ART, 
2. To assess the effects of a PTExs programme post 12 weeks of its intervention in 
PLHIV on ART, 
3. To identify factors associated with and influencing the improvement of PN, 
related lower extremity functional limitations and QoL, in PLHIV on ART 
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5.3 Study setting, participants, sample size and selection 
5.3.1 Study setting and participants 
This study was carried out in Kigali city Rwanda and the setting for the intervention was 
located near the city centre, at the Kigali Health Institute (KHI)’s physiotherapy clinic 
and fitness centre, located about 200 metres from the main road to the city centre. This 
location was convenient for participants travelling with public transport and was easily 
accessible for participants from the three districts that constitute Kigali city. 
 
As described in chapter four, the study participants were PLHIV on ART, who were 
systematically randomly screened from four simple randomly selected ART clinics at 
health centres and hospitals in the Kigali districts; namely; Kicukiro Health Centre in 
Kicukiro district, Kimironko Health Centre and Kacyiru Hospital both in Gasabo district, 
and Biryogo Health Centre commonly known as Kwa-Nyiranuma in the Nyarugenge 
district. Kigali city was considered to be the most appropriate study site due to the fact 
that being a city and an urbanised area, the populations’ life style was likely to be more 
homogeneous than in rural areas where people have a range of different life styles. Also 
Kigali being a city with a large population living close together in the three districts of 
the city, made it convenient for participants to travel to the intervention site. In addition 
transport in the city is better than in rural areas as it is more accessible making it easier 
for participants to reach the centre easily.  
 
5.3.2 Inclusion and exclusion criteria of the participants 
The following inclusion and exclusion criteria were considered in addition to what is 
listed in Chapter four (prevalence; Study 2). 
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5.3.2.1 Inclusion criteria 
Only participants screened with obvious PN in Study 2 were invited to participate in the 
intervention; Study 3. 
 
5.3.2.2 Exclusion 
 
 Any clinical history that would be an exercise contraindication ; according to the 
American College of Sports Medicine guidelines for exercise prescription for PLHIV 
(Sonya and Anderson, 2006). 
 Unwilling to participate in the PTExs and the rest of the follow up programme, very weak 
patients who could not walk without support, other neuromusculoskeletal impairments 
such as, musculoskeletal deformity, amputation, scoliosis, and inability to actively and 
functionally move ankle and knee joints, lower extremity arthritis, and central 
neuropathies like hemiparesis and central paralyses.  
 PLHIV with a known history of diabetes, and substance abuse, Vitamin B12 deficiency, 
TB or taking TB medication such isoniazide, renal failure, hypothyroidism and other 
pathologies that may be associated with neuropathy.  
 
5.3.3 Sample size and selection  
 
The sample for the exercise intervention was one hundred and twenty (120) 
participants. The participants in the sample were consecutively invited from one 
hundred and sixty four (164) PLHIV on ART who were randomly screened with PN in 
Kigali, during the prevalence study (Study 2; Chapter four) with the methodology 
described in chapter four. The 164 participants were invited from respective selected 
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ART clinics in Kigali, to the Kigali Health Institute physiotherapy clinic where screening 
for eligibility and baseline assessment took place prior to the start of the exercise 
intervention. One hundred and thirty nine (139) out of the 164 participants responded 
to the invitation at the clinic, and only 120 were eligible for the exercise intervention, 
according to the eligibility criteria discussed in the above section. Thus, 60 participants 
were allocated to each group. The statistical power with an allowance for a dropout of 
30% per group demonstrated that the sample of 120 participants would give the desired 
effect with a power of more than 80% and detect a difference in the of pain improvement 
(effect size) for p=0.05, from the exercise intervention. 
 
5.3.4 Randomisation and concealed allocation to the groups  
The 120 participants assessed for baseline data were randomised into two groups of 
60 in the experimental group and 60 participants in the control group, with random 
computer generated numbers. An independent research assistant put the numbers into 
opaque sealed envelopes which were randomly given to the eligible participants by 
another research assistant who did not participate in putting the numbers into the 
opaque sealed envelopes. This ensured concealed allocation of the participants into the 
groups. The study was a single blinded RCT design, whereby the assessor was blinded 
to which group was experimental or control, until after the last assessments.  
 
5.4 Procedure for the exercise intervention 
The experimental group of 60 participants continued receiving Routine Health Care 
(RHC) from the respective ART clinics plus PTExs (RHC+PTExs). The control group 
continued receiving only the RHC without PTExs (RHC–PTExs), that is the ARVs and 
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other prophylactic medications such as the ones that were used to reduce/treat pain; 
including antidepressants, multivitamins, as well as routine medical consultations, CD4 
testing and counselling services. 
 
5.4.1 Physiotherapeutic exercise protocol (Appendix 2)  
The PTExs protocol was mainly comprised of exercises for the extremities that were 
identified in the literature (Gale, 2003; White, 2004; Hess and Woollacott, 2005; Nixon 
et al., 2005; O’Brien et al., 2010) and were recommended as safe and beneficial to 
PLHIV.  
 
The exercises included aerobic exercises that constituted a start of 15 minutes warm 
up by walking (slow then to brisk walk plus full range of upper and lower limb flexibility 
exercises), 15 minutes of mobility training with self-stretching in standing, lying and long 
sitting, positions, 10 minutes of muscle conditioning with isometric exercises in various 
starting positions, 10 minutes of balance exercises and finally 10 minutes of cooling 
down exercises (stretching and deep breathing) among others. Systematic reviews of 
effectiveness of PTExs of an aerobic nature for various patient conditions indicate that 
a combination of the above exercises is safe, affordable and is recommended (Smidt et 
al., 2005; O’Brien et al., 2010). The PTExs were given for 60 minutes per session three 
times a week for a period of 12 weeks. 
 
In addition, the participants in the exercise intervention were educated on how to 
exercise on their own as a home exercise programme. This was so that after the 
supervised and guided exercise sessions of 12 weeks at the centre, the participants 
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were expected to continue exercising on their own at home. The participants were 
encouraged to continue exercising at home and were assessed again at 12 weeks after 
the supervised and guided exercise intervention at the centre. At the centre, the 
exercise intervention was conducted in a room suitable for aerobic and therapeutic 
exercises. A qualified physiotherapist with a master’s degree and who had experience 
in conducting aerobic exercise programme, conducted and supervised the intervention 
exercise programme with the experimental group. The research assistant was also 
trained by the author to conduct the exercise sessions, with emphasis on the exercise 
protocol guide designed for the intervention.  
 
5.4.2 Outcome measures and assessment procedure 
The blinded assessor, that is the author did the assessments for both groups and was 
blinded to the group allocation (experimental or control) prior to the beginning of the 
exercise programme (baseline), after 12 weeks (end of exercise programme) and after 
12 weeks post intervention. The outcome measures described and adapted in Study 1 
and used in Study 2 were also used in this study (Study 3); namely, the checklist for 
demographic and health status characteristics, BPNS & DN4 for PN, LEFS-M for LEFLs, 
& WHOQOL-BREF, for the QoL. All the procedures and protocols used in the 
assessment for this study were described in Chapter four (Study 2). 
 
5.4.4 Precautions and follow up of the participants during the intervention 
During the exercise sessions, precautions were taken to prevent fatigue, check for 
abnormal heart rate and any other clinical signs such as blood pressure or symptoms 
contraindicated to exercises. Participation at each session was registered and followed 
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up with telephone calls to those who had mobile phones, to establish the reasons as to 
why any participant missed session(s). Also monthly, calls were made to the control 
group, to remind them of the schedules for the assessment after 12 weeks and after 24 
weeks. They were only reminded of the assessment schedules during these calls. 
 
5.5 Data management and analysis 
 
All the questionnaires and other data collection material were kept in a well locked room 
reserved at the Kigali Health Institute physiotherapy clinic where the intervention and 
assessments took place. The data entry took place at the same place. Questionnaire 
variables were coded with numbers and the codes were entered into an Excel spread 
sheet by two research assistants trained by a statistician on how to enter data. The 
variables were re-checked and verified by the author before and after entry for 
correctness and any errors. The data were transferred into a STATA programme for 
cleaning of any errors that might have occurred during the data entry process. Any error 
identified was rectified from the questionnaires and from recording spread sheets. The 
author was blinded to the data of which group was the experimental or control, until after 
the analysis.  
 
Using descriptive analysis such as tabulations for frequencies and percentages for 
categorical variables and measures of central tendency (means) and measures of 
variability (standard deviations) for continuous variables such as age and the measures 
of lower extremity functional limitations and QoL, were done with Wilcoxon rank-sum 
(Mann-Whitney) test. A bivariate analysis using Pearson’s Chi-square test for significant 
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differences between the experimental and control groups, at baseline, after 12 weeks 
of PTExs and after 12 weeks post intervention, was done. A generalised linear model 
with generalised estimating equations (GEE) and logit link function, was used to identify 
the significant factors associated with, and influencing improvement changes, their 
magnitude, for the outcome measures of interest for PN and lower extremity functional 
limitations. While analysis for the overall QoL was done with multilevel mixed effects 
linear regression. The factors tested for the association with, and influence of 
improvement changes of PN, lower extremity functional limitations and QoL, included 
the demographic and health status related characteristics; such as age, gender, level 
of education, marital status, occupation, duration since HIV diagnosis, CD4 cell count 
levels, duration on ART, treatment regime (ARVs) the participants were taking, ARV 
regimen changes, and whether PN started before or after the start on ARVs. Adjusted 
odds ratios and their 95% confidence level were reported to have a magnitude of 
association and influence for PN and lower extremity functional limitations, as binomial 
outcomes, while coefficient correlations were reported for QoL as a linear outcome in 
the model. Significance level acceptance was set at p-value ≤0.05. Data were analysed 
using STATA (version 11, Stata Corp, College Station, Texas, USA). All analyses were 
done with an intention-to-treat analysis, whereby all analyses included all the 
participants who were randomised according to each group assignment (the baseline 
observation carry forward analysis). The results of the intervention are presented in 
Chapter six.  
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CHAPTER 6 
 
 
6.0 STUDY 3: RESULTS OF THE INTERVENTION  
 
 
6.1 Introduction 
Chapter six presents the results of Study 3 which was an intervention using a RCT, to 
test the effects of PTExs on PN, related lower extremity functional limitations and the 
QoL in PLHIV on ART. During the intervention, three interval assessments were done; 
namely at; 1) baseline, 2) after twelve (12) weeks of PTExs and 3) after twelve weeks 
post  intervention. The results are presented for all three interval assessments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
Figure 2: Flow diagram of the participants randomised into the intervention and control, groups  
 
Assessed (n=56) after 12 
Wks 
60 (rHC+PTExs) 
Eligible for PTExs and 
randomised (n=120)  
Dropped out (n=6); 
Lack of time = 2 
Lost follow up = 1 
Moved away =2 
Death = 1 
60 (rHC-PTExs) 
 
Dropped out (n=4); 
Lack of time = 2 
Moved away =1 
Lost follow up = 1 
Assessed (n=54) after 12 
Wks 
Dropped out (n=2); 
Moved away = 1 
Health issue = 1 
Dropped out (n=6); 
Lost follow up = 2 
Lack of time = 4 (3 
got better & went 
back to work, 1 just 
lack of time) 
 
Assessed (n=50) after 12 Wks 
post PTExs 
Assessed (n=52) after 12 
Wks post PTExs 
Responded to invitation and 
assessed for eligibility (n=139) 
Not eligible for PTExs 
(n=19) 
Did not respond to the 
invitation (n=25) 
Screened with PN 
(n=164) 
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Out of 164 participants who were screened with PN and invited for the intervention 
study, 25 did not respond to the invitation, and 19 were not eligible for exercises due to 
a known clinical condition that was contraindicated for exercise, such as cardiovascular 
abnormalities, and any neuromusculoskeletal disorder that is exacerbated by exercise 
(Kisner and Colby, 2007). Four people dropped out of the exercise intervention during 
the 12 weeks of PTExs. Reasons for dropout being; one participant was a primary 
school administrator and because of her work demands she was unable to get enough 
time for exercising at the site, another person moved to one of the other provinces, two 
other participants were unable to attend because also of work related reasons. This 
brings the adherence to the exercise intervention in the experimental group during the 
12 weeks to 93%, with approximately 7% dropout.  
 
In the control group, six participants dropped out during the first 12 weeks. Common 
reasons were lack of time (n=two), moving away from Kigali (n=two), one participant 
died of meningitis, one participant lost to follow up. The follow up of the control during 
the 12 weeks was 90% with a 10% drop out.  
 
After 12 weeks post exercise intervention, six participants did not return for assessment 
in the experimental group, giving a follow up of 89%. Three participants improved 
sufficiently and returned to work and were unable to come back during the time of the 
assessment; one was a driver, another a night watchman and the third was a business 
woman who had gone to neighbouring country for business reasons. The reasons for 
two people (lost to follow up) were unknown and one person also reported lack of time 
to come back for the third assessment. Only two participants did not come for the third 
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assessment (after 24 weeks) for the control group and the follow up at this stage was 
calculated as 96%. The reasons for the drop out being that one had moved away from 
Kigali and the second one was sick and could not make it for the last round of the 
assessments.  
 
6.2 Objectives  
Objectives for the intervention study (Study 3) were set to guide the analysis and 
presentation of the results appropriately. The objectives were; 
 
6.2.1 Specific objectives 
 
1. To test the effects of PTExs on PN as the primary outcome, 
2. Test effect of PTEs on PN related lower extremity functional limitations and QoL, 
in PLHIV on ART, as the secondary outcomes.  
3. To assess the effect of a physiotherapeutic exercises programme post 12 weeks 
of its intervention in PLHIV on ART 
4. To identify factors associated with and influencing the improvement of PN, 
related lower extremity functional limitations and QoL, in PLHIV on ART 
 
6.2.2 Demographic and health status differences between the groups at baseline  
Participants in the intervention group were adult women and men, living with HIV, 
attending ART programmes at selected ART clinics in Kigali Rwanda, and who were 
screened with PN during the prior prevalence study (Study 2; chapter four). Table 19 
below compares the demographic and health status characteristics between the 
experimental and control groups at baseline.  
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Table 19: Demographic and health status characteristics of the participants: 
comparison between the experimental and control groups at baseline (n=120) 
 
Characteristics  Experimental group 
(n=60) n (%) 
Control group 
(n=60) n (%) 
Group differences 
n(%) 
p-value 
Age (mean±SD years)  41.2  ±7.8 
CI: 95% (40,45) 
40.4±7.7 
CI: 95% (39, 43) 
1.01±  CI: 95% 
(1,2) 
0.59 
Gender 
Female 
Male  
 
48 (80) 
12 (20) 
 
50 (83) 
10 (17) 
 
2(3) 
2(3) 
 
0.64 
Education 
No schooling 
Some primary school 
Some secondary and university education   
 
11 (18) 
3 (58) 
14  (24) 
 
13 (22) 
29 (48 ) 
18  (30) 
 
3(4) 
6(10) 
4(6) 
 
 
0.54 
Occupation  
Employed        
Self-employed/Peasant/farmers             
Unemployed  
 
5  (8) 
13 (21) 
4 (70) 
 
6 (10) 
18 (30) 
36 (60) 
 
1(2) 
5(9) 
6(10) 
 
 
0.51 
Marital status 
Single     
Married   
Separated/Divorced    
Widow/Widower   
 
1 (2) 
16 (26) 
4 (7) 
39 (65) 
 
2  (3) 
18 (30) 
12 (20) 
28 (48) 
 
1(1) 
2(4) 
7(13) 
11(17) 
 
 
0.10 
Duration since HIV diagnosis 
Less or equal to 3 years ago  
4 to 6 years ago 
7 and above years ago  
 
8(13) 
18 (30) 
34 (57) 
 
3  (5) 
19  32) 
38 (63) 
 
5(8) 
1(2) 
4(6)) 
 
 
0.31 
CD4 cell count 
 ≤ 350           
 351 >         
 
22 (37) 
38 (63) 
 
15 (25) 
45 (75) 
 
7 (12) 
7(12 
 
0.17 
Duration on ARVs 
Less or equal to 3 years ago  
4 to 6 years ago 
7 and above years ago 
 
15 (25) 
36 (60) 
9   (15) 
 
18 (30) 
34 (54) 
8 (13) 
 
3(5) 
2(6) 
1(2) 
 
 
0.82 
ARV regimen combination started with 
None D4T including 
D4T including 
 
33 (55) 
27 (45) 
 
40(66) 
20 (34) 
 
7 (11) 
7 (11) 
 
 
0.78 
Current ARV regimens’ combination 
None D4T including 
D4T including 
 
53 (88) 
7 (12) 
 
50 (83) 
10 (17) 
 
3(5) 
3(5) 
 
0.60 
ARV regimen changes since started on ART 
No change           
One or more changes    
 
18 (30) 
42 (70) 
 
16 (27) 
44 (73) 
 
2  (3) 
2 (3) 
 
0.69 
The onset of PN symptoms and/Signs  
Before starting on ARVs 
After starting on ARVs 
 
5 (8) 
55 (92) 
 
12 (20) 
48 (80) 
 
7 (12) 
7 (12) 
 
0.07 
After how long on ARVs when PNS started 
Within the 1st 12 months 
After the 1st 12 months           
 
25 (45) 
30 (55) 
 
14  (29) 
34 (61) 
 
11 (16) 
4 (6) 
 
0.09 
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The results of the comparison of the demographic and health status characteristics 
indicated non-significant differences between the two groups at baseline.  
 
6.3 The effect of the physiotherapeutic exercises on the PN, lower 
extremity functional limitations and QoL 
 
The following sections present the results for each of the three major outcomes of 
interest in regard to the effects of PTExs.  
 
6.3.1.1 The effects of physiotherapeutic exercises on the PN 
Peripheral neuropathy characteristics included more than one symptom and sign which 
were; PN symptom grades or severity, distribution of PN to different locations of the 
lower extremity, sense of vibration and ankle tendon reflex. The results on the effect of 
the PTExs on each characteristic are presented with respective figures that show the 
trend of differences and changes over time during the 12 weeks of intervention and 12 
weeks post intervention. Finally, the results on the overall diagnosis of PN are also 
shown.  
 
6.3.1.1 The effect of physiotherapeutic exercises on the PN symptoms 
Peripheral neuropathy symptoms were measured at three time intervals; at baseline, 
after 12 weeks of the PTExs intervention and 12 weeks post intervention. The PN 
symptoms were measured as none, mild or moderate to severe. Figure 3 below 
indicates how PN symptoms changed from severe to none and or mild PNS through the 
three assessments  
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Differences in PN symptom severity: baseline; p= 0.20, at 12 weeks; p<0.001, and 24 weeks; p<0.001.  
Figure 3: The difference and change in percentage of participants who improved 
from severe to mild/none PN symptoms, between the groups 
 
The participants improved from severe PN symptoms to mild or none. The above figure 
demonstrates the percentage increase of participants who improved. At baseline, there 
were 60% and 55% of participants with PN symptoms for control and experimental 
groups, respectively. There were statistically significant differences between the groups, 
with improvement in the intervention group compared to the control group after 12 
weeks of PTExs (85% vs 62%; p<0.001) and 12 weeks post intervention (76% vs 58%; 
p<0.001). 
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6.3.1.2 Effect of PTExs on the distribution of PN symptoms to parts of the lower 
extremity 
 
Usually the PN symptoms of DSP type are distributed to the lower extremity in a 
“stocking” pattern, however in cases of severe symptoms; the participants had radiation 
of symptoms above the common region of distribution, such as the lower leg and knee, 
above the knee and sometimes to the hip region. Figure 4 below indicates the 
percentage of participants who had an improvement of the radiating PN symptoms 
above the ankle region, after 12 weeks of PTExs intervention and after 12 weeks post 
intervention.  
 
Differences in PN symptoms distribution: baseline; p= 0.190, at 12 weeks; p<0.001, and 24 weeks; p<0.001 
 
Figure 4: Change in percentage of participants who improved in terms of PN 
symptoms distribution to various parts of the lower extremity 
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There were significant differences between the groups with an improvement in the 
experimental group after 12 weeks of PTExs and 12 weeks post intervention; (80% vs 
37%; p<0.001) and (85% vs 33%; p<0.001) respectively.  
 
6.3.1.3 The effect of PTExs on the neuropathic pain 
Neuropathic pain includes sensations such as; burning, pins & needles and tingling 
sensations, numbness, painful cold, pains in the form of “electric shocks” hyper and 
hypo-aesthesia to touch and pin prick, among people with PN. Figure 5 below indicates 
the differences between the groups and change in percentage of participants with 
neuropathic pain from baseline to 12 weeks of intervention and 12 weeks post 
intervention. 
 
 Differences in neuropathic pain; at 12 weeks; p<0.005, and 24 weeks; p<0.005  
Figure 5: The change from higher to lower percentages of participants with 
neuropathic pain for the intervention group 
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There was a statistically significant difference in improvement of the peripheral 
neuropathic pains in the intervention group compared to the control group, which is 
evident with the reduced percentages of participants still presenting with pain, after 12 
weeks of the PTExs (71% vs 94; p<0.005) and 12 weeks post intervention (70% vs 
92%; p<0.005).  
 
6.3.1.4.1 The effect of physiotherapeutic exercises on sense of vibration 
Sense of vibration was one of the objective measures for the diagnosis of PN. Figure 6 
below indicates whether there was a change in terms of improvement of the sense of 
vibration from none/severely reduced to normal or minimally reduced. 
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Differences in sense of vibration; baseline; p= 0.58, at 12 weeks; p =0.26, and 24 weeks; p = 0.16.  
 
Figure 6: Changes from severely reduced/none, to normal/minimally reduced 
vibration sense 
 
 
There were no significant differences in improvement in the sense of vibration from 
severely reduced/none to minimally  reduced or normal sense of vibration, between the 
two groups after 12 weeks of PTExs intervention and 12 weeks post intervention, (59% 
vs 48%, p=0.26) and (57% vs 42%, p=0.16) 
 
6.3.1.4.2 The effects of PTExs on ankle tendon reflex 
Figure 7 below indicates the results of the changes in terms of improvement of the ankle 
tendon reflex from no reflex to reduced /normal reflex.  
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Differences in the ankle tendon reflex; baseline; p= 0.54, at 12 weeks; p=0.10, and 24 weeks; p=0.06.  
 
Figure 7: Improvement in ankle tendon reflex from “no reflex” to “minimal or 
normal” 
 
The measure of improvement in the ankle tendon reflex was based on the improvement 
from “no reflex” to “reduced/normal” because of slight changes that were observed 
within the reflex scores. There were very few participants who gained back the reflex 
from “none” and or “reduced”, to “normal” reflex hence reduced and normal reflex was 
used to define improvement/change for the reflex. There were no differences in 
improvement between the two groups, (87% vs 75%; p=0.10) after 12 weeks and (83% 
vs 68%; p=0.06) after 12 weeks post intervention.  
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6.3.1.6 The effect of physiotherapeutic exercises on the overall diagnosis of PN 
 
Figure 8 below indicates the changes in the percentages of participants who were still 
diagnosed with PN at the three assessments. 
 
 
PN differences; at 12 weeks; p<0.05, and 24 weeks; p = 0.13 
Figure 8: Change in the percentages of participants still with PN 
 
Every participant who entered into the intervention study was diagnosed with PN. Seven 
percent of the participants in the experimental group were no longer diagnosed with PN 
post intervention. There were differences after 12 weeks  between the experimental and 
control group; whereby 93% still had PN vs 100% (p<0.05), respectively. There was a 
non-statistically significant change observed between the intervention and the control 
group 12 weeks post intervention (96% vs 100%; p=0.13),  
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6.3.2 The effect of PTExs on the lower extremity functional limitations measures  
The results for each activity score of the lower extremity functional limitations in means 
and standard deviations are presented in Table 20 and the overall measure of function 
is presented in Table 21 below.  
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Table 20: Comparison of participants’ Lower Extremity Functional Limitations; at baseline, 12 weeks of PTExs 
and 12 post the PTExs intervention (n=120) 
 
 At baseline  At 12 weeks of PTExs for exp group  At 12 weeks post PTExs intervention  
Activity limitation Experimental  Control p-value  Experimental  Control  p-value Experimental  Control  p-value 
Doing any usual work  1.8(±0.8) 2.1 (±0.9) 0.16 3.1(±0.7) 1.7 (±0.9) <0.001 3.3(±0.7) 1.6 (±0.9) <0.001 
Hobbies, Recreational and 
sporting 
1.9 (±0.9)  2.1  (±0.9) 0.15 3.1 (±0.7) 1.7 (±0.9) <0.001 3.3 (±0.8)  1.6 (±1.0) <0.001 
Getting into or out of the bath 1.9(±0.9) 2.1(±1.0) 0.36 3.1(±0.8) 1.7 (±0.9) <0.001 3.2(±0.8) 1.6(±1.0) <0.001 
Walking between rooms   2.5(±0.9) 2.7(±0.7) 0.32 3.2(±0.8) 2.1 (±0.6) <0.001 3.2(±0.8) 2.1(±0.8) <0.001 
Putting on any kind of shoes 
or socks 
1.8(±0.9) 1.9(±0.9) 0.37 3.1(±0.8)  1.6(±1.0) <0.001 3.2(±0.8) 1.5(±1.0) <0.001 
Squatting  1.7(±1.0) 2.0(±1.0) 0.13 3.1(±0.8)    1.7(±1.0) <0.001 3.2(±0.7) 1.4(±0.9) <0.001 
Lifting an object 1.9(±0.9) 1.9(±0.9) 0.77 3.0(±0.8) 1.7 (±0.9) <0.001 3.2(±0.8) 1.6(±1.1) <0.001 
Doing light activities around 
home 
1.9(±1.0) 2.0(±1.0) 0.80 3.2(±0.8) 1.7 (±1.0) <0.001 3.3(±0.8) 1.6(±1.0) <0.001 
Doing heavy activities around 
home 
1.9(±1.0) 2.0(±0.9) 0.71 3.1(±0.8) 1.7 (±1.0) <0.001 3.3(±0.8) 1.5(±1.0) <0.001 
Getting into or out of a 
car/taxi. 
2.0(±1.0) 1.9(±1.0) 0.85 3.1(±0.8) 1.6 (±0.9) <0.001 3.3(±0.9) 1.5(±1.0) <0.001 
Walking across between 
buildings 
2.1(±1.0) 2.2(±0.8) 0.97 3.1(±0.7) 1.6 (±0.9) <0.001 3.3(±0.7) 1.5(±0.9) <0.001 
Walking a Km 1.9(±0.9) 1.9(±0.9) 0.64 3.1(±0.8) 1.6 (±0.9) <0.001 3.2(±1.0) 1.5(±1.0) <0.001 
Going up or down 10 stairs 1.7(±0.9) 2.0(±0.9) 0.78 3.1(±0.8) 1.5 (±0.9) <0.001 3.2(±0.9) 1.4(±0.9) <0.001 
Standing for 1 hour 1.7(±0.9) 0.8(±1.0) 0.47 3.0(±0.8) 1.5 (±0.9) <0.001 3.1(±0.9) 1.4(±1.0) <0.001 
Sitting for 1 hour 1.6(±0.9) 1.7(±0.9) 0.44 3.0(±0.8) 1.5 (±0.8) <0.001 3.2(±0.8) 1.4(±0.9) <0.001 
Fast walking on even ground 1.7(±0.9) 1.9(±0.9) 0.56 3.1(±0.8) 1.7 (±0.9) <0.001 3.2(±0.9) 1.4(±0.9) <0.001 
Fast walking on uneven 
ground 
1.6(±0.8) 1.7(±0.9) 0.37 3.0(±0.8) 1.4 (±0.8) <0.001 3.2(±0.9) 1.4(±0.9) <0.001 
Making sharp turns while 
walking 
1.6(±0.9) 1.7(±0.9) 0.59 3.0(±0.8) 1.4 (±0.8) <0.001 3.1(±0.8) 1.4(±0.9) <0.001 
Standing up fast from 
squatting  
1.7(±0.9) 1.9(±0.9) 0.21 3.0(±0.9) 1.5 (±0.9) <0.001 3.2(±0.9) 1.6(±1.0) <0.001 
Turning in bed  2.4(±0.9) 2.6(±0.9) 0.37 3.3(±0.8) 2.2 (±0.7) <0.001 3.4(±0.7) 1.8(±0.8) <0.001 
Data presented in means (±SD) 
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Table 20 above demonstrates that there were no differences in the activities of the 
LEFLs at the baseline assessment (p>0.05). Statistically significant differences 
(p<0.001) were observed in the average scores of all activities between the 
experimental and control groups after 12 weeks of PTExs and after 12 weeks post 
intervention. Improvements in function were seen in the experimental group after 12 
weeks of PTExs intervention and 12 weeks post intervention.  
 
6.3.2.2 Comparison of the lower extremity functional measure between the 
experimental and control groups 
 
The overall measure of the function of the lower extremity is functional levels of abilities, 
namely; extremely difficult or unable to perform activity, quite a bit of difficulty, moderate 
difficulty, a little bit of difficulty and no difficulty. Table 21 below compares the 
percentages of the participants at the three time interval measurements between the 
experimental and control groups.   
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Table 21: Comparison of participants’ functional ability at baseline, 12 weeks of PTExs and 12 weeks post PTExs 
intervention (n=120) 
 
 At baseline   At 12 weeks of PTExs for exp 
group  
At 12 weeks post PTExs intervention 
Measure of 
function 
Experimental  Control  p-value Experimental  Control  p-value Experimental  Control  p-value 
Extremely 
difficulty 
0(0) 1 (2)  
 
 
 
0.67 
0(0) 6 (10)  
 
 
 
<0.001 
0(0) 8 (13)  
 
 
 
<0.001 
Quite a bit of 
difficulty 
35(58) 
 
32 (53) 14(23) 
 
37 (62) 13(21) 
 
35 (58) 
Moderate 
difficulty 
17(28) 20 (33) 14(23) 12 (20) 7(12) 11(19) 
A little a bit of 
difficulty 
7(12) 7 (12) 28(47) 5 (8) 31(52) 6(10) 
No difficulty 1(2) 0(0) 4(7) 0(0) 9(15) 0(0) 
 
 
 Table 19 above indicates that there were no significant differences (p=0.67) in the lower extremity functional level 
between the experimental and control groups of the participants at the baseline assessment. Significant differences 
were observed for the functional ability level after 12 weeks of PTExs intervention and after 12 weeks post PTExs 
intervention; (p<0.001). A higher percentage of participants in the experimental group presented higher levels of function 
“a little or a bit of difficulty” in performing the activities compared to the control. Higher percentages among the 
participants in the control group presented with a lower level of “quite a bit of difficulty” throughout all three 
assessments.  
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6.3.3 The effect of PTExs on the QoL  
The facets were categorised (according to the guidelines of WHO; in Chapter 3) into the 
domains; physical health, psychological health, social relationships, environmental and 
overall QoL, domains (Table 22). 
 
6.3.3.1 The effects of PTExs on the facets of QoL 
The results on the effects of PTExs on the facets indicated in Table 20 below. 
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Table 22: Comparison of participants’ facets of QoL; at baseline, Comparison of participants’ facets of QoL; at 
baseline, after 12 and 24 weeks post of intervention (n=120) 
Data presented in mean (±SD), * Denotes Non-statistically significant difference in the compared facets between the groups at interval assessments.  
 At baseline  At 12 weeks of PTExs for exp group  At 12 weeks post PTExs intervention 
Items / Responses Experimental  Control  p-value Experimental  Control  p-value Experimental  Control  p-value 
Physical health domain          
Physical pain and discomfort  3.0 (±0.8) 2.9(±0.8) 0.58 3.5 (±0.9) 3.0(±0.9) 0.01 3.7(±0.8) 3.0 (±1.0) 0.001 
Dependence on medication to function  3.1(±0.7) 3.2 (±0.7) 0.54 3.8 (±0.9) 3.5(±0.7) 0.03 3.9 (±0.7) 3.4(±0.8) 0.007 
Energy  and fatigue    2.6 (±0.6) 2.7(±0.7) 0.50 3.3 (±0.8) 2.7(±0.7) <0.001 3.4 (±0.8) 2.7(±0.7) <0.001 
Ability to get around   2.6 (±0.7) 2.7(±0.7) 0.32 3.4 (±0.7) 2.6(±0.7) <0.001 3.6 (±0.7) 2.7(±0.7) 0.001 
 Sleep and rest   2.6 (±0.7) 2.7(±0.7) 0.43 3.4 (±0.8) 2.5(±0.9) <0.001 3.6 (±0.8) 2.7(±0.8) <0.001 
Ability  to perform your daily activities  2.6 (±0.7) 2.7(±0.7) 0.53 3.5 (±0.7) 2.7(±0.7) <0.001 3.5 (±0.8) 2.7(±0.8) 0.001 
Capacity for work   2.7 (±0.7) 2.8(±0.7) 0.49 3.4 (±0.7) 2.7(±0.7) <0.001 3.5 (±0.8) 2.7(±0.8) <0.001 
Psychological health domain          
Positive feeling of life 2.6 (±0.6) 2.7(±0.7) 0.50 3.3 (±0.8) 2.7(±0.7) <0.001 3.4 (±0.8) 2.7(±0.7) <0.001 
Spirituality or personal beliefs  2.9 (±0.7) 2.7(±0.7) 0.84 3.5 (±0.7) 2.6(±0.7) <0.001 3.4 (±0.8) 2.6(±0.7) <0.001 
Thinking, memory and concentration  2.6 (±0.6) 2.7(±0.7) 0.87 3.4 (±0.7) 2.6(±0.7) <0.001 3.4 (±0.8) 2.7(±0.7) <0.001 
Bodily image and appearance 2.7 (±0.8) 2.8(±0.7) 0.58 3.5 (±0.8) 2.7(±0.7) <0.001 3.6 (±0.7) 2.7(±0.7) <0.001 
Self esteem   2.7 (±0.7) 2.7(±0.6) 1.00 3.5 (±0.7) 2.6(±0.7) <0.001 3.6 (±0.8) 2.7(±0.8) 0.001 
Having negative feelings 3.1 (±0.6) 3.1(±0.8) 0.64 4.2 (±0.7) 3.1 (±0.7) <0.001 4.1 (±0.7) 3.0(±0.7) 0.001 
Social relationship domain           
Personal relationships  2.7 (±0.7) 2.7(±0.7) 0.80 3.5 (±0.5) 2.6(±0.7) <0.001 3.5 (±0.8) 2.8(±0.8) <0.001 
Sexual activity   2.6 (±0.8) 2.6(±0.8) 0.54 3.4 (±0.8) 2.6(±0.7) <0.001 3.5 (±0.9) 2.7(±0.7) <0.001 
Social support  2.7 (±0.7) 2.8(±0.7) 0.424 3.5 (±0.8) 2.7(±0.7) <0.001 3.6 (±0.8) 2.7(±0.7) <0.001 
Environmental domain          
Physical safety and security  2.6 (±0.6) 2.7(±0.7) 0.53 3.3 (±0.7) 2.7(±0.7) <0.001 3.4 (±0.8) 2.7(±0.7) <0.001 
Financial resources   1.7 (±0.7) 1.8(±0.7) 0.61 2.4 (±0.5) 2.3(±0.6) 0.75* 2.4 (±0.5) 2.1(±0.5) 0.002 
Healthy physical environment  2.6 (±0.6) 2.7(±0.7) 0.80 2.8 (±0.6) 2.5(±0.5) 0.01 2.8(±0.7) 2.4 (±0.5) 0.003 
Opportunity for acquiring new information 
and skills   
2.7 (±0.7) 2.7(±0.7) 0.65 3.5 (±0.8) 2.6(±0.7) <0.001 3.5(±0.8) 2.7 (±0.7) <0.001 
Participation and opportunity for leisure 
activities  
2.6 (±0.7) 2.7(±0.7) 0.51 3.6 (±0.7) 2.6(±0.6) <0.001 3.6 (±0.7) 2.7(±0.7) <0.001 
Home environment conditions  2.7 (±0.7) 2.7(±0.6) 0.75 3.5 (±0.7) 2.7(±0.7) <0.001 3.5 (±0.7) 2.7(±0.7) <0.001 
Access to health services  2.7 (±0.7) 2.7(±0.5) 0.24 3.5 (±0.7) 2.7(±0.7) <0.001 3.6 (±0.7) 2.7(±0.7) <0.001 
Transport facility  2.7 (±0.7) 2.8(±0.7) 0.35 3.6 (±0.7) 2.8(±0.8) <0.001 3.7 (±0.7) 2.7(±0.7) <0.001 
Overall  quality of life          
Rating of quality of life 2.6 (±0.7) 2.6(±0.8) 0.76 3.4 (±0.8) 2.6(±0.8) <0.001 3.4 (±0.8) 2.7(±0.6) <0.001 
Satisfaction with general health    2.6 (±0.7) 2.8(±0.7) 0.11 3.3 (±0.8) 2.6(±0.7) <0.001 3.4 (±0.8) 2.6(±0.7) <0.001 
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Table 22 above indicates that there were no significant differences for all the facets of QoL between the experimental and 
control groups, at the baseline assessment. However, significant differences (p<0.05) for almost all the facets were 
observed between the groups after  12 weeks of exercising and 12 weeks post PTExs, with improvement for the 
intervention group in most of the facets of QoL.  The only non-significant difference was in the facet of “financial resources”, 
which appeared at baseline, after 12 weeks (p=0.75). 
 
6.3.3.2 Comparison of the QoL domains between the experimental and control groups 
The QoL domains were calculated from the total mean scores of the facets (procedures described in Chapter 5) and the 
results are indicated in Table 23 below.  
 
Table 23: Comparison of participants’ QoL; at baseline, after 12 of PTExs and after 12 weeks post intervention 
(n=120) 
Data presented in mean (±SD), * Denotes non statistically significant difference in the compared values 
 At baseline  At 12 weeks of PTExs for exp group  At 12 weeks post PTExs intervention 
Items / Responses Experimenta
l  
Control  p-value Experimental   Control   p-value Experimental   Control   p-value 
Physical health domain 11.1(±3.0) 11.1(±2.7) 0.46 14.1(±3.8) 11.3(±3.1) <0.001 14.5(±3.9) 11.4(±3.3) <0.001 
Psychological health domain 11.4(±2.9) 11.6(±3.2) 0.81 14.3(±3.3) 11.5(±3.3) <0.001 14.5(±3.8) 11.5(±3.3) <0.001 
Social relationship domain  10.7(±2.0) 10.8(±2.0) 0.87    13.7(±2.0) 10.7(±2.0) <0.001 14.1(±2.2) 10.9(±2.1) <0.001 
Environmental domain 10.2(±4.1) 10.5(±3.7) 0.30 12.1(±3.5) 10.7(±3.9) 0.10* 13.3(±3.7) 10.4(±4.0) <0.001 
Overall  quality of life 10.6(±4.8) 10.8(±5.0) 0.36 13.4(±1.4) 10.4(±1.4) <0.001 13.6(±1.6) 10.4(±1.3) <0.001 
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It was observed that there were no differences (p>0.05) at baseline between the groups 
for all domains, but significant differences in improvements appeared at 12 weeks after 
PTExs and after 12 weeks post intervention for the experimental group, with the 
exception for the environmental domain at 12 weeks of PTExs (p=0.10). However, this 
domain (environmental) indicated a difference (p<0.001) with improvement for the 
experimental group at 12 weeks post PTExs intervention 
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6.4 Factors associated and influencing the change on PN, lower 
extremity functional limitations and QoL, during and post the 
PTExs intervention 
 
The effect of PTExs on different measures of PN, lower extremity functional 
limitations, and QoL, was measured in terms of changes and differences between 
the experimental and the control groups. The changes and differences observed 
were the improvements in the PN, lower extremity functional limitations, and QoL, 
among the experimental group compared to the control group. It is likely that most 
of the changes were due to the PTExs intervention; however there might be other 
factors that influenced the changes in the outcomes of PN, lower extremity functional 
limitations & QoL, during and after the intervention. The influencing factors on the 
changes in the improvement are described for each outcome of PN, lower extremity 
functional limitations and QoL, in the sections below; 
 
6.4.1 Factors associated and influencing the changes in improvement of PN, 
during and post the exercise intervention. 
 
The improvement of PN assessed by the positive changes in the symptoms of the 
PN. Some factors likely influenced the improvement. The factors tested included; 
age, gender, marital status, occupation, level of education, duration since HIV 
diagnosis, CD4 cell count, duration on ARV, ARV combination started with, current 
ARV regimen combination, ARV regimen changes since started on ART,  and the 
onset of PN symptoms and/signs. Table 24 below illustrates the associated and 
influencing factors for the change in the improvement of PN.    
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Table 24: Generalised linear regression with general estimating equation 
(GEE) for the associated and influencing factors of improvement on PN  
 
Factors  Univariate analysis Multivariate analysis 
Univariable  
(OR)(95% CI) 
p-value Adjusted Odds 
Ratio (aOR) (95% CI) 
p-value 
Age/years (Mean±SD) 1.0 (1.0, 1.1) 0.12   
Gender       
Male  0.9(0.5,1.7) 0.75   
Female      
Marital status     
Non married 1.0(ref)    
 Married 1.2(0.3, 5.1) 0.77  
Separated/Divorced/Wido
wed 
1.6(0.4, 5.9) 0.51   
Occupation      
 Employed  1.0(ref)    
Self-employed/peasant 1.5 (0.6, 3.7) 0.35   
Unemployed  1.7(0.8, 4.0) 0.20   
Level of Education       
 No schooling 1.0(ref)    
Primary 0.9 (0.5, 1.7) 0.73   
>=Secondary 0.6(0.3, 1.2) 0.15   
Duration since HIV diagnosis     
Less or equal to 3 years 1.0(ref)    
4 to 6 years 0.5(0.2, 1.2) 0.12 0.4(0.2, 1.0) 0.06 
7 and above years 0.4(0.2, 1.0) 0.05 0.4(0.2, 0.9) 0.02* 
CD4 cell count                 
≤ 350                     
351 > 1.4(0.8, 2.3) 0.24   
Duration on ARV     
Less or equal to 3 years 1.0(ref)    
4 to 6 years 0.8(0.5, 1.3) 0.39   
7 and above years 1.1(0.5,2.1) 0.89   
ARV regimen combination started 
with 
    
Non D4T containing     
D4T containing 0.7(0.4, 1.2)   0.14   
Current ARV regimens’ combination     
Non D4T containing     
D4T containing 0.6(0.3, 1.3)     0.21   
ARV regimen changes since started 
on ART 
    
No change               
One or more changes    1.6(1.0, 2.7)   0.05 1.7(1.0, 3.0) 0.04* 
The onset of PN symptoms 
and/Signs  
    
Before starting on ARVs     
After starting on ARVs 2.1(1.1, 3.8)  0.01 2.2(1.2, 4.2) <0.01* 
* Statistically significant for the factors associated and influencing improvement of PN 
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Table 24 above indicates the results of factors associated and influencing 
improvement of PN after 12 weeks and 12 weeks post, PTExs intervention. A 
univariate analysis was done to determine the factors associated with improvements. 
There were no demographic factors associated with the improvement. Associated 
factors were observed among the health related characteristics; such as duration 
since the participant was diagnosed with HIV, regimen changes and at which point 
the PN symptoms started (before or after start on ARVs). These factors which were 
statistically significant in the univariate model reporting odds ratio (OR) were further 
confirmed with multivariate analysis models with adjusted odds ratios (aOR). The 
participants who were diagnosed with HIV for seven years and above were likely to 
have less improvement [OR=0.4, 95%CI (0.2, 1.0); p=0.05 & aOR = 0.4, 95% CI 
(0.2, 0.9); p=0.02], compared to less or equal to 3 years since the diagnosis. Having 
changed the ARV regimen was likely to predict improvement (OR=1.6, 95%CI(1.0, 
2.7) p=0.05; aOR=1.7, 95%CI(1.0, 3.0) p=0.04) compared to no change and the 
participants who developed PNS after the start on ARVs were likely to have faster 
improvements [OR=2.1, 95%CI(1.1, 3.8); p=0.01; & aOR = 2.2, 95%CI(1.2, 4.2); 
(p<0.01)].  
 
6.4.2 Factors associated and influencing the changes in improvement of 
lower extremity functional limitations, during and post the exercise 
intervention 
 
Factors associated with lower extremity functional limitations were also tested in a 
univariate analysis and confirmed with multivariate analysis models.  Table 25 below 
indicates the results of the associated and influencing factors for the change in the 
improvement of lower extremity functional limitations 
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Table 25: Generalised linear regression with general GEE for the associated 
and influencing factors of improvement on lower extremity functional 
limitations  
Factors  Univariate analysis  Multivariate Analysis 
Univariate  
(OR)(95% CI) 
p-value Adjusted Odds 
Ratio (aOR) (95% 
CI) 
p-value 
Age/years (Mean ±SD) 1.0(0.9, 1.0) 0.84   
Gender       
Female     
Male  3.5(1.0, 6.2) <0.001 3.9(2.0, 7.5) <0.001* 
Marital status     
Non married 1.0(ref)   0.34 
Married 3.1(1.7, 5.8) <0.001 1.4(0.7, 2.9) 
Separated/Divorced/ 
Widowed 
1.7(1.0, 3.0) 0.07 1.0(0.5, 1.8) 0.98 
Occupation      
 Employed  1.0(ref)    
Self-employed/peasant 0.5 (0.2, 1.0) 0.08   
Unemployed  0.6(0.2, 1.0) 0.11   
Education       
 No schooling 1.0(ref)    
Primary 1.5 (0.8, 2.6) 0.17   
>=Secondary 1.2(0.6, 2.2) 0.86   
Duration since HIV diagnosis     
Less or equal to 3 years 1.0(ref)    
4 to 6 years 0.8(0.3, 1.7) 0.49   
7 and above years 0.6(0.3, 1.2) 0.11   
CD4 cell count                 
≤ 350                     
351 > 0.7(0.2, 0.5) 0.23   
ARV regimen combination 
started with 
    
Non D4T containing     
D4T containing 0.6(0.4, 1.0) 0.03 1.0(0.5, 2.0) 0.98 
Current ARV regimens’ 
combination 
    
Non D4T containing     
D4T containing 1.0(0.5, 1.9) 0.95   
ARV regimen changes 
since started on ART 
    
No change               
One or more changes    1.4(0.9, 2.3) 0.15   
The onset of PNS and/Signs     
Before starting on ARVs     
After starting on ARVs 1.9(0.9, 4.00) 0.11   
PNS               
Severe                     
Mild 4.3(2.7, 6.9) <0.001 4.8(2.8, 8.0) <0.001* 
* Statistically significant for the factors associated and influencing improvement of LEFLs
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Gender and PN symptoms significantly predicted the improvement of lower 
extremity functional limitations during and after the intervention, confirmed with 
univariate model reporting odds ratio (OR) and were further confirmed with 
multivariate analysis models with adjusted odds ratios (aOR). The results 
demonstrate males improved faster [OR=3.5, 95%CI (1.0, 6.2); p<0.001; & aOR = 
3.9; 95%CI (2.0, 7.5); p<0.001], compared to females. The odds ration of the 
participants with mild PNS were 4.8 times greater than the odds ratio of the the 
participant with severe PNS, in improving; [OR=4.3, 95%CI (2.7, 6.9); p<0.001; & 
aOR = 4.8, 95%CI (2.8, 8.0) p<0.001].than the ones with severe PN symptoms. 
 
6.4.3 Factors associated and influencing the changes in improvement of QoL 
overall measure, during and post the exercise intervention 
 
Factors predicting improvement changes in the QoL were tested on the overall 
measure of QoL, which was calculated from the sum scores of the domains of QoL; 
the physical, psychological, social relationship and environmental, health domains 
plus the outcomes on the facets of the overall QoL and health status. A single 
continuous variable to take the total scores of all the domains of QoL was created, 
and tested with a multilevel mixed effects linear regression model, against the 
predicting factors. Table 26 below illustrates the results. 
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Table 26: Multilevel mixed effects linear regression for the associated and 
influencing factors of improvement changes on the overall QoL 
 
Predicting factors       Univariate analysis Multivariate Analysis 
Unadjusted coef. Corr. 
(uCC.)(95% CI) 
p-value Adjusted coef. Corr. 
(aCC.) (95% CI) 
p-value 
Age/years (Mean±SD) 1.0 (-0.1, 0.3) 0.36   
Gender     
Female      
Male 6.7(3.3, 10.2) <0.001 6.9(3.5, 10.4) <0.001* 
Marital status     
Non married 1.0(ref)    
 Married 0.4(-8.0, 8.8) 0.92  
Separated/Divorced/Wido
wed 
-5.6(-14.0, 3.3) 0.22   
Occupation     
Employed 1.0(ref)    
Self-employed/peasant -7.0(-12.2,-1.8) 0.008   
Unemployed -6.8(-10.6,-1.0) 0.018 0.03(-0.8, 0.9) 0.95 
Education     
No schooling 1.0(ref)    
Primary 0.8(-2.9, 4.6) 0.65   
>=Secondary 1.4(-2.8, 5.6) 0.51   
Duration since HIV diagnosis     
Less or equal to 3 years 1.0(ref)    
4 to 6 years -9.2(-14.2, -4.2) <0.001   
7 and above years -10.4(-15.2,-5.7) <0.001 -3.0(-5.0,-1.0)  0.003* 
CD4 cell count     
≤ 350     
351 > 1.1(-2.0, 4.2) 0.48   
ARV regimen combination started 
with 
    
Non D4T containing     
D4T containing -3.4(-6.2,-0.6) 0.02 -1.8(-4.5, 1.0) 0.195 
Current ARV regimens’ 
combination 
    
Non D4T containing     
D4T containing -1.2(-5.3, 2.9) 0.56   
ARV regimen changes since 
started on ART 
    
No change     
One or more changes 0.3(-2.8, 3.3) 0.86   
The onset of PN symptoms 
and/Signs 
    
Before starting on ARVs     
After starting on ARVs 4.2(-0.6, 9.0) 0.09 3.5(-1.0, 8.0) 0.129 
PNS               
Severe                     
None/mild 7.0(3.9, 10.0) <0.001 5.9(2.9, 8.8) <0.001* 
* Statistically significant for the factors associated and influencing improvement of QoL 
 
Gender, duration since diagnosis of HIV and PN symptoms are associated with and 
predict the improvement changes in the overall QoL during and after the intervention 
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of PTExs.  With the multilevel mixed linear regression model, the results show that 
in terms of gender, males improved faster [uCC=6.7, 95%CI (3.3, 10.2); p<0.001; & 
aCC = 6.9, 95%CI (3.5, 10.4); p<0.001], compared to females. The participants who 
were diagnosed with HIV for 7 years and above were likely to have less improvement 
[uCC=-10.4, 95%CI(-15.2, -5.7); p<0.001; & aCC = -3.0; 95%CI(-5.0, -1.0); p=0.003], 
compared with those who had been diagnosed in the last 3 or less years, and 
participants with mild PN symptoms improved their QoL faster [uCC=7.0; 95%CI(3.9, 
10.0); p<0.001; & aCC = 5.9; 95%CI(2.9, 8.8); p<0.001] than those with  severe PN 
symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 159 
CHAPTER 7 
7.0 DISCUSSION OF RESULTS OF THE INTERVENTION (STUDY 3) 
 
7.1 Introduction 
 
Physical exercise is considered to be a key strategy, by rehabilitation professionals 
to address the disabling health-related consequences of HIV (O’Brien et al., 2010); 
(Maharaj and Chetty, 2011). But rehabilitation professionals still lack evidence on 
the effects of exercise on the management of PN, and the related functional 
limitations that compromise the QoL of PLHIV, particularly, in  resource-limited 
settings (Apker et al., 2006). Several studies with exercise interventions on PLHIV 
have been conducted, including studies identified in systematic reviews by Nixon et 
al., (2002), Nixon et al., (2005) O’Brien et al., (2008), and O’Brien et al., (2010). 
However, in all of those studies there is a dearth of evidence on the effects of 
exercise on PN among PLHIV on ART.  
 
The aim of study 3 was to test the effects of physiotherapeutic exercise on PN, 
related lower extremity functional limitations, and QoL, in PLHIV on ART in Rwanda. 
A RCT was used to test the effects of the exercise intervention. The intervention 
included the physiotherapeutic exercises that were identified from the systematic 
reviews (Nixon et al., 2005); O’Brien et al., 2008 and O’Brien et al., 2010) and that 
have been used and described as safe for PLHIV.  
 
The overall effect in this study was that the exercise reduced PN symptoms, 
improved lower extremity functional ability and QoL among PLHIV on ART who 
exercised for 12 weeks. It is known from the literature and common physiotherapy 
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practice that therapeutic exercises have beneficial effects in the management of 
painful neuromuscular conditions, functional activity limitations and improve QoL 
through enhancing participation in daily life activities (Taylor et al., 2007; Adeniyi et 
al., 2010), but there is insufficient data from studies that might have tested the effects 
of exercise on PN symptoms in PLHIV on ART. The few that attempted were pilot 
studies, which did not use a controls and the results were not conclusive (Sandoval 
et al., 2010). 
 
The PN symptoms that limited functional mobility and activity of PLHIV in this study 
were improved with exercise that included stretching as one of the important 
techniques used (appendix 2; exercise protocol). This resulted in improved activity 
participation and improved QoL. To my knowledge, this study with RCT is the first 
one to show that physiotherapeutic exercise can reduce PN symptoms and improve 
the lower extremity functional ability and QoL in PLHIV on ART in Rwanda and most 
likely in the whole of Sub Saharan Africa. The findings are similar  to the few existing 
studies, particularly the study by Graham et al. (2007) who found that a community 
exercise intervention reduced activity limitations among PLHIV with inflammatory 
peripheral neuropathy type of peripheral neuropathy, however their study was not a 
RCT. 
 
The significant effects of the physiotherapeutic exercises on the PN symptoms, 
related lower extremity functional limitations and QoL in PLHIV on ART, are therefore 
discussed in detail in this chapter. The factors that may have influenced the effects 
of the exercise during the intervention are highlighted. 
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7.2 The effects of physiotherapeutic exercise on peripheral 
neuropathy 
 
There were remarkable improvements in the PN symptoms among PLHIV on ART, 
who exercised for 12 weeks. Specifically, there were improvements in the 
neuropathic pain, numbness, paraesthesia and distribution of the symptoms along 
the lower extremities. The reduced symptoms led to the overall reduced percentage 
of participants diagnosed with PN at the end of the intervention. This implies that the 
improvements of PN symptoms observed in the experimental group after 12 weeks 
of exercise are attributable to the exercise intervention as there were no 
improvements in the control group (Sandoval et al., 2010).  
 
The mechanism of how exercise reduces symptoms of PN is not yet clear. 
Nevertheless, the antidepressant effect that has been reported as one of the 
exercise effects (Schroder et al., 2013; Schuch et al., 2013; Eng and Reime, 2014) 
might play a role. An antidepressant effect is one of the treatments of choice for 
neuropathic pain in PLHIV (Lana et al., 2008; Brix Finnerup et al., 2013). Exercise 
has been known to have effects such as; antidepressant, reduction of anxiety, 
inducement of sleep in people with insomnia, among others (Salmon, 2001; Suna et 
al., 2014). The antidepressant effect of exercise is likely a result of the increased 
blood circulation that enhances the discharge of neuro-chemical pain inhibitors. The 
discharged pain inhibitors, inhibit the pain receptors by enhancing the closing of the 
pain gate at the spinal dorsal horn of the small diameter nerves (Baron et al., 2010), 
thus, relieving the pain. 
 
Additionally, exercise leads to a feeling of relaxation by exercising participants hence 
improving their mood. In cases of pain, the psychologically feeling of good mood as 
 162 
a result of exercise inhibits the nociceptive mechanism and release of the neuro-
chemical pain inhibitors hence modifying pain perception (Dworkin et al., 2003). 
Similarly, exercise has been recommended as a complementary non 
pharmacological treatment for postoperative pain (Topcu and Findik, 2012).  
 
The exercises were prescribed and supervised by a physiotherapist, and the usual 
therapeutic exercise techniques were applied. These included stretching for joint 
mobility, isometric strengthening, as well as aerobic exercises for “warm-up” and 
finally “cool down” at the end of the every session (appendix 2). Stretching exercises 
after warming-up are known for their effect on improving flexibility (Zakas et al., 2006; 
O’Sullivan et al., 2009) and enhancing pain free range of movements about a joint 
to promote better performance (Marek et al., 2005). Neuromuscular flexibility has 
been reported as a benefit of stretching before performing strength training exercises 
(Rubini et al., 2007). The stretching exercises might have induced muscle relaxation, 
nerve stretching and its flexibility, consequently improving pain free movements. For 
example, most of the participants were able to do squatting activities such as sitting 
on a pit latrine, and walk up and down stairs, more easily after the intervention which 
they had found very difficult before the intervention. Therefore, with the participants 
able to achieve pain free movements they reported reduced PN symptoms. 
 
Furthermore, stretching exercises are reported to improve neural tissue flexibility. 
The stretching mechanism includes the “sliding and tensioning techniques, which 
are thought to enhance nerve gliding and restore neural tissue mobility” (Oskay et 
al., 2010). This may have induced nerve flexibility and mobility (Oskay et al., 2010) 
that resulted in reduced pain during the performance of activities. Pain is one of the 
common symptoms that limits the ability to perform activities of daily living (Dorsey 
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and Morton, 2006). The reduction of the pain as a result of the exercise intervention 
in this study was a considerable beneficial effect for PLHIV with PN.  
 
Exercise interventions that include mobility and stretching exercises are commonly 
used to increase the neuromuscular flexibility and hence improve mobility (Stanziano 
et al., 2009; Sobolewski et al., 2013). A study that used stretching techniques for 
improvement of a non–flexible piriformis nerve and strengthening of the lower 
extremity muscles, reported an improvement of the nerve pain and resulted in pain-
free movement, and improved functional activity (Tonley et al., 2010). Thus, 
peripheral nerve injury or compression may make the nerve lose its flexibility which 
later causes pain on movement. This results in muscle weakness and muscle spasm 
that further leads to  more nerve and muscle pain (Parlak et al., 2014). Therefore, 
increasing the nerve flexibility with stretching or mobility exercises and muscle 
strengthening improves the pain, consequently allowing free movement and 
improved functional activity (Tonley et al., 2010).  
 
To my knowledge, the only study so far that has tested the effects of exercise on 
neuropathic pain in PLHIV is a pilot study by Sandoval et al. (2010). However, it did 
not significantly show changes in the pain. The differences in the results of these two 
studies may be because of the differences in the methodologies. The study by 
Sandoval and colleagues was a pilot study with few participants (17), and without a 
control group.  
 
There were no significant improvements found in the PN signs, namely; sense of 
vibration and ankle tendon reflex. Sense of vibration and tendon reflexes are 
mediated by large sensory nerves,  unlike PN symptoms such as neuropathic pain 
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which result from small sensory nerve fibre damage (Devigili et al., 2008). In addition, 
the development of PN signs is progressive and takes some time, though the time 
frame is uncertain. Consequently, it is possible that the treatment and relief or 
recovery of PN signs may occur after a longer exercise intervention than the one 
conducted in this study. The improvements shown with the PN symptoms, may be 
because the recovery is quicker in small nerve fibres than in large fibres. Hence, the 
change in the improvement of the PN signs may need to be evaluated after a longer 
period of intervention.  
 
It appears that the improvement of the PN symptoms was as a result of the 
improvement in the neuro-tissue flexibility and in mobility, and possibly an 
improvement in the nerve regeneration or growth. However, as stated above further 
studies need to investigate and test exercise interventions over prolonged periods 
of time, to establish if there is an improvement in the recovery of the larger nerve 
fibres for an improvement in PN signs.  
 
7.4 The effects of exercise on the lower extremity functional 
limitations 
 
Lower extremity functional ability was one of the outcome measures of interest in 
this study. There were trends of changes in improvement of the functional ability in 
the experimental group. Prior to the exercise intervention, the participants in both the 
experimental and control groups had similar levels of functional abilities; described 
as “quite a bit of difficulty” in performing the various activities assessed with the 
LEFS. All functional activity measures in the experimental group after 12 weeks of 
exercise improved from “quite a bit of difficulty” to a “little a bit of difficulty” and some 
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to “no difficulty” in performing their daily activities. No change in functional activity 
measures was observed in the control group. Improvement was maintained in the 
experimental group at 12 weeks post intervention.  
 
The improvement of the functional ability among the participants in the experimental 
group may have been as a result of improved lower extremity movements which 
were earlier restricted/limited by the neuropathic pain and other PN symptoms. For 
example, after the exercise intervention the participants reported that they were able 
to move around more, walk longer distances, sit and stand for longer periods 
because of reduced or no neuropathic pain. The participants with severe PN 
symptoms had more difficulty in performing their daily activities as measured by the 
LEFS, than the ones who had mild PN symptoms. This implies that the severely 
affected PLHIV were almost unable to carry out their routine activities of living, such 
as walking distances, before the intervention. Similarly, Ellis et al. (2010) found that 
neuropathic pain was significantly associated with functional limitations in the form 
of disability and hence affected people’s QoL. The prevention and treatment of 
neuropathic pain is inadequate and in addition some drugs used for treatment have 
side effects (Brix Finnerup et al., 2013). For example the long term use of the tricyclic 
antidepressants is associated with “nausea, sedation, dry mouth, drowsiness, 
dizziness, blurred vision, weight gain, urinary retention, peripheral oedema, and 
constipation” (Dworkin et al., 2007). Thus the management of the neuropathic pain 
to prevent functional limitations and, or disability in PLHIV needs a multidisciplinary 
approach that specifically includes a non-pharmacological approach. Thus, reducing 
PN symptoms and especially the neuropathic pain with exercises is a fundamental 
approach to improve the functional ability, with the aim of promoting functional 
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independence and reducing the side effects of the pharmacological treatments, in 
PLHIV with PN. 
  
Although muscle strength was not measured in this study, there is evidence that 
therapeutic exercise moderately improves muscle strength and stamina in people 
with PN associated to diabetes (White et al., 2004), and muscle strength in PLHIV 
(O’Brien et al., 2010). The exercise intervention in this study provided a combination 
of exercises that included isometric strengthening, mobility and aerobic activities. 
There is a possibility that this intervention improved their lower extremity muscle 
strength and endurance, which might have contributed to their improved functional 
activities. For instance, the participants improved in activities such as getting up from 
sitting to standing, squatting on pit latrines and walking up stairs, which were difficult 
to perform prior to the intervention. These findings are similar to other studies which 
found that exercise improved muscle strength, flexibility and mobility of soft tissues, 
and stamina among PLHIV (Taylor et al., 2007; O’Brien et al., 2008; O’Brien et al., 
2010). Equally, exercise has been shown to improve physical function (Mbada et al., 
2013), and strength in the elderly (Souza et al., 2011). However, there has been 
limited literature specifically on the effects of exercises on functional activities among 
PLHIV with PN, such as those found in this study. To the author’s knowledge this 
study might be one of the first studies to establish the effects of exercise on functional 
limitations related to PN in PLHIV on ART.  
 
7.5 The effects of physiotherapeutic exercises on quality of life 
The participants who exercised for 12 weeks, improved in most of the facets that 
comprise the QoL domains. The domains of QoL according to the WHOQOL-BREF, 
are; physical, psychological, social relationship, environmental, health domains, plus 
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overall life satisfaction (Gholami et al., 2013). The improvements were observed in 
all the physical and social relationship domain facets and the overall QoL measures, 
in the experimental group after the 12 weeks intervention and 12 weeks post 
intervention. 
 
The improvements in the physical domain included; physical pain and discomfort, 
dependence on medication to function, energy and fatigue, ability to get around, 
sleep and rest, ability to perform daily activities, and capacity for work. The possible 
explanations for the improvement include; improvements in neuropathic pain and 
other PN symptoms that caused discomfort, as well as reduced severity and 
distribution of PN symptoms. With such improvements in the PN symptoms and 
specifically neuropathic pain, participants were able to feel comfortable in their daily 
activities. For instance, participants reported that were able do their usual work at 
home, put on socks and “closed shoes”, walk around the home and have a good 
night’s sleep and rest. The participants with less pain and fewer PN related functional 
limitations might have felt more independent and less likely to depend on medication 
to relieve pain.  
 
With improved pain and fewer functional activity limitations, participants were able to 
perform their usual activities and felt more energetic. As a result, the improved 
activities enhanced their mobility and their ability to participate in social activities. For 
example, participants reported that they were able to move around, walk long 
distances, sit and stand for longer when attending social events such as weddings, 
funerals, church, and going to markets, visiting friend and relatives, more easily than 
before the exercise programme. These activities are important in the lives of people 
in Rwanda as well as elsewhere, and if an individual is unable to participate in such 
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activities or events, she/he feels disassociated from the community and it affects 
their QoL. As a result, the participants achieved their lost or reduced former activities 
and these achievements likely restored their QoL in most of the domains.  
 
Furthermore, participants had less sleep disturbances likely from the neuropathic 
pain at night and this may have contributed to their improved capacity to work during 
the day. In addition, the improved mobility that resulted in improved functional 
activities may have contributed to the improved capacity to work as assessed in the 
physical domain of their QoL. Such improved activities might have contributed to 
their working and doing activities on their own leading to improving their income and 
hence improving their independence. Maharaj and Chetty (2011) similarly showed 
that rehabilitation with exercise to maximise patients’ functional independence, 
minimises their functional limitations, and increases their functional status, thus 
improving their QoL. 
 
Although some components of the social domain of QoL such as the social 
interaction of the participants during the intervention were not assessed, but an 
improvement as a result of the social interaction and support to each other may have 
occurred. Possible reasons being that during the exercise sessions, participants 
might have enjoyed and benefited from the interactions with their peers. They may 
have shared their life experiences and might have started supporting each other. 
Social interactions and support for each other are some of the influences that 
improve psychological well-being (Jia et al., 2004). The interactions and sharing of 
experiences might have relieved some of the psychological depression, negative 
feelings, and promoted positive feelings, self-esteem and person beliefs 
(Skevington, 2002). According to the WHO (2003) psychological well-being is 
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improved with socialisation, support from peers, friends, family and spouses. 
Additionally, the improved functional activities such as walking long distances to 
attend social events, namely; weddings, funerals, church, and going to other public 
places such as markets, improved their social domain.  
 
Moreover, the improved physical health domain facets such as mobility might have 
resulted in improved psychological health domain facets. For example, the exercise 
improved positive feelings about their body image, appearance, and function and 
this improved their self-esteem. It has been  reported in previous studies that 
physical exercise programmes improve physical health, and  improve life satisfaction 
perceptions in PLHIV (Mutimura et al., 2008; Gomes et al., 2010). 
 
There was improvement in almost all QoL health domains, with the exception of the 
overall environmental health domain that did not show a significant improvement, at 
the end of 12 weeks of exercise. This is probably because there was no improvement 
demonstrated for the financial resources which is one of the important facets of the 
environmental health domain. According to Skevington (2002) environmental health 
domain assesses “the influence of factors like financial resources, the work 
environment, accessibility to health and social care, freedom, security, participation 
and opportunities for leisure activities”. People would like to have the financial 
resources that they need to meet their daily needs (WHO, 2003). Participants in this 
study demonstrated poor financial resources at the end of 12 weeks of exercise, 
simply because these QoL facets cannot be improved with exercise and are 
dependent on other social factors.  
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7.6 The effects of physiotherapeutic exercises at 12 weeks post 
intervention 
 
The improvement attained by the participants during the 12 weeks of exercise was 
maintained and could still be demonstrated 12 weeks post exercise, although there 
was a slight decline compared to the previous improvements at 12 weeks of 
exercising. The improvement of PN symptoms was maintained and is likely 
attributable to the probable continuation of exercises by the participants after the 
structured exercise programme at the centre, though this was not examined. As the 
participants went through the exercise sessions at the centre, the physiotherapist 
conducting the sessions educated and encouraged them to continue exercising after 
the intervention. The main goal of the education was to empower them such that 
after the intervention the participants would continue exercising on their own. Thus, 
it was important to evaluate if the exercises taught to the participants, were 
maintained and still beneficial at 12 weeks post intervention. Importantly, the 
participants maintained the improvements and further studies could evaluate a home 
exercise programme among PLHIV with PN. This could encourage PLHIV to 
continue exercising as a life time strategy to prevent and reduce the impact of PN 
(Silberberg and Katabira, 2006).  
 
Surprisingly, it was shown in the 12 weeks post intervention evaluation that the 
financial facet had improved, hence the whole environmental domain also improved. 
It is not clear how this facet improved. However, although this study did not assess 
the return to work of the participants after the exercise intervention some participants 
who did not come back for the assessment at 12 weeks post intervention revealed 
during the follow up telephone calls that they had gone back to their former activities 
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and were not able to get time to come back for the follow up assessment at the 
centre. One of the participants mentioned that he had started up a new business and 
was unable to get time to come back for the assessment. Another one highlighted 
that he had gone back to his former employment in a security company and could 
not get permission to come back for the assessment, while another was a driver and 
started up again after getting relief from the “pins and needle” symptoms that had 
disturbed him when driving. It is therefore possible that some participants, who 
improved during the 12 weeks of exercise, and who did come back for the 12 weeks 
post intervention assessment had also started gainful employment. Again, among 
the participants who were re-assessed after the 12 weeks post intervention some 
reported their improved work activities; for example some reported being able to 
continue their usual business activities such as those working in public markets. 
Consequently, such earnings likely improved the financial resources of those who 
were able to come for assessment, hence demonstrating a significantly improved 
environmental domain.  
 
Furthermore, improved financial resources might have resulted from the reduced 
severity of PN symptoms and the improved functional ability. Severity of HIV-related 
symptoms have been reported to be associated with economic costs and low QoL 
in PLHIV compared to asymptomatic PLHIV (Lopez-Bastida et al., 2009). This 
suggests that an exercise intervention to reduce HIV-related disorders such as PN 
might have an impact on reducing the costs participants might have been incurring 
for treatment of pain and other PN symptom management, consequently improving 
their QoL.  
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7.7 Factors that influenced the improvement during the exercise 
intervention  
 
There were factors that likely influenced the improvement and these were assessed. 
Some factors significantly predicted the improvement. These factors include health 
related characteristics namely; the duration of HIV infection, ART regimen changes 
and the PN that developed post ART initiation. 
 
The participants diagnosed with HIV for seven and above years were likely to have 
less improvement as a result of the exercise intervention. Since HIV infection might 
be one of the causes of PN (Dubey et al., 2013; Gabbai et al., 2013), this implies 
that living with the infection for a long time results in more severe PN or that 
prolonged exposure to HIV may render the nerve damage permanent. Robinson-
Papp et al. (2012) reported that a long duration of HIV infection is one of the risks 
for PN. This implies that the duration of HIV infection is a risk for developing PN and 
hampers the improvement of PN during treatment. Early screening of the PN 
immediately after a person is diagnosed and treating appropriately is important. This 
is supported by the participants who had PN for a relatively short period, for example 
three years and below, improving more than those with PN for four and above years. 
This means that managing a chronic health condition at an early stage has benefits 
to the individual in terms of a quicker improvement of the treated condition and thus, 
is cost-effective, rather than interventions when the health problem is at an advanced 
stage (Armbruster and Brandeau, 2010; Hutton et al., 2010). PN is a chronic and 
disabling condition and early management including physiotherapeutic exercises 
might give relief and better health outcomes. 
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The participants who developed PN after the start on ART had significantly greater 
improvements compared to those who developed PN before starting on ART. The 
participants who developed PN before starting on ART had a longer period with PN 
than those who developed it later after starting on ART. This means that the longer 
the duration the person has had PN the longer it takes for the intervention to have 
health benefits (Armbruster and Brandeau, 2010) such as the improvement of PN 
symptoms and function. Alternatively, the PN that develops after the start on ART is 
more likely to be related to ART than HIV. A change in the drug regimen will facilitate 
improvement of the pain, and with exercise as a supplementary treatment the 
improvement may be quicker. It is therefore, important to include exercise in addition 
to drug regimen changes in the management of PN that occurs as a result of ART. 
 
Likewise, the participants in whom the ARV regimen was not changed had more 
improvement. This is likely because in cases where there were no regimen changes; 
 it is either that the PN was not severe or, 
 it was not suspected to be augmented with a particular toxic ARV type (Woldemedhin 
and Wabe, 2012) or, 
  the PN had just started.  
Usually changing the ARV regimen is one of the strategies used to deal with PN 
(Sarah and Nath, 2012). However, in some cases, the changing of the regimen does 
not show an improvement (Gabbai et al., 2013). The probable reasons for non-
improvement might be that the neuropathy is not a result of the neurotoxic ART type 
(Robinson-Papp et al., 2012), and changing the suspected offending drug is not 
helpful. On the other hand, the neuropathy might have already contributed to other 
physical impairments such as reduced mobility and muscle weakness. In such 
cases, the reduced mobility is as result of reduced flexibility of the soft tissues, and 
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muscle weakness due to the limited active use of muscles because of the 
neuropathic pain. The treatment approach should include pain management 
modalities and exercise rehabilitation of the reduced flexibility and muscle weakness. 
  
Gender was associated with and predicted an improvement during and after 
exercise. Males improved their lower extremity functional ability faster compared to 
females. It is not clear why males improved faster as this study did not assess the 
reasons, however, it has been reported that females are affected by PN more 
severely than males (Mehta et al., 2011), and this may delay their improvement. A 
related explanation is that females probably have a high body mass index (BMI) 
which is likely a risk factor for PN. Body mass index is one of the established risk 
factors for PN among people with diabetes (Tesfaye et al., 2005). In their study, 
Mutimura et al., (2008) also found that HIV–positive women had higher BMI than 
men. Additionally, it was hypothesised that females are more likely affected with 
lower haemoglobin levels than males, in which case this could be an influencing 
factor for having PN (Mehta et al., 2011). Although this study did not assess the 
haemoglobin levels, a previous study in Rwanda indicated that haemoglobin levels 
are  lower in HIV-positive women (Munyazesa et al., 2012). However, this study 
cannot give conclusive reasons as to why gender predicted improvements in PN, as 
the above factors, namely BMI and haemoglobin levels were not measured.   
 
7.8 Summary, conclusions and implications of the 
physiotherapeutic exercise effects  
 
The manegement of PN – related to HIV has commoly depended on the use 
pharmacological agents but they have not yieded substantial relief of the neuropathy. 
The findings of this study add to the existing body of knowledge in that exercises 
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prescribed and supervised by physiotherapists are effective in reducing PN 
symptoms, improving functional ability and related QoL among PLHIV in this era of 
ART, where people likely live with such complications for their lifetime. Additionally, 
this study adds to the results of other studies that tested the effects of exercise in 
PLHIV (Nixon et al., 2002; Nixon et al., 2005; O’Brien et al., 2008 ; O’Brien et al., 
2010) for the management of the HIV and ART-related conditions. Specifically, the 
findings are similar to the study by Mutimura et al. (2008), who evaluated the effects 
of exercise training on lipodystrophy and QoL in PLHIV in Rwanda. Mutimura and 
colleagues demonstrated that exercises are safe and cost – effective in improving 
QoL among PLHIV on ART.  
 
The findings from these two studies can be used to establish exercise programmes 
that can be integrated into the routine health care and management of HIV and ART- 
related co-morbidities particularly, PN and lipodystrophy. The exercise programme 
can be conducted at health facility level (ART clinics) in Rwanda and probably in 
other resource limited countries, where neurological disorders as a result of HIV are 
reported to be high (Silberberg and Katabira, 2006).  
 
Functional limitations as results of PN and poor QoL are common challenges for 
PLHIV, and this study showed improvement of function and QoL with exercise. It 
should be emphasised that exercise is an important management approach that 
should be introduced and be used as supplementary PN management in the routine 
health care of PLHIV.  
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7.9 Strengths and limitations of the intervention study 
7.9.1 Strengths 
The outcomes measures used in this intervention were re-validated and adapted to 
the African culture and environment, particularly the Rwandan. This made the 
strength of the results which were well captured in the exact local context particularly 
the functional activities done, and were evaluated with the re-validated LEFS. 
 
The intervention used simple aerobic exercises that are safe, inexpensive and need 
little equipment other than a room and an instructor. The approach can be easily 
extended to the community for the prevention of disabling complications associated 
with HIV.  
 
The use of a RCT, with concealed allocation, blinded assessor and standardised 
appropriate outcome measures, and a good sample size, were all strengths of this 
study.   
 
Again, the participation in the exercise intervention study was high with a 93% follow 
up of participants. This was good compared to most RCTs, in which high rates of 
dropouts and low adherence rates have been reported (O’Brien et al., 2010). The 
good adherence rate in this study is possibly attributable to; having a strategic 
location for the exercise intervention that is in the centre of Kigali city, and from which 
participants could easily access public transport. Secondly, the scheduled time for 
the exercise was convenient for most of the participants, both working and non-
working, being in the afternoon from 3pm to 5pm. A probable reason for the good 
follow up of the participants was the regular phone calls to remind them of the 
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exercise and assessment dates, ensuring that participants felt they were part of an 
important study. 
 
The study also assessed the sustainability of the exercise benefits at 12 weeks post 
intervention. Participants maintained the improvements they had achieved during 
the 12 week exercise period. They were able to demonstrate the improvement at the 
12 weeks post intervention assessment, although the improvement had dropped a 
little from the end of the 12 weeks of the exercise intervention.  
 
7.7.2 Limitations 
Participants in the exercise intervention were educated and encouraged to exercise 
back home after the structured exercises programme at the centre. However, this 
study did not assess or monitor the exact exercises and frequency of the home- 
based exercise.  
 
The intervention group might have had more interractions with the investigators than 
the control group, which may influence the possiblility of “care effect”, thus the 
intervention group getting greater improvements compared to the control group. It is 
known and sometimes unavoidable that the therapist lead intervention might lead to 
participants feel better (Hojat et al., 2011).  This study recognises the limitation.  
 
The exercise intervention was conducted in the urban setting and results may be 
more applicable to participants from urban settings than rural settings.   
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CHAPTER 8 
 
8.0 SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
 
8.1 Introduction 
This chapter restates the aims and methods of the three studies in summary, and 
highlights the conclusions drawn from the main findings of the three studies in the 
thesis. The recommendations specifically focus on suggesting clinical approaches 
and further research regarding improving the management of PN, the related lower 
extremity functional limitations and the QoL, among PLHIV on ART.  
 
8.2 Summary of the aims and methods 
The primary aim of the study was to establish the effects of physiotherapeutic 
exercises on PN, related lower extremity functional limitations and the QoL, among 
PLHIV on ART. However, prior to establishing the effects, two studies namely; study 
1 and study 2 were conducted.  
 
Study 1 aimed at re-establishing the validity and reliability of the outcome measures 
used in the three studies and adapted the measures to the Rwandan environment 
and cultural contexts. The reliability establishment included the intra and inter-
assessor reliability of the LEFS. The lower extremity functional scale was the only 
outcome measure re-validated and tested for intra and inter-assessor reliability. The 
re-validation included contextual validation and translating the LEFS from English to 
Kinyarwanda, the local language in Rwanda. The intra and inter-assessor reliability 
was carried out in a cross-sectional study of 50 PLHIV on ART attending an ART 
clinic at an urban health centre. The other outcome measures that included the 
BPNS and DN4 were piloted and adapted to the local context during the same cross-
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sectional study. The re-validated and adapted outcome measures were used in the 
rest of the studies in this thesis. 
 
Study 2 established the prevalence of PN and its associated functional limitations of 
the lower extremities and the QoL in PLHIV. Studies 1 and 2, prepared for study 3, 
which was a randomised controlled trial to test the effects of physiotherapeutic 
exercises on PN, the associated lower extremity functional limitations and QoL, in 
PLHIV on ART in Rwanda. The prevalence of PN, its association with the lower 
extremity functional ability and QoL, were identified through a cross sectional study 
(Study 2) of 507 PLHIV on ART who were attending eight randomly selected ART 
clinics from rural and urban health facilities across the provinces and city of Kigali.  
 
The effects of physiotherapeutic exercises were established through an RCT (Study 
3). One hundred and twenty (120) PLHIV attending four ART clinics in Kigali were 
randomly invited from those identified with PN in Study 2. The 120 participants were 
equally randomised to exercise and control groups. The exercise group underwent 
12 weeks of exercise intervention and the post exercise assessment results were 
compared with the baseline, for both groups. In addition, at 12 weeks post exercise 
intervention, an assessment was also carried out for both groups to examine the 
sustainability of the exercise benefits, in the intervention group.   
 
8.3 Conclusions 
The conclusions highlight the major findings from each of the three studies that 
comprised the whole thesis. 
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8.3.1 Re-established validity and adapted outcome measures for PN, lower 
extremity functional limitations and QoL, among PLHIV in Rwanda  
 
The LEFS was tested and re-validated to evaluate the lower extremity functional 
limitations related to PN in PLHIV in Rwanda. The re-validated and test re-tested 
reliability of LEFS yielded optimal and good reliability. Thus, this study represents 
the first validation of the LEFS in PLHIV on ART, from English into Kinyarwanda and 
appropriate adaptation to a specific cultural context. The study demonstrated the 
importance of validating tools derived from developed world contexts to the African 
environmental setting.  
 
In addition, the BPNS which is a well-used and considered gold standard tool to 
assess PN associated with HIV, and DN4 to screen for neuropathic pain, were also 
adapted for use in Rwanda. WHOQOL-BREF was not re-validated as it had already 
been adapted and used among PLHIV in Rwanda.  
 
8.3.2 Established prevalence of peripheral neuropathy in Rwanda  
The overall prevalence of PN was very high at 59% but differently distributed; higher 
(78%) in the urban than (40%) in the rural, settings. An older age and living in an 
urban setting, were the demographic characteristics significantly associated with PN. 
The findings demonstrate that older aged PLHIV, and those living in urban settings 
are likely more vulnerable to having PN. The findings can be generalized for both 
rural and urban dwellers in Rwanda and possibly in other poorly resource-limited 
settings where the lifestyle of the populations is similar.  
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8.3.3 Peripheral neuropathy is associated with the functional limitations of 
the lower extremities and quality of life in PLHIV on ART 
 
Peripheral neuropathy was significantly associated with low performance of 
functional activities of the lower extremities, and thus resulted in poorer QoL. The 
functional ability of the lower extremities among PLHIV with PN was lower than those 
without PN. Having PN likely caused limited mobility of the lower extremities in the 
group with the neuropathy. Such limitations in mobility eventually contributed to the 
limitations in the functional activities and eventually led to lower QoL.  
 
Furthermore, participants with PN from urban settings had more difficulty in 
performing their daily functional activities, than their counterparts from rural settings. 
This is likely because the PN in urban PLHIV was more prevalent and probably more 
severe than in rural participants. 
 
8.3.4 The physiotherapeutic exercises benefited PLHIV on ART with PN 
Physiotherapeutic exercises improved all the clinical PN symptoms among the 
participants who exercised for 12 weeks. This implies that the improvements of PN 
symptoms observed in the experimental group after 12 weeks of exercise are 
attributable to the exercise intervention as there were no improvements in the control 
group. Importantly, the improvement of the PN symptoms attained by the participants 
during the exercise intervention was maintained during the 12 weeks post 
intervention. This is likely a result of the probable continuation of exercises by the 
participants after the structured exercise programme at the centre. During the 
intervention the participants were educated and encouraged to continue exercising 
after the intervention. 
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8.3.5 The physiotherapeutic exercises improved the functional ability and 
QoL of PLHIV on ART with PN 
 
There were trends of changes in improvement of the functional ability among the 
participants who exercised. No improvement was observed in the functional ability 
measures among the control group. The change in the improvement was maintained 
in the exercise group at 12 weeks post exercise intervention. The reduced PN 
symptoms such as neuropathic pain, muscle tightness and improved flexibility, might 
have played a role in the improvement of the functional ability. The same effects that 
began with improved PN symptoms improved functional ability might have resulted 
in the improved QoL of the exercised group. Thus, the improved QoL was 
demonstrated in this group after 12 weeks of exercising and at 12 weeks post 
exercise intervention.   
 
8.3.6 Factors that influenced the improvement during the exercise intervention 
 
The participants, who had HIV infection for the last seven and above years, were 
likely to have less improvement. Living with the infection for a long time may result 
in more severe PN, and this negatively affects the improvement of the PN during 
treatment.  
 
The participants, who had not undergone any change in the ART regimen and those 
who developed PN after the start on ART, improved more. More males improved 
their lower extremity functional ability, compared to females. Other studies have 
shown that females have more severe PN than males, but the findings of this study 
could not fully explain why males improved faster than females,  
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8.4 Recommendations and implications 
The recommendations are based on the findings of the study and are in two parts, 
namely; clinical and for further research. 
 
8.4.1 Clinical recommendations 
Due to the fact that there is a high prevalence of PN, there is a need for routine 
screening and evaluation for possible early detection of PN and to plan appropriate 
management. The re-validated outcome measures in this study are simple and can 
be used in the screening and evaluations of PN and its related functional activities 
limitations. The older group (40 years and above years) and those living in urban 
settings should be prioritised during screening as they are vulnerable to developing 
PN.  
 
Additionally, as there is poor availability of clinically – oriented evidence on tools to 
use in  routine management of HIV related functional limitations, the validated tools 
in this study may not only help in the Rwandan setting but also this type of research 
can be conducted in other settings, specifically in African countries.   
 
As the management of HIV – PN has been commonly depending mainly on 
pharmacological, the findings of this study open new ways of evidence – informed 
thinking about treatment option. The study therefore introduces discussions on the 
role of physiotherapy and rehabilitations in general within the HIV health care. Thus, 
the study provides a specific guidance on the role of particular physiotherapeutic 
exercises in the management of HIV – PN.  There is therefore a need to start 
exercise programmes and integrate them into clinical settings such as at ART clinics 
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in the health facilities, and make exercise part of the routine management for PLHIV 
identified with PN. The PLHIV on ART should be educated and encouraged to 
exercises at home. Periodical monitoring and evaluation of the exercise efficiency 
and sustainability will be needed.  
 
Also this study demonstrates that there is a need for further discussions about 
making the management of HIV – related conditions beyond the medical model. 
Thus, there is essential need for Inter-collaboration between the health care 
professionals who are involved in health care management of PLHIV at the ART 
clinics and the rehabilitation professionals such as physiotherapists. This will make 
it possible for early referral and appropriate management for interdisciplinary 
management. If possible, every ART clinic should have a rehabilitation professional, 
specifically a physiotherapist who will be in charge of any rehabilitation needs of 
PLHIV particularly those identified with PN and educate them for the lifestyle 
changes. 
 
8.4.2 Further Research  
Lifestyle, social and behaviour research in longitudinal studies needs to establish the 
exact factors predicting the occurrence of PN, examples include being physically 
active versus being inactive, living in urban versus rural areas, or being male or 
female.  
 
There is a need for further research to establish the mechanism of how exercise 
improves PN symptoms such as neuropathic pain. This may lead to a better 
understanding of how important exercises are, in the management of PN, and the 
associated functional limitations that compromise the QoL of PLHIV.  
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Furthermore, for the need of better understanding the effects of exercises on the PN 
and its development in this era of ART, where possible, it is important to carry out a 
study on the physiological effects of exercise on the toxicity of the ARVs, particularly 
at the mitochondrial level.  
 
Finally, there is a need to investigate and test the exercise interventions over 
prolonged periods of time, to establish if there is an improvement in nerve recovery, 
in particular the larger nerve fibres for the improvement of PN signs.  
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APPENDICES 
 
 
Appendix 1: Outcome measures 
 
Outcome measures for screening of Peripheral Neuropathy, related functional 
limitation and quality of life, among PLWHA on ART in Rwanda 
 
Section A: Checklist 
Date of screening -------------------- 
ID No given. ……………………. .........................Code...................................................... 
Demographic characteristics and general health status of the patient 
 
Instruction: Circle the option corresponding to the answer given by the participant or as indicated in 
the participant’s medical file; unless otherwise indicated 
 
a) Gender:           Female   1)           Male  2) 
  
b) Fill in the D.O.B ---------------------------------------- 
 
c) Highest level of education 
1. None 
2. Primary education 
3. Secondary school education (S1 – 3) 
4. Secondary school education (S4 – 6) 
5. Tertiary education (University, Institution of higher learning 
 
d) Occupation 
1. Public (government) service 
2. Peasant (farmer, or livestock) 
3. Self – employed (business) 
4. Private organisation (NGO, bank, insurance, etc) 
5. Unemployed (do not have a job for the last 3 months) 
6. Any other (please specify) 
 
e) Marital status 
1 Single 
2 Married 
3 Divorced 
4 Separated  
5 Widow / widower 
6 Cohabitating (live together with a temporally male/female partner 
7 Any other (please specify)  
 
f) Place of residence          
1. Urban                   2. Rural  
 
g) When the patient’s HIV was diagnosed: 
1) 1 – 6 months ago            
2) 6 – 12 months ago 
3) 1 – 3 years ago 
4) 4 – 6 years ago 
5) 7 – 9 years ago 
6) 10 – 15 years ago 
7) More than 15 years ago 
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h)  Current CD cell count (/mm3) 
1)  ≤ 200 
2) 201-350 
3) 351-500 
4) > 500 
5) None  
 
i) Have you started on ARVs?     1) yes         2) No 
 
j) If yes, circle the current ARV regimens’ combination   
 
1) Triviro – 30 (D4T+ 3TC+ NVP)   
2) Duovir – N (AZT + 3TC+ NVP)  
3) TDF + 3TC + NVP 
4) TDF + 3TC + EFV 
5) TDF + 3TC + Kaletra 
6) D4T + 3TC + EFV 
7) ABC + 3TC + EFV 
8) ABC + ddI 
9) D4T + AZT + Kaletra 
10) AZT + 3TC+ Stocrin 
11) 3TC + NVP 
 
k) For how long the patient has been on ARVs treatment? 
1) 1 – 6 months           
2) 6 – 12 months 
3) 1 – 3 years 
4) 4 – 6 years 
5) 7 – 9 years 
6) 10 – 15 years 
7) More than 15 years 
 
l) How many regimen changes have you had so far? 
 
0) None 
1) One 
2) Two 
3) More than two 
 
m) If any change, which regimen did you start with? 
1) Triviro – 30 (D4T+ 3TC+ NVP)   
2) Duovir – N (AZT + 3TC+ NVP)  
3) TDF + 3TC + NVP 
4) TDF + 3TC + EFV 
5) TDF + 3TC + Kaletra 
6) D4T + 3TC + EFV 
7) ABC + 3TC + EFV 
8) ABC + ddI 
9) D4T + AZT + Kaletra 
10) AZT + 3TC+ Stocrin 
11) 3TC + NVP 
 
For exclusion Criteria  
k) Please indicate if the patient has been known to have the following condition(s): (Circle all 
that apply) (ask the patient in case the information is not available in the file) 
1) Diabetes mellitus  
2) Spinal cord disorders 
3) Alcoholism 
4) TB and is taking anti – TB 
5) Any other (please specify).................................................................... 
6) None  
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l) Please indicate if the patient presents the following symptoms :( Tick all that apply) 
1) Pain: (muscle pain)       Hand and arms         Feet and Legs    
2) Paraesthesia/tingling    Hand and arms         Feet and Legs    
3) Numbness:                  Hand and arms          Feet and Legs   
4) None 
 
 
m) If the patient presents any of the above symptoms, when did the symptoms start? (If 
remember/ recorded) 
1) Before start ARVs      
2) After starting ARVs  
 
n) If after start ARVs, after how long on ARVs did the symptoms commence (if remember or 
recorded) 
1) 1 – 6 months         
2) 6 – 12 months 
3) 1 – 3 years 
4) 4 – 6 years 
5) 7 – 9 years  
6) 10 – 15 years 
7) More than 15 years 
 
Section B: Neuropathic diagnosis  (DN4) 
 
To estimate the probability of neuropathic pain, please answer yes or no for each item of the 
following four questions. 
 
INTERVIEW OF THE PATIENT 
 
QUESTION 1: 
Does the pain have one or more of the following characteristics?   YES NO 
Burning . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
Painful cold . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
Electric shocks . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
 
QUESTION 2: 
Is the pain associated with one or more of the following symptoms in the same area?  
                           YES NO 
Tingling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
Pins and needles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ❏ ❏ 
Numbness. . …..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
Itching . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
 
EXAMINATION OF THE PATIENT 
 
QUESTION 3: 
Is the pain located in an area where the physical examination may reveal one or more of the 
following characteristics?                         YES NO 
Hypoesthesia to touch . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. ❏ ❏ 
Hypoesthesia to pinprick . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. ❏ ❏ 
  
QUESTION 4: 
In the painful area, can the pain be caused or increased by:            YES NO 
Brushing? . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❏ ❏ 
YES = 1 point 
NO = 0 points Patient’s Score: /10 
 
Neuropathic pain is diagnosed if the total score ≥ 4/10 
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Section C: Recording Subjective Elicited Symptoms (completed by the researcher/ trained 
research assistant)  
 
Instructions  
Ask the participant to rate the severity of each symptom listed in question 1 on a scale of 01 (mild) to 
10 (most severe) for right and left feet and legs. Enter the score for each symptom in the columns 
marked R (right lower limb) and L (left lower limb). If a symptom has been present in the past, but not 
since the last visit, enter ‘00-Currently Absent’. If the symptom has never been present, enter ‘11-
Always Been Normal’  
 
Always been 
normal 
Currently 
absent  
Mild______________________________________ Severe 
11 00 01 02 03 04 05 06 07 08 09 10 
 
1. SYMPTOMS                                     R          L  
 
 a. Pain, aching, or burning in feet, legs …………………… 
  
 b. “Pins and needles” in feet, legs …………………………      
  
 c. Numbness (lack of feeling) in feet, legs …………………          
 
Instructions for grading subjective elicited symptoms  
Use the single highest severity score from question 1. above to obtain a subjective sensory 
neuropathy score. If all severity scores are ’00’ or ‘11’, the subjective sensory neuropathy score will 
equal ‘0’  
Presence/Severity Score of:  
01 – 03 = Grade of 1  
04 – 06 = Grade of 2  
07 – 10 = Grade of 3  
11 or 00 = Grade of 0  
                      R        L  
 
2. Subjective sensory neuropathy grade ………………………… 
 
3. Location of symptoms  
Use Score of:  
0 = None  
1 = feet only  
2 = extends to ankles  
3 = extends above ankle but not to knee  
4 = extends to knees  
5 = extends above knees  
 
                        R           L  
 
a. Pain, aching, or burning in feet, legs ………………………… 
 
b. “Pins and needles” in feet, legs ………………………………. 
 
 
c. Numbness (lack of feeling) in feet, legs ……………………          
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Instructions for evaluating perception of vibration  
Compress the ends of a 128 Hz tuning fork just hard enough that the sides touch. Immediately place 
the vibrating tuning fork gently but firmly on the top of the distal interphalangeal (DIP) joint of one 
great toe and begin counting the seconds. Instruct the participant to tell you when the “buzzing” stops. 
Repeat for the other great toe.  
 
 
4. Vibration Perception  
            R         L  
  
 a. Great toe DIP joint perception of vibration in seconds            
  
            R        L  
                  
                  b. Vibration perception score Vibration Perception                    
 
0 = felt > 10 seconds  
1 = felt 6-10 seconds  
2 = felt < 5 seconds  
3 = not felt  
8 = unable/did not evaluate  
 
 
Instructions for evaluating deep tendon reflexes  
With the subject comfortably kneeling on a chair (with a cushion/pillow on) with foot free, the examiner 
uses a reflex hammer and strikes the Achilles tendon. The tendon reflex is seen as a plantar flexion 
of the foot, appearing after a slight delay from the time the Achilles tendon was struck. Use 
reinforcement by having the subject clench his/her fist before classifying the reflex as absent.  
 
Ankle reflexes  
0 = absent  
1 = Hypoactive  
2 = Normal deep tendon reflexes  
3 = Hyperactive  
4 = Clonus  
8 = unable/did not assess  
            R        L  
5. Ankle reflexes …………………………………………………..  
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Section D: Lower Extremity Functional Scale (LEFS-Modified) 
We are interested in knowing whether you are having any difficulty at all with the activities listed below because of your lower limb problem (s). 
Please provide an answer for each activity. Today, do you or would you have any difficulty with: 
(Circle one number on each line that corresponds to your appropriate answer) 
Activity Unable to 
perform activity 
Quite a bit of 
difficulty 
Moderate 
difficulty 
A little a bit 
difficulty 
No 
difficulty 
1.Any of your usual work, (e.g work that earns you income, or any other 
work you do) housework, or school activities 
0 1 2 3 4 
2.Your usual hobbies, recreational or sporting activities, eg attending 
weddings, church or visiting friends 
0 1 2 3 4 
3. Getting into or out of the bath/taking bath. 0 1 2 3 4 
4.Walking between rooms  (such as walking from your room to toilet, 
bath room, kitchen,  etc)  
0 1 2 3 4 
5. Putting on any kind shoes or socks you want, including slippers or 
open shoes, if applied. 
0 1 2 3 4 
6.Squatting (e.g squatting on pit latrine/doing any squatting activity) 0 1 2 3 4 
7.Lifting an object, like a bag of groceries or a small container like 5 
litres container full of water,  basket of potatoes, etc, from floor 
0 1 2 3 4 
8.Performing light activities around your home(such as prepare a meal, 
cleaning a house, making bed, or any other light activity at home)   
0 1 2 3 4 
9.Performing heavy activities around your home (digging, lifting a heavy 
bag of potatoes, 20 litres Jerican of water, shifting big items, etc 
0 1 2 3 4 
10. Getting into or out of a car/taxi. 0 1 2 3 4 
11.Walking across from your home to neighbours or walk like 100m 
across 
0 1 2 3 4 
12.Walking a Km, such as going to market, church or any other place 
where you walk 
0 1 2 3 4 
13.Going up or down 10 stairs (about 1 flight of stairs) or walking up a 
steep and irregular ground 
0 1 2 3 4 
14.Standing for 1 hour,  0 1 2 3 4 
15.Sitting for 1 hour,  like when in church, tax, or meetings 0 1 2 3 4 
16.Fast walking on even ground  0 1 2 3 4 
17.Fast walking/running on uneven ground 0 1 2 3 4 
18.Making sharp turns while walking/running very fast    0 1 2 3 4 
19.Standing up fast from squatting as needed  0 1 2 3 4 
20.Turning in bed 0 1 2 3 4 
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Section E: ASSESSMENT OF QOL: WHOQOL-HIV BREF QUESTIONNAIRE  
 
After reading each question, assess your feelings, and circle the number on the scale for each 
question that gives the best answer that corresponds to your feelings 
  Very poor Poor Neither poor 
nor good 
Good Very good 
1(G1) How would you rate your 
QOL? 
1 2 3 4 5 
 
  Very 
dissatisfied 
Dissatisfied Neither 
satisfied nor 
dissatisfied 
Satisfied Very satisfied 
2(G4) How satisfied are you with 
your life? 
1 2 3 4 5 
The following questions ask about how much you have experienced certain things in the last two 
weeks. 
  Not at all A little moderate 
amount 
Very 
much 
An extreme 
amount 
3(F1.4) To what extent do you feel that 
physical pain prevents you from 
doing what you need to do? 
5 4 3 2 1 
4(F11.3) How much do you need any 
medical treatment to function in 
your daily life? 
5 4 3 2 1 
5(F4.1) How much do you enjoy life? 1 2 3 4 5 
6(F24.2) To what extent do you feel your 
life to be meaningful? 
1 2 3 4 5 
 
  Not at all A little  moderate Very 
much 
Extremely 
7(F5.3) How well are you able to 
concentrate? 
1 2 3 4 5 
8(F16.1) How safe do you feel in your 
daily life? 
1 2 3 4 5 
9(F22.1) How healthy is your physical 
environment? 
1 2 3 4 5 
The following questions ask about how completely you experience or were able to do certain things in 
the last 2 weeks 
  Not at all A little Moderately 
amount 
Mostly Completely 
10(F2.1) Do you have enough energy 
for everyday life? 
1 2 3 4 5 
11(F7.1) Are you able to accept your 
bodily appearance? 
1 2 3 4 5 
12(F18.1) Have enough money to meet 
your needs? 
1 2 3 4 5 
13(F20.1) How available to you is 
information that you need in 
your day-to –day life? 
1 2 3 4 5 
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14(F21.1) To what extent do you have 
opportunity for leisure 
activities? 
1 2 3 4 5 
 
  Very poor Poor Neither poor 
nor good 
Good Very good 
15(F9.1) How were you able to get 
around? 
1 2 3 4 5 
The following questions ask you to say how good or satisfied you have felt about various aspects of 
your life over the last two weeks. 
  Very 
dissatisfied 
Dissatisfied Neither 
satisfied nor 
dissatisfied 
Satisfied Very satisfied 
16(F3.3) How satisfied are you with 
your sleep? 
1 2 3 4 5 
17(F10.3) How satisfied are you with 
your ability to perform your 
daily activities? 
1 2 3 4 5 
18(F12.4) How satisfied are you with 
your capacity for work? 
1 2 3 4 5 
19(F6.3) How satisfied are you with 
yourself? 
1 2 3 4 5 
20(13.3) How satisfied are you with 
your personal relationships? 
1 2 3 4 5 
21(F15.3) How satisfied are you with 
your sex life? 
1 2 3 4 5 
22(F14.4) How satisfied are you with the 
support you get from your 
friends? 
1 2 3 4 5 
23(F17.3) How satisfied with the 
conditions of your living place? 
1 2 3 4 5 
24(F19.3) How satisfied are you with 
your access to health 
services? 
1 2 3 4 5 
25(F23.3) How satisfied are you with 
your transport? 
1 2 3 4 5 
 
The following question refers to how often you have felt or experienced certain things in the last two 
weeks. 
  Never Seldom Quite often Very 
often 
Always 
26(F8.1) How often do you have negative 
feelings such as blue mood, 
despair, anxiety, depression? 
5 4 3 2 1 
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Appendix 2: Physiotherapeutic exercise1 protocol for the intervention on PN 
among PLHIV on ART in Rwanda 
 
For lower extremities 
Design of the programme: An exercise interventional programme.  
Table of detailed exercises programme 
S/N Order of 
exercise  
Type of 
exercise 
Duration Exercise technique and instructions 
1. Warm up 
exercises 
Moderate 
aerobic 
exercises 
10 minutes Walking slowly at start for the first 5 minutes and 
then progress brisk walking. Patient are instructed 
to walk according their capacity and in pain free 
limits 
2. Mobility and 
flexibility 
Self - stretching 15 minutes In long sitting, cross sitting and lying positions: 
stretching of the toes, ankle and knee muscles. 
Each stretch is held 15 seconds, followed by 
relaxation of 10 seconds; then repeat twice the 
procedure for the same muscle, and change to 
another muscle group and do the same: should 
breath normally and stretch into pain free limits  
3. Muscle 
conditioning 
Isometric 
exercises  
15 minutes For muscles of the foot, leg and thigh. Starting with 
foot; Hold and count up to 5: at “time second pace” 
(participants will be taught to do that counting): 
relax for 10 seconds: repeat the procedure twice for 
the same group of muscles and then change to 
other groups of muscles: participants are instructed 
not to hold the breath during performance of 
exercises; and counting helps them not to hold 
breath. 
4.  Stability  Balance 
exercises 
10 minutes Moving from sit to stand with partial support, then 
without support, bilateral squat with support and 
then progress to without support, body weight 
transfer to one limb as much as he/she can while 
standing with support from wall/wall bar, progresses 
to lift one leg to a step while keeping the opposite 
leg down, with support, progress by reducing the 
support and eventually stands with a step un 
                                                 
1 Physiotherapy prescribed and supervised therapeutic exercise protocol  
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supported. Progression continues until the 
participant may stand on one leg un supported. 
participants are always instructed to exercise to 
their capacity limits 
5. Cool down Stretching and 
relaxation 
exercises 
10 minutes Long sitting, side and prone lying positions, then 
stretches the muscles of the toes, foot, ankle and 
knee slowly hold for 10 seconds while breathing in 
and out deeply. Relax for 15 seconds and repeats 
twice and then change to another muscle group 
 
N.B: Progression in any of the exercises above may start after the first and second sessions of the 
program and will be according to participant’s improvement performance 
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Appendix 3: Research ethics clearance certificate from the University of 
Witwatersrand 
 
Appendix 4:  Research protocol approval by the national commission in 
charge of HIV and AIDS in Rwanda, 
 
Appendix 5: Research ethics clearance from IRB at Kigali Health Institute in 
Rwanda 
 
(Indicated on the next pages; the appendices 3, 4 & 5) 
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